Bases moleclears de la Leucooecefalopatia Megalencefàllca amb Quists subcorlicals. Utilització de models animals i cel·lulars

Sònia Sirisi Dolcet
Bases moleculars de la Leucoencefalopatia Megalencefàlica amb Quists subcorticals. Utilització de models animals i cel·lulars.

Tesi doctoral: Sònia Sirisi Dolcet
Departament de Ciències Fisiològiques II, Unitat de Fisiologia
Universitat de Barcelona 2014

Directors:
Raúl Estévez Povedano i Virginia Nunes Martínez
Departament de Ciències Fisiològiques II, UB
Mutant GlialCAM Causes Megalencephalic Leukoencephalopathy with Subcortical Cysts, Benign Familial Macrocephaly, and Macrocephaly with retardation and autism.

(The American Journal of Human Genetics, 2011)

Contribució:

- Purificació de l’anticós contra la proteïna GlialCAM
- Anàlisi de la mielina (Figura 3 G)
Mutant GlialCAM Causes Megalencephalic Leukoencephalopathy with Subcortical Cysts, Benign Familial Macrocephaly, and Macrocephaly with Retardation and Autism

Tania López-Hernández,1,9 Margreet C. Ridder,5,9 Marisol Montolio,1,4 Xavier Capdevila-Nortes,1 Emiel Polder,3 Sónia Sirisi,1,6 Anna Duari,1,4 Uwe Schulte,7 Bernd Fakler,7 Virginia Nunes,2,5,6 Gert C. Schepers,3 Albert Martínez,8 Raúl Estévez,1,4,10,* and Marjo S. van der Knaap3,10,*

Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a leukodystrophy characterized by early-onset macrocephaly and delayed-onset neurological deterioration. Recessive MLC1 mutations are observed in 75% of patients with MLC. Genetic-linkage studies failed to identify another gene. We recently showed that some patients without MLC1 mutations display the classical phenotype; others improve or become normal but retain macrocephaly. To find another MLC-related gene, we used quantitative proteomic analysis of affinity-purified MLC1 as an alternative approach and found that GlialCAM, an IgG-like cell adhesion molecule that is also called HEPACAM, is a direct MLC1-binding partner. Analysis of 40 MLC patients without MLC1 mutations revealed multiple different HEPACAM mutations. Ten patients with the classical, deteriorating phenotype had two mutations, and 18 patients with the improving phenotype had one mutation. Most parents with a single mutation had macrocephaly, indicating dominant inheritance. In some families with dominant HEPACAM mutations, the clinical picture and magnetic resonance imaging normalized, indicating that HEPACAM mutations can cause benign familial macrocephaly. In other families with dominant HEPACAM mutations, patients had macrocephaly and mental retardation with or without autism. Further experiments demonstrated that GlialCAM and MLC1 both localize in axons and colocalize in junctions between astrocytes. GlialCAM is additionally located in myelin. Mutant GlialCAM disrupts the localization of MLC1-GlialCAM complexes in astrocytic junctions in a manner reflecting the mode of inheritance. In conclusion, GlialCAM is required for proper localization of MLC1. HEPACAM is the second gene found to be mutated in MLC. Dominant HEPACAM mutations can cause either macrocephaly and mental retardation with or without autism or benign familial macrocephaly.

Introduction

Megalencephalic leukoencephalopathy with subcortical cysts (MLC, MIM 604004) is a leukodystrophy with autosomal-recessive inheritance.1 Patients develop macrocephaly during the first year of life. After several years, there is evidence of slow neurological deterioration, including cerebellar ataxia, spasticity, epilepsy, and mild cognitive decline. From early on, magnetic resonance imaging (MRI) reveals diffuse signal abnormality and swelling of the brain white matter and subcortical cysts (Figure S1, available online).1 In follow-up exams, the white matter abnormalities remain and atrophy ensues.1 A brain biopsy from an MLC patient showed extensive myelin vacuolation, mainly affecting the outer myelin layers, which causes the swollen appearance of the white matter.2 In 2001, we demonstrated that mutations in MLC1 (MIM 605908) cause MLC.3 MLC1 mutations are found in approximately 75% of the MLC patients.4 MLC1 is an oligomeric membrane protein that is expressed almost exclusively in the brain. It has some degree of homology to ion channels.5,8 Within the brain, MLC1 is mainly located in astrocyte-astrocyte junctions close to blood- and cerebrospinal fluid (CSF)-brain barriers, Bergmann glia, and main axonal tracts.5–7 Thus far, the physiological role of MLC1 has remained unknown, and a suggested role in ion transport has not been confirmed.3,5,8

In some families, members with MLC do not have MLC1 mutations, and these families do not show linkage to the MLC1 locus, indicating that mutations in at least one other gene are involved in MLC.9,10 but genetic-linkage studies failed to identify another disease gene. We recently described two distinct phenotypes among MLC patients without MLC1 mutations.11 The classical phenotype retains typical clinical and MRI features, as seen in patients with MLC1 mutations.1,11 The second, improving phenotype is initially the same as the classical phenotype but lacks clinical deterioration and shows major improvement or normalization of the MRI abnormalities (Figure S1).11 Because of the unsuccessful genetic-linkage studies and the possibility of further genetic heterogeneity, we decided to use alternative strategies to identify eligible candidate genes.
Material and Methods

The studies on human samples were performed with approval of the institutional review board, VU University Medical Center, Amsterdam, and informed consent from the families. The animal experimental protocols were approved by the Animal Care and Ethics Committee of the University of Barcelona. Protocols for the use and manipulation of the animals were approved by the Government of Catalonia.

Biochemistry
Preparation of Source Material
Plasma membrane-enriched protein fractions were prepared from pools of freshly isolated whole rat or mouse brains according to the procedure used in Zolles et al. For solubilization, the prepared membrane vesicles were resuspended in ComplexioLyte buffer 47a (at 0.8 mg protein/ml, LOGOPHARM GmbH, Germany; with protease inhibitors added) and incubated for 30 min at 4 °C; nonsoluble components were removed afterward by ultracentrifugation (10 min at 150,000 × g). Efficiency of solubilization was determined by immunoblot analysis of SDS-PAGE-resolved aliquots of solubilized and pellet fractions. Polyanovylidene fluoride (PVDF) membranes were probed with rabbit polyclonal antibodies (α-N1 or α-NH, 1:10,000, see below), stained with goat anti-rabbit-HRP (Santa Cruz Biotechnologies, USA) and developed with ECL+ (GE Healthcare, USA).

Preparation of Antibodies
Immune sera against N-terminal mouse MLC1 peptides (α-N1 and α-N2) and the α-NH (anti-N-terminus of human MLC1) antibody were generated and characterized previously. The α-NH also recognizes mouse rat MLC1. Immune sera against a mouse GlialCAM synthetic peptide (QRIREQDESQGVEISA), corresponding to amino acids 403–418 of GlialCAM, were raised in rabbits with the help of the services provided by Eurogentec. The peptide was coupled to keyhole limpet hemocyanin via a cysteine residue that has been added to the N-terminal end of the peptide. After three boosts of immunization, the antisera were affinity purified with the peptide covalently coupled to Sulpholink (Pierce). The polyclonal antibody was tested by immunoblotting, immunofluorescence, and immunoprecipitation on HeLa cells expressing human GlialCAM and on mouse brain tissue.

Affinity Purification
For each experiment, 1.5 ml freshly prepared solubilisate (rat or mouse) was incubated for 2 hr at 4 °C with 20 μg of the respective immobilized antibody (α-N1, α-N2 α-NH, α-GlialCAM, IgG = control rabbit IgG [Upstate, USA]). After a brief washing (twice for 5 min each time) with ComplexioLyte 47a, bound proteins were eluted with Laemmli buffer (dithiothreitol [DTT] was added after elution). Eluates were then briefly run on SDS-PAGE gels followed by silver staining and tryptic digestion. During these experiments, samples were taken for immunoblot analysis with the indicated MLC1 and GlialCAM antibodies.

Preparation of Myelin
Myelin was prepared as described previously. Two brains from 6- to 8-week-old wild-type mice were homogenized in 20 volumes of homogenization buffer (0.32 M sucrose in 10 mM HEPES [pH 7.4]) with five strokes with a loose pestle and seven strokes with a tight pestle. The homogenate was layered over 0.85 M sucrose, centrifuged at 25,000 rpm for 30 min in a swinging bucket rotor. Proteins located in the interphase were removed, resuspended in 10 volumes of water, and centrifuged at 25,000 rpm for 15 min. The pellet was twice cleansed of sucrose by water suspension and centrifugation. Then, pellets were suspended again in homogenization buffer and layered over 0.85 M sucrose and centrifuged at 25,000 rpm for 30 min. The interphase layer was again suspended in water, centrifuged for 15 min, and resuspended in 10 mM HEPES buffer (pH 7.4) containing 1% Triton X-100. Protein was quantified by bicinchoninic acid, and 20 μg was used for SDS-PAGE and immunoblot analyses.

Mass Spectrometric Analysis
Liquid Chromatography-Mass Spectrometry/Mass Spectrometry Analysis
Stained gel lanes were excised in two parts (upper and lower), and proteins were digested with trypsin according to the procedure described previously. Extracted peptides dissolved in 0.5% trifluoroacetic acid were loaded on a precolumn (C18 PepMap100, 5 μm; Dionex, Idstein, Germany) of an UltiMate 3000 HPLC (Dionex, Idstein, Germany). An aqueous organic gradient was then applied for elution and separation of peptides on a 75 μm column packed with C18 beads (ReproSil-Pur 120 5 OD-3; Dr. A Maisch, Ammerbuch-Entringen, Germany) and directly electrospayed into an LTQ-FT mass spectrometer (Thermo Scientific, Bremen, Germany; ion source: Proxeon, Odense, Denmark). Each scan cycle consisted of one FTMS full scan and up to five ITMS dependent MS/MS scans of the five most intense ions. Dynamic exclusion (30 s, mass width 20 ppm) and monoisotopic precursor selection were enabled. Using Mascot (Matrix Science, UK) we searched extracted MS/MS spectra against the Swiss-Prot database (Mammalia). We allowed common variable modifications and one missed tryptic cleavage; peptide tolerance was ± 10 ppm and MS/MS tolerance was ± 0.8 Da. Proteins that (1) were identified by only one specific MS/MS spectrum or (2) presented exogenous contaminations like keratins, trypsin, or immunoglobulins were not considered in further evaluations.

Protein Quantification
We used two previously detailed protein quantification methods that are both based on liquid chromatography-mass spectrometry (LC-MS) peptide signal intensities extracted (as peak volumes [PVs]; m/z tolerance was 6 ppm) and aligned (between individual LC-MS runs by their retention times; tolerance was 8%) with MS Inspect (Computational Proteomics Laboratory, Fred Hutchinson Cancer Research Center, Seattle, WA, USA) and in-house written software. The relative quantity of a protein in affinity purification sample versus control was calculated as a median of consistent peak volume ratios of respective peptides (rPV). Ensuring the significance of rPVs, required that at least two peptide ratios had assigned PVs totaling 100,000 volume units. Proteins were regarded as specifically (co-) purified when their rPV values were higher than 10. The molar amounts of different proteins were compared by using abundance_rPV norm values (as in Figure 1), calculated as the sum of all assigned peak volumes (totalPV) divided by the number of MS-accessible amino acids (sequence of tryptic peptides with masses between 740 and 3000 Da under the MS settings used).

Genetic Analysis
The diagnosis of MLC was established by MRI criteria. In those MLC patients in whom we found no mutations in MLC1 by sequence analysis of genomic DNA, as well as analysis of MLC1 cDNA and MLPA, we analyzed HEPACAM (hepatic and glial cell adhesion molecule, MIM 611642), the gene encoding GlialCAM. HEPACAM primers were designed with ExonPrimer (Table S1). Accession numbers of the reference sequences are NM_152722.4.
(mRNA) and NT_033899.8 (gDNA). PCR amplification of exons 1–6 of HEPACAM and their surrounding intronic regions was carried out with Platinum TAQ DNA Polymerase according to the manufacturer's instructions (Invitrogen). For exon 7, which has a very high-GC content, Platinum TAQ DNA-polymerase (Invitrogen) was used in combination with 5X AccuPrime™ GC-Rich Buffer A (Invitrogen). The PCR products were analyzed by cycle sequencing on an ABI3730 Genetic Analyzer (Applied Biosystems) with the same primers used for PCR amplification, with the exception of the forward primer of exon 1. The resulting chromatograms were analyzed with Sequence Pilot (JSI Medical Systems GmbH) with ENSG00000165478 as reference sequence.

Figure 1. Proteomic Identification of GlialCAM as a Major Binding Partner of MLC1

(A) Affinity purification (AP) strategy based on efficient MLC1 solubilization (left) as visualized by immunoblot analysis of SDS-PAGE-resolved samples from rat brain membrane, solubilisate, and pellet (stained with anti-MLC1 (α-N1)) and three antibodies (right) directed against N-terminal epitopes of MLC1. Similar results were obtained when two different antibodies were applied or when the three antibodies were applied simultaneously, confirming the specificity of the proteomics data.

(B and C) Evaluation of MLC1 affinity purifications with the indicated antibodies. (B) 2D plot of protein abundances determined by mass spectrometry (for abundance$_{\text{norm}}$ values see Material and Methods) of AP with α-N1 (from rat brain) versus AP with α-NH (from mouse brain). Only proteins specifically enriched (more than 10-fold of the amount in the respective IgG control) and identified in both APs are shown (as dots). Note the distinct quantitative correlation of GlialCAM with MLC1. Pearson correlation of GlialCAM and MLC1 abundance$_{\text{norm}}$ values across all three APs and controls is $r = 0.96$. (C) Immunoblot analysis of APs with the indicated antibodies stained with anti-MLC1 (α-N1; upper) and anti-GlialCAM (lower); lanes resolve aliquots of solubilisate before (S) and after AP (U), of eluates from APs (E), and of corresponding IgG control APs (C). (D) Immunoblots showing specific copurification of MLC1 in an AP with anti-GlialCAM (samples and antibodies labeled as before). “-” indicates no sample was loaded.

Immunofluorescent and Electron Microscopic Studies in Tissue

Tissue immunohistochemistry was performed as previously described.$^5,7$ For electron microscopic (EM) studies, small human cerebellum samples were obtained postmortem, fixed in 4% paraformaldehyde and 0.1% glutaraldehyde in 0.12 M phosphate buffer, and processed. They were cryoprotected gradually in sucrose and cryofixed by immersion in liquid propane. Freeze substitution was performed at $-90^\circ C$ during 3 days in an Automatic Freeze Substitution System (AFS, Leica); methanol containing 0.5% uranyl acetate was used as a substitution medium. Infiltration was carried out in Lowicryl HM20 at $-50^\circ C$ and then polymerized with UV lamps. Ultrathin sections were collected and processed for
postembedding immunostaining. For double immunostaining, grids were incubated with rabbit anti-N4-human MLC1 (1:10) and mouse anti-GliaCAM (1:10) antisera. The binding of primary antibodies was visualized by incubating with goat anti-rabbit or goat anti-mouse secondary antibodies conjugated to either 12 or 18 nm gold particles (British BioCell, International). In control experiments, the primary antibodies were omitted—no immunogold labeling occurred under these conditions.

Primary Culture and Adenoviral Transduction
Rat primary astrocytes were prepared as described previously with some modifications. Cortex and hippocampus were removed from newborn (1 to 3 days old) Sprague Dawely rats (Charles River). Cerebral cortices were dissected and the meninges were carefully removed in cold sterile 0.3% BSA and 0.6% glucose in PBS. The tissue was trypsinized for 10 min at 37°C and mechanically dissociated in complete Dulbecco’s modified Eagle’s medium (DMEM; with 10% heat-inactivated fetal bovine serum [Biological Industries], 1% penicillin/streptomycin [Invitrogen] and 1% glutamine [Invitrogen] plus 40 U/ml DNase I [Sigma]) through a small bore fire-polished Pasteur pipette. The cell suspension was pelleted and resuspended in fresh complete DMEM, filtered through a 100-μm nylon membrane (BD Falcon) and plated into 75 cm² cell-culture flasks (TPP). When the mixed glial cells reached confluence, contaminating microglia, oligodendrocytes, and precursor cells were dislodged by mechanical agitation and removed as previously described.

Astrocytes were plated in 6-well plates at a density of 4 × 10⁵ cells per well or in poly-D-lysine-coated coverslips at 7.5 × 10⁴ cells per 24-well plate. Medium was changed every 3 days. To increase the expression of MLC1 and GliaCAM detection at the plasma membrane (data not shown), we arrested astrocytic cultures in the cell cycle by addition of 2 μM cytosine β-D-arabinofuranoside (AraC, Sigma). Cultured astrocytes were identified by their positive GFAP staining (Dako).

Construction of adenovirus expressing wild-type HA-tagged human MLC1 has been described. In a similar manner, we constructed and produced adenoviruses expressing three copies of the flag epitope fused to wild-type human GliaCAM or to human GliaCAM containing either the recessive mutations p.Arg92Gln, p.Arg98Cys, and p.Ser1967yr or the dominant mutations p.Arg92Trp and p.Gly89Asp.

To infect astrocytes, we added adenoviruses at multiplicity of infection (MOI) 3 and kept them overnight at 37°C. Cells were washed, and then fresh medium was added. Astrocytes were incubated at 37°C until they were processed.

Results

MLC1-Interacting Proteins
We used a method of quantitative proteomic analysis of affinity-purified MLC1 to identify candidate genes for MLC. Independent affinity-purification experiments with MLC1 were performed with solubilized brain membranes and three different antibodies directed against peptides from the MLC1 N terminus (Figure 1A). Protein abundance determined by quantitative mass spectrometry identified HepaCAM, more correctly called GliaCAM, as the protein with the second highest yield (after MLC1) in all purifications (Figure 1B and Figure S2A). Immunoblots with antibodies against GliaCAM (Figure S3) demonstrated that the protein was present in all purifications with all different MLC1 antibodies (Figure 1C). Not all GliaCAM coimmunoprecipitated with MLC1 (Figure 1C), possibly because not all GliaCAM is associated with MLC1 or because the coassembly dissolves during membrane protein solubilization. We confirmed the interaction between GliaCAM and MLC1 in reverse affinity purification experiments by using an antibody against GliaCAM that specifically coimmunoprecipitated GliaCAM and MLC1 from brain membranes. In the reverse purification, nearly all MLC1 was associated with GliaCAM (Figure 1D). Coimmunoprecipitation experiments with extracts from cells transfected with both genes also showed positive interaction (Figure S2B), indicating a direct interaction between the proteins. These findings made HepaCAM an excellent candidate gene for MLC patients without MLC1 mutations.

HEPACAM Mutations in MLC Patients without MLC1 Mutations
We analyzed the exons and surrounding intronic regions of HEPACAM in 40 patients from 34 families from around the world. In ten patients from eight families, we found two HEPACAM mutations (Table 1). Sequence analysis of HEPACAM in the parents showed autosomal-recessive inheritance of the two mutations in all cases except for one family with a de novo mutation. None of the patients had two mutations that abrogate expression of GliaCAM. In 18 patients from 16 families, we found one HEPACAM mutation, which was either inherited from a parent or arose de novo (Table 1). In 12 patients from ten families, we did not find HEPACAM mutations.

The observed nucleotide changes in HEPACAM are most likely pathogenic. They were not observed in 400 control chromosomes. All missense mutations affect amino acids that are conserved across a wide range of species (Figure 2B). Nine missense mutations affect amino acids in the predicted immunoglobulin domains in the extracellular part of GliaCAM (Figures 2A and 2C). p.Pro148Ser affects a residue between the two immunoglobulin domains. All these amino acid substitutions are predicted to affect protein function (SIFT). The substitution of residue Leu23 by His is predicted to affect the signal peptide, which spans the first 33 amino acids (SignalP 3.0 Server). Patient EL775 had two missense mutations, both inherited from the father. p.Asp128Asn is probably the pathogenic mutation because it is also observed in patients EL158 and EL708.

In 12 patients from ten families, neither MLC1 nor HEPACAM mutations were found. In these families, we could not exclude linkage with both the MLC1 and HEPACAM loci with certainty (data not shown). The possibility of hidden MLC1 or HEPACAM mutations cannot, therefore, be excluded, and it is not certain that there must be a third gene mutated in MLC.
Inheritance, Phenotypes, and Mutations

All ten patients with two HEPACAM mutations inherited in an autosomal-recessive fashion had the classical phenotype (Table S2). They had infantile-onset macrocephaly and delayed-onset motor deterioration, epilepsy, and cognitive decline of variable severity. The MRI showed typical white matter abnormalities in all stages of the disease (Figure S1). The parents were normal, but two of the 16 had macrocephaly (Table 1).

All 18 patients with one HEPACAM mutation had the improving phenotype (Table S3). They developed macrocephaly within the first year. In two of the 18, the head circumference subsequently normalized. The motor capabilities became normal or almost normal. Some patients had normal intelligence, and others, with intelligence quotients (IQs) between 50 and 75, had a stable mental retardation. Three of the mentally retarded patients also had autism or pervasive developmental disorder not otherwise specified according to DSM IV criteria. In summary, 11 of the 18 patients became clinically normal, apart from macrocephaly. MRI initially showed typical abnormalities but, on follow up, major improvement or normalization (Figure S1). For 13 patients from 11 families, eight of the 11 parents with the mutated allele had macrocephaly; one had transient macrocephaly as a child, and two never had macrocephaly as far as they could remember. Regarding the five remaining patients, the HEPACAM mutation arose de novo in three, and their parents had normal head circumference; DNA of the parents was not available in two. Only one of the parents without the mutated allele had macrocephaly. The family data suggest autosomal-dominant inheritance for the single HEPACAM mutations with variable penetrance. An analysis of microsatellite markers near HEPACAM in the families with the two most common dominant mutations (p.Gly89Ser and p.Arg92Trp) revealed no shared haplotype, excluding the possibility of founder effects for these two mutations (data not shown).

The HEPACAM mutations were either recessive or dominant. The recessive mutations were spread over the extracellular region of GlialCAM, whereas the dominant mutations were clustered in one of the predicted immunoglobulin-like domains (Figure 2C). Molecular modeling of the extracellular domain of GlialCAM showed that dominant mutations are located in a putative interface of the first immunoglobulin domain (Figure 2D).

GlialCAM-MLC1 Interaction

Immunohistochemistry of human brain tissue demonstrated GlialCAM expression mainly around blood vessels (Figure 3 and Figure S3). Double immunostaining with a monoclonal antibody against GlialCAM and a polyclonal antibody against human MLC113 showed that MLC1 and GlialCAM colocalize at astrocytic end-feet (Figure 3A). Immunogold EM confirmed this colocalization in astrocyte-astrocyte junctions (Figure 3B).

GlialCAM mRNA and protein have been detected in oligodendrocytes, astrocytes,18 and neurons19 (Figure S3), whereas MLC1 has not been detected in oligodendrocytes.5–7,20 In MLC, vacuolation mainly affects the outer layers of myelin sheaths.2 We investigated whether GlialCAM is localized in myelin. EM immunogold revealed

### Table 1. HEPACAM Mutations

<table>
<thead>
<tr>
<th>Patient</th>
<th>Exon</th>
<th>DNA</th>
<th>Protein</th>
<th>P/M/de novo*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Two Mutations</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EL84/85</td>
<td>3</td>
<td>c.587C&gt;A</td>
<td>p.Ser196Tyr</td>
<td>P⁵</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>c.798G&gt;A</td>
<td>p.Trp263X</td>
<td>M</td>
</tr>
<tr>
<td>EL106</td>
<td>3</td>
<td>c.580delC, 582C&gt;T (hom)</td>
<td>p.Leu194ProfsX60</td>
<td>P + M</td>
</tr>
<tr>
<td>EL125</td>
<td>3</td>
<td>c.442C&gt;T (hom)</td>
<td>p.Pro148Ser</td>
<td>P + M</td>
</tr>
<tr>
<td>EL726</td>
<td>2</td>
<td>c.275G&gt;A</td>
<td>p.Arg92Gln</td>
<td>P</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>p.631G&gt;A</td>
<td>p.Asp211Asn</td>
<td>M</td>
</tr>
<tr>
<td>EL774</td>
<td>2</td>
<td>c.292C&gt;T (hom)</td>
<td>p.Arg98Cys</td>
<td>-⁵</td>
</tr>
<tr>
<td>EL785</td>
<td>1</td>
<td>c.68T&gt;A</td>
<td>p.Leu23His</td>
<td>de novo</td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>c.461_462del</td>
<td>p.Ser154TrpfsX16</td>
<td>P¹</td>
</tr>
<tr>
<td>EL816</td>
<td>3</td>
<td>c.442C&gt;T (hom)</td>
<td>p.Pro148Ser</td>
<td>P + M</td>
</tr>
<tr>
<td>EL889/890</td>
<td>2</td>
<td>c.292C&gt;T (hom)</td>
<td>p.Arg98Cys</td>
<td>P + M</td>
</tr>
<tr>
<td><strong>One Mutation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EL128</td>
<td>2</td>
<td>c.265G&gt;A</td>
<td>p.Gly89Ser</td>
<td>de novo</td>
</tr>
<tr>
<td>EL158</td>
<td>2</td>
<td>c.382G&gt;A</td>
<td>p.Asp128Asn</td>
<td>P⁵</td>
</tr>
<tr>
<td>EL604</td>
<td>2</td>
<td>c.265G&gt;A</td>
<td>p.Gly89Ser</td>
<td>P</td>
</tr>
<tr>
<td>EL611</td>
<td>2</td>
<td>c.274C&gt;T</td>
<td>p.Arg92Trp</td>
<td>M</td>
</tr>
<tr>
<td>EL624/625</td>
<td>2</td>
<td>c.274C&gt;T</td>
<td>p.Arg92Trp</td>
<td>M</td>
</tr>
<tr>
<td>EL683/684</td>
<td>2</td>
<td>c.265G&gt;A</td>
<td>p.Gly89Ser</td>
<td>P</td>
</tr>
<tr>
<td>EL686</td>
<td>2</td>
<td>c.266G&gt;A</td>
<td>p.Gly89Asp</td>
<td>P</td>
</tr>
<tr>
<td>EL700</td>
<td>2</td>
<td>c.274C&gt;T</td>
<td>p.Arg92Trp</td>
<td>–</td>
</tr>
<tr>
<td>EL708</td>
<td>2</td>
<td>c.382G&gt;A</td>
<td>p.Asp128Asn</td>
<td>–</td>
</tr>
<tr>
<td>EL743</td>
<td>2</td>
<td>c.274C&gt;T</td>
<td>p.Arg92Trp</td>
<td>M</td>
</tr>
<tr>
<td>EL775</td>
<td>2</td>
<td>c.382G&gt;A</td>
<td>p.Asp128Asn</td>
<td>P⁵</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>c.862C&gt;T</td>
<td>p.Arg288Cys</td>
<td>P⁵</td>
</tr>
<tr>
<td>EL847</td>
<td>2</td>
<td>c.404_406del</td>
<td>p.Lys135del</td>
<td>P</td>
</tr>
<tr>
<td>EL862</td>
<td>2</td>
<td>c.265G&gt;A</td>
<td>p.Gly89Ser</td>
<td>M</td>
</tr>
<tr>
<td>EL882</td>
<td>2</td>
<td>c.265G&gt;A</td>
<td>p.Gly89Ser</td>
<td>de novo</td>
</tr>
<tr>
<td>EL903</td>
<td>2</td>
<td>c.265G&gt;A</td>
<td>p.Gly89Ser</td>
<td>M⁵</td>
</tr>
<tr>
<td>EL944</td>
<td>2</td>
<td>c.274C&gt;T</td>
<td>p.Arg92Trp</td>
<td>de novo</td>
</tr>
</tbody>
</table>

* P, paternal; M, maternal; bold and italic indicates macrocephaly.
*² Probably from father but no DNA available.
*⁵ No DNA of the parents available.
*⁶ Both changes from same parental allele.
*⁷ Transient macrocephaly.
particles inside axons, in contact regions between myelin and axons, and surrounding myelin (arrows in Figure 3C). In human medulla oblongata sections, where axons and myelin can be observed easily, immunostainings combining antibodies against GlialCAM with antibodies against neurofilament heavy chain (NF-H) or myelin basic protein (MBP) demonstrated that GlialCAM and NF-H staining coincide in axons (Figures 3D and 3E) and that not only is GlialCAM observed on the outside of myelin sheaths (inset in Figure 3E), but there is also a weak colocalization with MBP in myelin (Figure 3F). Classical biochemical fractionation protocols to purify myelin14 and immunoblotting to detect specific proteins revealed GlialCAM but not MLC1 in the myelin fraction (Figure 3G).

The effect of mutations located in the extracellular domain of GlialCAM was studied in cultures of primary astrocytes, the cell type with the highest natural abundance of both MLC1 and GlialCAM. After adeno- viral mediated expression, lysates of astrocytes were analyzed by immunoblot and immunofluorescence. Expression levels of all types of mutant GlialCAM were not statistically different from wild-type GlialCAM (Figure S4). Immunofluorescence revealed that MLC1 and GlialCAM are located in cell-cell junctions between astrocytes (Figure 4A). Coexpression of wild-type MLC1 and GlialCAM containing the recessive mutations p.Arg92Gln or p.Arg98Cys resulted in diffuse intracellular MLC1 and GlialCAM localization with partial enrichment in cell membranes but not specifically in cell junctions (Figure 4B and Figure S5A). No defect.
was found for the mutation p.Ser196Tyr (Figure S5C). Similar mislocalization of MLC1 and GlialCAM was observed after coexpression of wild-type MLC1 and GlialCAM containing the dominant mutations p.Arg92Trp and p.Gly89Asp (Figures 4D and Figure S5D).

To address the mode of inheritance of the mutations biochemically, we performed experiments with equal levels of wild-type GlialCAM and GlialCAM containing a dominant or recessive mutation together with MLC1. The localization of MLC1 and GlialCAM was analyzed by immunofluorescence. Coexpression of wild-type GlialCAM rescued the MLC1-trafficking defect caused by the...
by GlialCAM with recessive mutations (Figures 4C and 4F and Figure S5B) but did not rescue the trafficking defect caused by GlialCAM with dominant mutations (Figures 4E and 4F and Figure S5E). No difference in protein levels was observed between the mutants and the wild-type (Figure S4), making it unlikely that the trafficking defect is due to gene-dosage effects.

Discussion

The leukodystrophy MLC is characterized by infantile-onset macrocephaly and delayed neurological deterioration. The diagnosis is based on MRI criteria. In 2001, causative mutations of MLC were identified in MLC1, accounting for approximately 75% of the patients. The fact that genetic-linkage studies failed to identify a second gene was ascribed to further genetic heterogeneity. We recently identified two presumably autosomal recessive, phenotypes among MLC patients without MLC1 mutations, corroborating the notion of genetic heterogeneity. We now show that the genetic heterogeneity does not involve the gene but the mode of inheritance. We circumvented the problem of genetic heterogeneity by using a proteomic approach. This method is validated by the discovery of HEPACAM (hepatic and glial cell adhesion molecule, MIM 611642) as a gene disrupted in MLC and...
can be considered in the future to identify disease genes for other rare or genetically heterogeneous disorders.

We prefer the name GlialCAM above HepaCAM for the related protein. Although the protein was first isolated from liver and called HepaCAM, it was subsequently found to be predominantly expressed in the central nervous system and was renamed GlialCAM. In the present paper, we show that mutations in HEPAIRCAM lead to a neurological phenotype without any sign of liver involvement.

That mutations in one gene cause both autosomal-recessive and -dominant disease is rare but not unique. It has been described for a few other genes, including LMNA (MIM 150330), SOX18 (MIM 601618), ANKI (MIM 612641), COL6A1 (MIM 120220), PMP22 (MIM 601097), and MPZ (MIM 159440). However, patients with the dominant mutations in these genes do not display an improving phenotype, as seen in our MLC patients with dominant HEPAIRCAM mutations. In MLC, the macrocephaly and cerebral white-matter disease on MRI arise in the first year of life, the period of most rapid myelin deposition in the brain. Apparently, MLC1 and GlialCAM exert their most important function during this process. The functions of both MLC1 and GlialCAM are unknown. We, therefore, do not understand the mechanism of the improving phenotype for the dominant HEPAIRCAM mutations. A hypothetical gene-dose effect is not supported by the finding that normal GlialCAM does not partially rescue the localization of the GlialCAM-MLC1 complex in astrocytes expressing a dominant HEPAIRCAM mutation. The dominant mutations are located in a putative pocket of the immunoglobulin domain and might disrupt interactions with GlialCAM itself and other unknown molecules.

GlialCAM acts as a MLC1 beta subunit needed for its correct trafficking to cell-cell junctions. Probably, cis- or trans-interactions mediated by GlialCAM are necessary for its correct localization. The function of GlialCAM as an adhesion molecule suggests that both GlialCAM and MLC1 have a role in the maintenance of correctly sealed cell-cell contacts. Interestingly, GlialCAM and not MLC1 is detected in myelin, the place where most vacuoles are found in MLC. GlialCAM is not obligatorily associated with MLC1, indicating that it might have other functions by itself or in association with other molecules. Recently, it has been suggested that MLC1 interacts with the β1 subunit of the Na,K-ATPase pump. We did not detect this protein in our affinity purifications. Further studies on MLC1-interacting proteins might provide better insights into the pathophysiology of MLC.

GlialCAM is an interesting protein. In 60% of the families with dominant HEPAIRCAM mutations, the affected persons in fact display benign familial macrocephaly (MIM 153470). They have macrocephaly, but they are otherwise normal. MRI shows large but normal brains. The parents did not undergo MRI as children, and a transient leukoencephalopathy was not documented in any of them. Benign familial macrocephaly is most likely genetically heterogeneous, and HEPAIRCAM is likely to be one of the related genes. Another interesting finding is that in 40% of the patients with a dominant HEPAIRCAM mutation, macrocephaly, and mental retardation with or without autism, which are known to be associated features, persist. This clinical syndrome is probably genetically heterogeneous, and specific HEPAIRCAM mutations could cause it. The fact that single HEPAIRCAM mutations might be associated with different phenotypes requires the geneticist to be cautious when counseling an affected family. From the age of approximately 2–3 years, the combination of clinical picture and MRI findings allows an accurate prediction of the phenotype.

In conclusion, we have found that HEPAIRCAM is mutated in MLC. Recession mutations cause a progressive leukodystrophy that is indistinguishable clinically and by MRI from the disease caused by recessive MLC1 mutations. Dominant mutations can cause transient clinical and MRI features of MLC, benign familial macrocephaly, and the clinical syndrome of macrocephaly and mental retardation with or without autism.

Supplemental Data

Supplemental Data include five figures and three tables and can be found with this article online at http://www.cell.com/AJHG/.

Acknowledgments

Research in our laboratories was supported by Ministerio de Ciencia y Tecnología (SAF) 2009-07014 (R.E.), Fundación Ramon Areces project (R.E.), European Leukodystrophy Association Foundation 2007-017C4 project (R.E. and M.S.v.d.K.), PS09/02672-ERARE (R.E.), ERARE grant 11-330-1024 (G.C.S. and M.S.v.d.K.), 2009 Grups de Recerca de Catalunya 719 (R.E.), SAF 2009-12606-C02-02 (V.N.), CIBERER INTRA08/750 (R.E. and V.N.), and 2009 SGR01490 (V.N.). M.S.v.d.K., G.C.S., and M.C.R. are supported by the Dutch Organization for Scientific Research ZonMw (TOP Grant 9120.6002), the Herenstichting (Grants 13F05.04, 15F07.30 and 2009[2]-14), and the Optimix Foundation for Scientific Research. R.E. is a recipient of an ICREA Academia prize. We thank all colleagues who contributed MRI, clinical information, and blood samples. We thank Alejandro Barrallo, Michael Pusch, and Jim M. Powers for critical review of the manuscript.

Received: December 7, 2010
Revised: January 12, 2011
Accepted: February 21, 2011
Published online: March 17, 2011

Web Resources

The URLs for data presented herein are as follows:

- SIFT, http://sift.jcvi.org/
References


Molecular mechanisms of MLC1 and GLIALCAM mutations in Megalencephalic Leukoencephalopathy with subcortical cysts

(Human Molecular Genetics, 2011)

Contribució:

- Construcció de la mutació de MLC1 S69L
- Estudis bioquímics in vitro de la mutació de MLC1 S69L (Figura 2)
- Anàlisis de MLC1 i GlialCAM en el teixit de la pacient (Figura 3)
Molecular mechanisms of MLC1 and GLIALCAM mutations in megalencephalic leukoencephalopathy with subcortical cysts

Tania López-Hernández1,†, Sonia Sirisi1,5,†, Xavier Capdevila-Nortes1, Marisol Montolio1,6, Victor Fernández-Dueñas3, Gert C. Schepers8, Marjo S. van der Knaap8, Pilar Casquero9, Francisco Ciruela3, Isidre Ferrer4,10, Virginia Nunes2,5,7 and Raúl Estévez1,6,*

1Sección de Fisiología, 2Sección de Genética, Departamento de Ciencias Fisiológicas II, 3Unidad de Farmacología, Departament Patologia i Terapèutica Experimental, Facultat de Medicina and 4Institut Neuropatologia, Servei Anatomia Patològica, Idiell-Hospital Universitari de Bellvitge, Hospitallet de Llobregat, Barcelona, Barcelona, Spain, 5Laboratorio de Genética Molecular-IDIBELL, Centro de Investigación en Red de Enfermedades raras (CIBERER), Barcelona, Spain, 6U-750 and 7U-730: ISCIII, Valencia, Spain, 8Department of Child Neurology, VU University Medical Center, Amsterdam, The Netherlands, 9Sección de Neurología, Hospital Mateu Orfila, Maó, Menorca, Spain and 10CIBERNED (Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas), ISCIII, Barcelona, Spain

Received April 12, 2011; Revised and Accepted May 22, 2011

Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare leukodystrophy caused by mutations in MLC1 or GLIALCAM. The GLIALCAM gene product functions as an MLC1 beta-subunit. We aim to further clarify the molecular mechanisms of MLC caused by mutations in MLC1 or GLIALCAM. For this purpose, we analyzed a human post-mortem brain obtained from an MLC patient, who was homozygous for a missense mutation (S69L) in MLC1. We showed that this mutation affects the stability of MLC1 in vitro and reduces MLC1 protein levels in the brain to almost undetectable. However, the amount of GlialCAM and its localization were nearly unaffected, indicating that MLC1 is not necessary for GlialCAM expression or targeting. These findings were supported by experiments in primary astrocytes and in heterologous cells. In addition, we demonstrated that MLC1 and GlialCAM form homo- and hetero-complexes and that MLC-causing mutations in GLIALCAM mainly reduce the formation of GlialCAM homo-complexes, leading to a defect in the trafficking of GlialCAM alone to cell junctions. GLIALCAM mutations also affect the trafficking of its associated molecule MLC1, explaining why GLIALCAM and MLC1 mutations lead to the same disease: MLC.

INTRODUCTION

Megalencephalic leukoencephalopathy with subcortical cysts (MLC, OMIM 604004) is a rare type of leukodystrophy (1), characterized by macrocephaly which appears during the first year of life. After several years, slow neurological deterioration with cerebellar ataxia and spasticity occurs. MRI reveals diffuse signal abnormality and swelling of the cerebral white matter and the presence of subcortical cysts, mainly in the anterior temporal regions. Initial studies of a brain biopsy from an MLC patient showed that myelin is vacuolated (2). The first disease gene, named MLC1, was identified in 2001 (3). Mutations in MLC1 have been identified in ~75% of the MLC patients (4).

MLC1 is an oligomeric membrane protein that is expressed mainly in the brain and in white blood cells (WBCs) (3,5). Within the brain, MLC1 is predominantly located in astrocyte–astrocyte junctions close to blood– and CSF–
brain barriers, Bergmann glia and main axonal tracts (6–8). Knockdown of MLC1 in astrocyte cultures causes vacuolation (9). In a similar manner, re-examination of the brain biopsy from an MLC patient (2) revealed that vacuoles are also consistently present in astrocytic endfeet (9). A role of MLC1 in volume regulation of astrocytes has been suggested based on changes in its localization in hypo-osmotic conditions (10). However, functional data indicating the role of MLC1 are lacking.

Genetic information suggested that at least one other gene is involved in MLC (11,12), but genetic linkage studies and studies of candidate genes were negative (13). Recently, two different phenotypes were described among MLC patients without MLC1 mutations: a classical phenotype which retains the typical clinical and MRI features, as seen in patients with MLC1 mutations, and an improving phenotype which shows transient MLC features and lacks clinical deterioration (14).

Quantitative proteomic analysis of affinity-purified MLC1 revealed that GlialCAM (15) interacts directly with MLC1. GlialCAM is an Ig-like protein of unknown function (15,16). It was shown that GLIALCAM, also called HEPACAM, is the second MLC gene (17). Interestingly, MLC-causing GLIALCAM mutations are inherited in a recessive manner in patients with the classical phenotype, and in a dominant manner in patients with the improving phenotype (17).

Missense mutations in MLC1 reduce MLC1 protein expression in vitro (5,18,19) and in vivo, as shown in WBCs (19), although no data are available from brain tissue of MLC patients with missense mutations. Studies in primary astrocytes indicate that most GLIALCAM mutations disrupt the normal localization of MLC1 and GlialCAM in astrocyte–astrocyte junctions (17), suggesting that their localization is crucial for physiological function.

In the present work, we present a more detailed characterization of the effect of mutations found in MLC1 and GLIALCAM. The availability of a brain obtained at autopsy from an MLC patient homozygous for an MLC1 missense mutation greatly facilitated our studies.

RESULTS

Studies on brain samples of an MLC patient

The patient studied was a female who developed a macrocephaly within the first few months of life and after several years experienced a slow motor deterioration, epilepsy and cognitive decline (Fig. 1A). MRI imaging at the age of 40 years [control (Fig. 1B) versus patient (Fig. 1C)] showed diffuse signal abnormalities in the cerebral white matter, with global atrophy and presence of subcortical cysts in the anterior temporal region, indicative of MLC. Analysis of the MLC1 gene showed that the patient is homozygous for the mutation c.206C>T. The mutation leads to an amino acid change (S69L) in the predicted first transmembrane domain (Fig. 1D). DNA of the parents was not available to confirm that they both carry the same mutation. The amino acid change affects a residue that is highly conserved among different species. It has not been observed in 400 control chromosomes and it was detected in other patients with MLC (4), indicating that the mutation is most likely pathogenic. The patient died at the age of 57 years following a...
cranial trauma. With the consent of the family, brain autopsy was performed.

Gross examination of the brain revealed reduced cerebral white matter with cavitation in the frontal and parietal lobes (Fig. 1E). Subcortical U-fibers, internal capsule, corpus callosum, anterior commissure and optic nerves and tracts were better preserved. The cerebellar peduncles and cerebellar white matter appeared normal. Myelin stains confirmed the predominant involvement of the deep cerebral white matter with better preservation of the other white matter structures (Fig. 1F).

Microscopic examination (Supplementary Material, Fig. S1) revealed preservation of the cerebral cortex and alterations limited to the white matter. These alterations consisted of lack of myelin of the deep white matter with cavitation in the most affected areas, reduction in the number of astrocytes and oligodendrocytes and accompanying loss of axons. Many astrocytes in the white matter lacking myelin and in the vicinity of cavities contained αB-crystallin, a stress protein. Rosenthal fibers were absent. Large numbers of corpora amylacea were found in the damaged white matter. Small and focal perivascular lymphocytes and macrophages were indicative of white matter damage (Supplementary Material, Fig. S1). We conclude that the degeneration and the infiltration of immune system cells observed in the MLC brain from the patient are mild.

In vitro studies of the mutation identified in the patient

We introduced the mutation S69L in human MLC1 containing two HA epitope tags, as already described (5). The first tag at the N-terminus allows detection by western blot and the second tag, which is located in an extracellular loop, allows detection of surface-expressed protein. Localization was assayed in HeLa cells after co-transfection with the GFP-tagged pleckstrin homology (PH) domain of the phospholipase C δ1 (PH-GFP), a fluorescent protein probe that specifically labels the plasma membrane. Wild-type MLC1 was mainly detected at the plasma membrane (Fig. 2A), co-localizing with...
PH-GFP. In contrast, the S69L-MLC1-defective protein was almost exclusively detected in intracellular compartments (Fig. 2B). Surface expression levels of the defective protein were quantified using a luminescence-based method, which indicated that the defective protein had a reduced surface expression (Fig. 2C). In other MLC1 proteins containing MLC-causing mutations, it was shown that increased endoplasmatic reticulum-associated degradation (ERAD) and endo-lysosomal-associated degradation (ELAD) contributed to the cell surface expression defect (19).

In these MLC1 pathogenic variants, reduced surface expression was a consequence of reduced stability (19). We therefore studied the protein stability of this variant in comparison with the wild-type protein, by measuring the remaining protein after incubation with the protein synthesis inhibitor cycloheximide (CHX) (Fig. 2D). Similarly, a reduced stability was detected for the defective S69L MLC1 protein. We also tested whether the stability of the wild-type and the defective protein S69L-MLC1 was altered by the co-expression of GlialCAM (Fig. 2D). The results showed that the S69L protein was stabilized by the presence of the GlialCAM molecule, but the defective protein still remained less stable than the wild-type (Fig. 2D).

Expression studies of MLC1 and GlialCAM in the patient brain

With brain tissue from the MLC patient, we validated the in vitro results in native tissue. No apparent MLC1 protein signal was detected by western blot in cell lysates from different brain regions from the patient, whereas MLC1 was clearly detected in a control case (Fig. 3A). In the control brain, MLC1 immunoreactivity was found in astrocytic processes surrounding blood vessels (Fig. 3B). In contrast, no MLC1 immunostaining was detected in the brain from the MLC patient (Fig. 3C).

Similar experiments were performed for GlialCAM (17). Western blot experiments detected expression in the MLC patient (Fig. 3D). Quantification of GlialCAM levels in three independent experiments revealed a 40% decrease versus the control brain. However, it cannot be concluded that its expression was changed compared with the control case, as the post-mortem time differs. Immunohistochemistry detected GlialCAM in astrocytic processes surrounding blood vessels, and subventricular and subpial astrocytes in the control case [Fig. 3E and (17)] and in the brain of the MLC patient.

Expression of GlialCAM in primary astrocytes depleted of MLC1 by RNA interference

We investigated the expression and localization of GlialCAM in primary cultures of astrocytes, which have been depleted of MLC1 by RNA interference (Fig. 4). Although knockdown of MLC1 was nearly complete, as confirmed by western blot, no changes in endogenous GlialCAM protein expression was found compared with control scrambled-shRNA (SCR)-infected astrocytes (Fig. 4A). GlialCAM was detected in astrocyte–astrocyte processes in both SCR-transduced (Fig. 4B) and MLC1-depleted astrocytes (shRNA 905) (Fig. 4C). Infection with adenovirus-expressing GlialCAM-flag in MLC1-depleted astrocytes also resulted in GlialCAM localization in astrocyte processes (data not shown). Overall, this result, together with the localization studies in the patient, suggests that the GlialCAM subcellular localization is independent of MLC1 expression.

In vitro characterization of GlialCAM–MLC1 interaction

To further increase our understanding of the relationship between MLC1 and GlialCAM, several studies were done expressing both proteins in heterologous systems. Split-TEV (tobacco etch virus protease) interaction assays (20)
demonstrated that MLC1 homo-oligomerizes, but also hetero-oligomerizes, with GlialCAM (Fig. 5A). As controls, no interaction was detected with the unrelated proteins 4F2hc [a single transmembrane protein as GlialCAM (21)] and with the adenosine A2A receptor [A2AR, a polytopic membrane protein as MLC1 (22)]. In the reverse experiment, GlialCAM homo-oligomerizes, as described earlier (23), and hetero-oligomerizes with MLC1, but does not interact with the control unrelated proteins 4F2hc and A2AR (Fig. 5A).

Additionally, we assessed the formation of MLC1 and GlialCAM hetero-complexes by means of fluorescence resonance energy transfer (FRET) experiments. HEK-293T cells were transiently transfected with MLC1 and GlialCAM tagged with a FlAsH epitope and cyan fluorescent protein (CFP), respectively (MLC1FlAsH and GlialCAM CFP). The GlialCAMCFP/MLC1FlAsH hetero-oligomer formation caused FRET between the fluorescent proteins (Fig. 5B, left panel). Significant FRET was not observed in cells expressing only glialCAMCFP or co-expressing glialCAMCFP with the negative controls YFP and A2ARYFP (Fig. 5B, right panel). Thus, both methods (split-TEV and FRET), together with previously reported co-immunoprecipitation experiments (17), indicate that GlialCAM and MLC1 interact directly, although every method has different sensitivity.

Next, we addressed whether GlialCAM expression modified the surface levels of the MLC1 protein. Using a luminescence-based assay, the levels of MLC1 at the plasma membrane were investigated in transfected cells expressing MLC1 with an extracellular HA epitope, in the presence or absence of GlialCAM. These studies revealed that expression of GlialCAM did not modify MLC1 surface levels (Fig. 5C).

Both MLC1 and GlialCAM were reported to be located in tissue in astrocyte–astrocyte junctions (6,17). In HeLa cells, MLC1 was detected at the plasma membrane [Fig. 5D and (5)], but not particularly enriched in cell junctions, as illustrated by the intensity profile of the associated fluorescence (Fig. 5D, inset). In contrast, GlialCAM expressed alone was clearly detected in most cells in junctions (Fig. 5E, inset), as reported previously (16,23). Interestingly, after co-expression of MLC1 with GlialCAM, both molecules were clearly enriched at cell junctions (Fig. 5F and G). Quantification of intensity profile calculations revealed that both GlialCAM and MLC1 are enriched at cell junctions in the presence of the other, but GlialCAM does not need MLC1 to be located in cell junctions (Fig. 5).

GlialCAM-defective proteins showed a reduced tendency to homo-oligomerize

Next, we aimed to analyze the molecular consequences of MLC-causing GLIALCAM mutations in its oligomerization abilities. Using the split-TEV interaction assay, it was shown that all defective proteins except S196Y had a lower tendency to homo-oligomerize than with the wild-type protein (Fig. 6A).

We subsequently studied whether GlialCAM-defective proteins affected the direct protein–protein interaction with MLC1 (Fig. 6B). Although the recessive pathogenic variants R92Q and R98C showed a reduction in their ability to hetero-oligomerize, the proteins containing the recessive mutation S196Y or the dominant mutations R92W and G89D still retained the capacity to oligomerize with MLC1 at similar levels as the wild-type protein.

GlialCAM-defective proteins show a trafficking defect independent of MLC1

As the mutations mainly affect the ability of GlialCAM to homo-oligomerize, then the question was whether the MLC-causing GLIALCAM mutations would affect the localization of GlialCAM per se.

In HeLa cells, wild-type GlialCAM mainly shows two localization patterns: at the plasma membrane (Fig. 7A) and in junctions (Figs 5E and 7B). Typical examples for different proteins containing recessive and dominant mutations expressed in HeLa cells are shown in Figure 7C–G. Multiple pictures from different experiments were taken and the percentage of cells in which GlialCAM was located either in junctions or not in junctions or intracellularly was quantified for...
each of the variants. As depicted in Figure 7H, GlialCAM-defective proteins showed an altered trafficking compared with wild-type GlialCAM, being located preferentially at the plasma membrane but not in cell junctions. Similar results were found in primary cultures of astrocytes (Supplementary Material, Fig. S2). No defect was observed for the GlialCAM

Figure 5. In vitro characterization of the interaction between MLC1 and GlialCAM. (A) HeLa cells were co-transfected with the indicated constructs, and interaction was monitored by split-TEV assays as described in Materials and Methods. The signal that was obtained for homo-oligomerization of MLC1 (upper panel) or GlialCAM (lower panel) was set to 100%. The result is the summary of five independent experiments. (B) Determination of the MLC1 and GlialCAM association by FRET experiments in living cells. Effect of photobleaching (left panel). Emission intensities of FlAsH (535 nm, green) and CFP (480 nm, blue) recorded from single cells co-expressing MLC1FlAsH and GlialCAMCFP using fluorescence microscopy. Emission intensities were recorded before and after FlAsH (the acceptor fluorophore) was photobleached by 5 min exposure to light at 500 nm. FRET efficiency (right panel) from cells expressing: GlialCAMCFP (n = 6), GlialCAMCFP and YFP (n = 6), GlialCAMCFP and A2ARYFP (n = 6), and GlialCAMCFP and MLC1FlAsH (n = 10); data indicate mean ± SEM and the double-asterisk indicates statistically significant differences (P < 0.01; Student’s t-test). (C) HeLa cells were transfected with wild-type MLC1 with HA tags or wild-type MLC1 together with GlialCAM. Plasma membrane levels were measured using a luminescence-based method, as described in Materials and Methods. Data correspond to the average of three experiments. (D–G) HeLa cells were transfected with plasmids expressing wild-type MLC1 (D), wild-type GlialCAM flag-tagged (E) or wild-type MLC1 plus wild-type GlialCAM flag-tagged (F and G). Cells were fixed and permeabilized and then immunofluorescence was performed using rabbit polyclonal antibodies against human MLC1 and flag monoclonal antibodies detecting GlialCAM protein. Scale bar: 20 µm. Pairs of cells were analyzed performing an intensity profile through the indicated white dashed line. The result of this profile is shown as an inset in every case. The analysis revealed that MLC1 alone had an R-value (see Materials and Methods) of 1.08 ± 0.06 (n = 45), and MLC1 in the presence of GlialCAM had a value of 3.95 ± 0.06 (n = 42). On the other hand, GlialCAM alone had a value of 2.43 ± 0.15 (n = 44), and GlialCAM in the presence of MLC1 had a value of 3.99 ± 0.23 (n = 42).
are also difficult to estimate due to the high intrafamilial variability of each patient. Possible genotype–phenotype correlations between protein expression and the phenotype was undetectable in the brain of the patient. The lack of expression of MLC patient to our knowledge. However, MLC1 protein was reconfirmed by the present studies on brain tissue from an MLC patient.

This hypothesis has been described in Materials and Methods. The signal that was obtained for homooligomerization of wild-type GlialCAM (upper panel) or the heterooligomerization of MLC1 and wild-type GlialCAM (lower panel) was set to 100%. Bars indicate the percentage of interaction compared with the interaction between the corresponding wild-type proteins ± SEM. The result is the summary of five independent experiments. Bonferroni’s multiple comparison test was used. *P < 0.05; **P < 0.01; ***P < 0.001. ns, no significant difference. Statistical significance was probably minor in the heteromeric interaction (MLC1–GlialCAM) compared with the homomeric interaction (GlialCAM–GlialCAM), as the fold signal induction in the split-TEV assays was higher in the homomeric studies.

We investigated whether the localization of MLC1 in junctions when co-expressed in HeLa cells with GlialCAM was altered by the mutations in GLIALCAM. We found that MLC1 was also mislocalized (Fig. 8) in all studied GlialCAM-defective proteins, except the S196Y variant.

**DISCUSSION**

Studies on MLC1 missense mutations indicate that a deficiency of cell-surface MLC1 protein expression is the molecular basis of MLC disease (19). This hypothesis has been reconfirmed by the present studies on brain tissue from an MLC patient.

Interestingly, the MLC patient studied here was the oldest MLC patient to our knowledge. However, MLC1 protein was undetectable in the brain of the patient. The lack of detailed clinical data for all the MLC patients limits possible correlations between protein expression and the phenotype of each patient. Possible genotype–phenotype correlations are also difficult to estimate due to the high intrafamilial phenotypic variability (24), the slow progression of the disease and the fact that the disease phenotype may worsen abruptly after trauma or infections. We conclude that, in MLC disease, no correlation can be established between the cellular or clinical phenotype and the genotype. Probably, unknown modifier factors could influence the phenotype.

GlialCAM was identified as a beta-subunit of MLC1 (17). The present work defines the role of GlialCAM as an escort molecule, necessary to bring MLC1 to cell–cell junctions.

In the MLC patient and in astrocytes depleted of MLC1 by RNA interference, the expression and localization of GlialCAM are independent of MLC1. GlialCAM molecules may form complex structures involving homo-cis, hetero-cis and trans-interactions with itself and with other molecules (25,26). Here, we show that recessive and dominant GLIALCAM mutations affect mainly the formation of homooligomeric structures, leading to a trafficking defect. An exception is the S196Y protein variant, for which we have not found any defect. Collectively, the results presented here indicate a direct correlation between the GlialCAM homooligomerization and the subcellular localization of this protein in cellular junctions, suggesting that GlialCAM homo-oligomerization is a prerequisite for correct targeting. Defective GlialCAM–MLC1 hetero-oligomerization is differentially affected by several GLIALCAM mutations, but it could also contribute to the trafficking defect of MLC1, as MLC1 alone is not able to reach cell–cell junctions.

At present, we do not understand why some mutations behave as recessive and others as dominant. As all dominant mutations identified so far are located in a putative pocket of the immunoglobulin variable domain (17), we could speculate that these mutations may affect trans-interactions between GlialCAM molecules or other unknown proteins, although experimental evidence is lacking.

GlialCAM protein has been also identified as a molecule with a role in cell growth, differentiation, motility and adhesion in various cell types (15,16,23,27–30). It could be suggested that these functions of GlialCAM are affected in MLC patients. Whether MLC1 cooperates with GlialCAM in these functions needs to be explored. The biology of the GlialCAM protein could facilitate the understanding of other discoveries that have been obtained about the cell biology of MLC1. For instance, MLC1 was reported to be associated with caveolin (31), and GlialCAM was shown to be associated with caveolin 1 (32). Furthermore, localization of MLC1 in astrocytes was found to be dependent on the actin cytoskeleton (9), whereas GlialCAM was also shown to have a direct interaction with actin (28). Whether the oligomerization state of GlialCAM molecules is necessary for interaction with intracellular complexes which may be important for its localization in cell junctions is an interesting hypothesis that should be tested. In this sense, affinity purification studies revealed co-immunoprecipitation between MLC1 and the junction-associated protein ZO-1 (9).

In summary, this work offers new interesting clues about the pathogenic mechanism of MLC1 and GLIALCAM mutations. We have shown that the MLC1 protein containing the S69L mutation can be stabilized by the presence of GlialCAM. Probably, GlialCAM increase the stability of the defective protein by protecting from the ERAD or the ELAD mechanisms. These data suggest that a therapeutical strategy aimed
at the over-expression of GlialCAM may be beneficial to improve the surface expression of MLC1 protein variants containing MLC-causing mutations, which could be envisaged as new therapies to MLC patients.

MATERIALS AND METHODS
Animal experimentation and human samples
All the experimental protocols have been approved by the Animal Care and Ethics Committee of the University of Barcelona and conformed to the rules set by the Government of Catalunya.

Neuropathological study in a patient’s brain sample
The post-mortem delay was 34 h. At autopsy, one hemisphere was cut in coronal sections, 1 cm thick, frozen on dry ice and stored at −80°C until use. The other hemisphere was fixed by immersion in 4% buffered formalin for 3 weeks. Selected samples were embedded in paraffin. De-waxed sections were stained with hematoxylin and eosin and Klüver–Barrera, or processed for immunohistochemistry. After incubation with methanol and normal serum, the sections were incubated with one of the primary antibodies overnight at 4°C. Antibodies to glial fibrillary acidic protein (Dako, Barcelona, Spain), β-amyloid (Boehringer-Ingelheim, Barcelona, Spain) and ubiquitin (Dako) were used at dilutions of 1:250, 1:50 and 1:200, respectively. CD68 (Dako), used as a marker of microglia, was diluted at 1:100. AT8 antibody (Innogenetics, Barcelona, Spain) was used at a dilution of 1:50. Anti-phosphorylated neurofilament antibody RT97 (Boehringer-Ingelheim) was used at a dilution of 1:100. Rabbit polyclonal anti-α-synuclein antibody (Chemicon, Barcelona, Spain) was used at a dilution of 1:3000. TDP-43 was examined using a mouse monoclonal antibody (Abnova, Tebu-Bio, Barcelona, Spain) raised against a full-length recombinant human TARDBP at a dilution of 1:1000. Monoclonal anti-αB-crystallin (Novocastra) was utilized at 1:50 (Stressgen, Bionova, Madrid, Spain). Antibodies to MLC1 (19) and GlialCAM (17) were used, both diluted 1:100. Following incubation with the primary antibody, the sections were incubated with EnvVision+ system peroxidase (Dako) for 15 min at room temperature (RT). The peroxidase reaction was visualized with diaminobenzidine and H2O2. Control of the immunostaining included omission of the primary antibody; no signal was obtained following incubation with only the secondary antibody. Sections were slightly counterstained with hematoxylin.

Figure 7. Trafficking defect of GlialCAM-defective proteins expressed in HeLa cells. HeLa cells were transfected with plasmids expressing flag-tagged wild-type GlialCAM (A and B) or containing recessive [R92Q (C), R98C (D), S196Y (E)] or dominant [R92W (F), G89D (G)] MLC-causing mutations. Cells were fixed and permeabilized and then immunofluorescence was performed using flag monoclonal antibodies detecting GlialCAM protein. Scale bar: 20 μm. (H) Pairs of cells were analyzed manually and quantified as being in junctions, around the plasma membrane or intracellularly. Intensity profile analysis was used to discern between junctional and plasma membrane localization. Data represent the mean of 4–11 independent experiments, corresponding to 954 cells (GlialCAM, n = 11), 744 cells (R92Q, n = 5), 644 cells (R98C, n = 5), 718 cells (S196Y, n = 5), 460 cells (R92W, n = 4) and 433 cells (G89D, n = 4). Bonferroni’s multiple comparison test versus ‘in junctions’ and not ‘in junctions’ was used. **P < 0.01; ***P < 0.001.
Molecular biology

A tetracysteine epitope, compatible with the fluorescein arsenical helix binder (FlAsH) staining method, was introduced at the N-terminus of human MLC1, thus resulting in the following sequence: MAFLNCCPGCCMCPF (tetracysteine epitope is in boldface). This epitope tag did not affect the subcellular localization and the surface expression levels of the tagged protein (data not shown). Plasmids presented herein were made using standard molecular biology techniques employing recombinant PCR and the MultiSite Gateway System (Invitrogen). The integrity of all cloned constructs was confirmed by DNA sequencing.

Cell culture and transfection

HEK-293T or HeLa cells were grown at 37°C in an atmosphere of 5% CO2 in Dulbecco’s modified Eagle’s medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 1 mM sodium pyruvate, 2 mM l-glutamine, 100 U/ml streptomycin, 100 mg/ml penicillin and 5% (v/v) fetal bovine serum. The cells were seeded into plates containing or not poly-D-lysine-coated cover slips. Cells were transiently transfected with the corresponding cDNA constructs using Transfectin (Bio-Rad, Hercules, CA, USA) and following the manufacturer’s instructions.

Measurement of surface expression in cells by luminescence

Surface expression in transfected mammalian cells was performed as previously described (5). Briefly, 48 h after transfection, cells were cleaned with PBS and fixed with 3% paraformaldehyde. After PBS washing, cells were then blocked with 1% BSA in PBS for 30 min, and incubated with 1 ml of 3F10 anti-HA antibody at 0.2 μg/ml in blocking solution for 1 h at RT. Cells were washed six times with blocking solution, and incubated for 20 min with 1 ml of a 1:1000 dilution horseradish peroxidase-coupled secondary antibody (donkey anti-rat IgG, Jackson, Suffolk, UK) in blocking solution. Cells were washed four times with blocking solution and eight times with PBS. Luminescence was measured of one dish at a time with 500 μl of Power Signal ELISA solution (Pierce) in a Turner TD-20/20 luminometer (Turner Biosystems, Madison, WI, USA).

Split-TEV method

Split-TEV assay was performed as described (20,33) but with some modifications. To this end, a mutant form of the TEV protease (S219V) was used, which prevents its self-digestion but does not affect its catalytic efficiency. The oligopeptide substrate used as the TEV protease-recognition site was ENLYFQS, and the chimeric transcription factor used was GV (obtained from the pM3-VP16 vector; Clontech, Nucliber, Madrid, Spain), which contains the yeast Gal4DNA-binding domain and the herpes simplex VP16 transactivation domain. After TEV protease cleavage, GV translocates into the nucleus and induces the reporter Gaussia luciferase gene.
expression (pNEBr-X1Gluc) (New England BioLabs, IZASA, Barcelona, Spain), which is secreted into the cell culture medium.

TEV protease was divided in two fragments: the TEV-N (residues 1–118) and the TEV-C (residues 119–242). We fused the TEV-N fragment, the TEV protease-recognition site and the chimeric transcription factor GV to the C-terminal of MLC1 and GlialCAM in a pCDNA3 vector containing a CMV promoter. In addition, we fused the TEV-C fragment to the C-terminal of MLC1, GlialCAM wild-type, GlialCAM containing the mutations R92Q, R98C, S196Y, R92W and G89D, and the adenosine 2A receptor (A2AR). The fusion of the TEV-C fragment to 4F2hc was done at the N-terminus. All the proteins with the TEV-C fragments were cloned in a pCDNA6.2/V5-pL Dest, containing the herpes simplex virus thymidine kinase promoter, to provide low-to-moderate levels of expression.

All the expression plasmids were constructed by PCR using a polymerase with proofreading (KOD Hot Start polymerase, Calbiochem, Darnstadt, Germany), adding the attB1, attB2, attB5R or attB5 recombination sites compatible with the MultiSite Gateway System (Invitrogen). All protocols were performed according to the manufacturer’s instructions (Invitrogen).

HeLa cells were transiently transfected with the corresponding cDNA constructs. The total DNA transfected was 2 μg, with the following ratios: 0.75 μg of each protein containing the TEV-N and the TEV-C fragments, 0.3 μg of the reporter vector pNEBr-X1Gluc and 0.2 μg of the pCMV-βGal vector, which was used to monitor the transcription efficiency. After 48 h, 20 μl of liquid were removed from the supernatant of the cells and Gaussia luciferase activity was measured in a TD-20/20 luminometer (Turner BioSystems), after the labelling of the cells and Gaussia luciferase activity was measured in a DCFM luminometer (BioTrend, Barcelona, Spain). Co-localization and intensity profile experiments were analyzed using ImageJ (http://rsbweb.nih.gov/ij/). After intensity profile calculations, we defined a ratio (R) considering the signal at the plasma membrane of two cells (cell 1 and cell 2) and the signal in junctions

\[ R = \frac{I_{\text{junctions}}}{(I_{\text{membrane1}} + I_{\text{membrane2}})/2} \]

FRET experiments

FRET between CFP and FlAsH in cells expressing the corresponding constructs was determined by donor recovery after acceptor photobleaching, in which FRET is revealed as a significant increase in the fluorescence of the donor (i.e. CFP) after photobleaching of the acceptor (i.e. FlAsH) (35). FlAsH-labeled cells were mounted in an Attofluor holder and placed on an inverted Axio Observer microscope (Zeiss Microimaging, Oberkochen, Germany) equipped with a 63 x oil immersion objective and a dual-emission photometry system (TILL Photonics, Gräfelfing, Germany). A Polychrome V (TILL Photonics) was used as the light source and signals detected by photodiodes were digitized using a Digidata 1440A analog/digital converter (Molecular Devices, Sunnyvale, CA, USA). pCLAMP (Molecular Devices) and GraphPad Prism (GraphPad Prism, San Diego, CA, USA) software were used for data collection and analysis. Therefore, upon excitation at 436 ± 10 nm [beam splitter dichroic long-pass (DCLP) 460 nm] and an illumination time set to 10 ms at 10 Hz, the emission light intensities were determined at 535 ± 15 nm (FlAsH) and 480 ± 20 nm (CFPpre) with a beam splitter DCLP of 505 nm. No corrections for spillover between channels or direct YFP excitation were made. Subsequently, acceptor photobleaching was performed by direct illumination of FlAsH at 500 nm for 5 min. Finally, the emission intensities of FlAsH and CFP (CFPpost) were recorded again. FRET efficiency was calculated according to the equation:

\[ \text{FRET efficiency} = 1 - \frac{\text{CFPpre}}{\text{CFPpost}} \]

Primary culture and adenoviral transduction

Rat primary astrocyte cultures were prepared as described previously (17). Construction of adenovirus-expressing wild-type HA-tagged human MLC1 has been described (19). Adenoviruses expressing human GlialCAM fused to three copies of the flag epitope, either wild-type or containing the recessive mutations R92Q, R98C and S196Y, or the dominant mutations R92W and G89D have been described recently (17). Transduction of astrocytes was performed as already described (19).

Immunofluorescence and immunohistochemical studies

Immune sera against N-terminal mouse MLC1 and the N4 anti-N-terminus of human MLC1 antibody were generated and characterized previously (5,6,19). Immune sera against a GlialCAM synthetic peptide have also been described recently (17). Tissue immunohistochemistry was performed as previously described (5,6). For immunofluorescent staining of cells, these were fixed with PBS containing 3% paraformaldehyde for 15 min, blocked and permeabilized with 10% FBS and 0.1% Triton X-100 in PBS for 2 h at RT. Primary antibodies were diluted in the same solution and incubated overnight at 4°C. Cells were washed and incubated for 2 h at RT with secondary antibodies: Alexa-568 goat anti-mouse and Alexa-488 goat anti-rabbit (1:500 dilution; Invitrogen). Cover slips were mounted in Vectashield medium (Vector Laboratories, ATOM, Barcelona, Spain) with 1.5 μg/ml DAPI (Sigma) and visualized using an Olympus DSU spinning disk confocal microscope (Barcelona, Spain). Co-localization and intensity profile experiments were analyzed using ImageJ (http://rsbweb.nih.gov/ij/). After intensity profile calculations, we defined a ratio (R) considering the signal at the plasma membrane of two cells (cell 1 and cell 2) and the signal in junctions

\[ R = \frac{I_{\text{junctions}}}{(I_{\text{membrane1}} + I_{\text{membrane2}})/2} \]

then if the
For western blot studies, lysates were prepared by homogenization of cells in PBS containing 1% Triton X-100 and protease inhibitors: 1 μM pepstatin and leupeptin, 1 μM aprotinin and 1 mM PMSF, incubated for 1 h at 4°C and centrifuged. Proteins in supernatants were quantified using the BCA Kit (Pierce, Thermo Scientific, Rockford, IL, USA) and mixed with SDS loading sample buffer. Western blot analysis was performed as described (5). Membranes were incubated with primary antibodies: anti-MLC1 (1:100), anti-GliaCAM (1:100) and anti-β-actin (1:10 000, Sigma) and secondary antibodies: HRP-conjugated anti-rabbit and anti-mouse (1:10 000; Jackson). Quantification of western blots was performed using MultiGauge (Fujifilm, Barcelona, Spain) or ImageJ.

Western blot analysis
For western blot studies, lysates were prepared by homogenization of cells in PBS containing 1% Triton X-100 and protease inhibitors: 1 μM pepstatin and leupeptin, 1 μM aprotinin and 1 mM PMSF, incubated for 1 h at 4°C and centrifuged. Proteins in supernatants were quantified using the BCA Kit (Pierce, Thermo Scientific, Rockford, IL, USA) and mixed with SDS loading sample buffer. Western blot analysis was performed as described (5). Membranes were incubated with primary antibodies: anti-MLC1 (1:100), anti-GliaCAM (1:100) and anti-β-actin (1:10 000, Sigma) and secondary antibodies: HRP-conjugated anti-rabbit and anti-mouse (1:10 000; Jackson). Quantification of western blots was performed using MultiGauge (Fujifilm, Barcelona, Spain) or ImageJ.

RNA interference
Conditions for knockdown of MLC1 in rat primary astrocytes have been described recently (9).

SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.

ACKNOWLEDGEMENTS
We thank Thomas J. Jentsch for advice in the intensity-profiling analysis and Alejandro Barrallo, Michael Pusch and Gergely Luckacs for critical reading of the manuscript.

Conflict of Interest statement. None declared.

FUNDING


REFERENCES


Boor, I., Aguado, F., Zorzano, A., Palacin, M., Martinez, A. et al. (2008)
Molecular pathogenesis of megalencephalic leukoencephalopathy with
subcortical cysts: mutations in MLC1 cause folding defects. *Hum. Mol.
Genet.*, 17, 3728–3739.
20. Wehr, M.C., Laage, R., Bolz, U., Fischer, T.M., Grunewald, S., Scheck,
system y+L4F2hc is a heteromultimeric complex. *FASEB J.*, 12,
1319–1329.
22. Ferre, S., Karcz-Kubicha, M., Hope, B.T., Popoli, P., Burgueno, J.,
(2002) Synergistic interaction between adenosine A2A and glutamate
mGlu5 receptors: implications for striatal neuronal function. *Proc. Natl
and functional analyses of a novel Ig-like cell adhesion molecule,
hepaCAM, in the human breast carcinoma MCF7 cells. *J. Biol. Chem.*, 280,
27366–27374.
24. Pascual-Castroviejo, I., van der Knaap, M.S., Pronk, J.C., Garcia-Segura,
megalencephalic leukoencephalopathy: 24 year follow-up of two siblings.
*Neurologia*, 20, 33–40.
and Antonsen, B. (2008) Purification of the extracellular domain of the
membrane protein GlialCAM expressed in HEK and CHO cells and
26. Favre-Kontula, L., Sattronnet-Roche, P., Magnenet, E., Proudfout, A.E.,
and identification of plasma proteins that bind GlialCAM using
ProteinChip arrays, SELDI-TOF MS, and nano-LC MS/MS. *Proteomics*, 8,
378–388.
characterization of hepaCAM, a novel Ig-like cell adhesion molecule
immunoglobulin-like cell adhesion molecule hepaCAM modulates cell
adhesion and motility through direct interaction with the actin
Expression of hepaCAM and its effect on proliferation of tumor cells in
immunoglobulin-like cell adhesion molecule hepaCAM is cleaved in the
human breast carcinoma MCF7 cells. *Int. J. Oncol.*, 37, 155–165.
31. Lanciotti, A., Brignone, M.S., Camerini, S., Serafini, B., Macchia, G.,
Raggi, C., Molinari, P., Crescenzi, M., Musumeci, M., Sargiacomo, M.,
et al. (2010) MLC1 trafficking and membrane expression in astrocytes:
immunoglobulin-like cell adhesion molecule hepaCAM with caveolin-1.
Analysis of transient phosphorylation-dependent protein–protein
interactions in living mammalian cells using split-TEV. *BMC Biotechnol.*, 8,
55.
34. Hoffmann, C., Gaietta, G., Zurn, A., Adams, S.R., Terrillon, S., Ellisman,
M.H., Tsien, R.Y. and Lohse, M.J. (2010) Fluorescent labeling of
alpha2A-adrenergic and mu-opioid receptors controls cell signaling.
GlialCAM, a Protein Defective in a Leukodystrophy, Serves as a CIC-2 Cl⁻ Channel Auxiliary subunit

(Neuron, 2012)

Contribució:

- Purificació de l’anticòs generat contra la proteïna CIC-2
- Estudis de localització de GlialCAM i CIC-2 en teixit (Figura 2 B,E,F)
- Estudis de localització de GlialCAM i CIC-2 en cèl·lules progenitores d’oligodendròcits (material generat per als referees).
SUMMARY

Ion fluxes mediated by glial cells are required for several physiological processes such as fluid homeostasis or the maintenance of low extracellular potassium during high neuronal activity. In mice, the disruption of the Cl⁻ channel ClC-2 causes fluid accumulation leading to myelin vacuolation. A similar vacuolation phenotype is detected in humans affected with megalencephalic leukoencephalopathy with subcortical cysts (MLC), a leukodystrophy which is caused by mutations in MLC1 or GLIALCAM.

We here identify GlialCAM as a ClC-2 binding partner. GlialCAM and ClC-2 colocalize in Bergmann glia, in astrocyte-astrocyte junctions at astrocytic endfeet around blood vessels, and in myelinated fiber tracts. GlialCAM targets ClC-2 to cell junctions, increases ClC-2 mediated currents, and changes its functional properties. Disease-causing GLIALCAM mutations abolish the targeting of the channel to cell junctions. This work describes the first auxiliary subunit of ClC-2 and suggests that ClC-2 may play a role in the pathology of MLC disease.

INTRODUCTION

Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare type of leukodystrophy (van der Knaap et al., 1995a) characterized by macrocephaly that appears in the first years of life. MRI of patients shows swelling of the cerebral white matter and the presence of subcortical cysts, mainly in the anterior temporal regions. In MLC patients, diffusion studies indicate increased water content of the brain (van der Knaap et al., 1995b). A brain biopsy from an MLC patient revealed myelin (van der Knaap et al., 1996) and astrocyte vacuolation (Duarri et al., 2011). It was suggested that MLC may be caused by impaired ion transport across cellular membranes, thereby leading to an osmotic imbalance and disturbed fluid homeostasis (Brignone et al., 2011; Duarri et al., 2011). Indeed, MLC1, the first disease gene discovered to underlie MLC in most patients (Leegwater et al., 2001), encodes an integral membrane protein with 8 putative transmembrane domains with low and questionable homology to ion channels (Teijido et al., 2004). Recently, MLC1 has been proposed to be related to the activation of the volume-regulated chloride transport (Ridder et al., 2011). However, the precise role of MLC1 in volume-regulated chloride transport is not clear (Ridder et al., 2011).

Among the ion channels that are expressed in glia, the hyperpolarization-activated and osmosensitive ClC-2 Cl⁻ channel (Gründer et al., 1992; Thiemann et al., 1992) has been proposed to be an important player in extracellular ion homeostasis (Blanz et al., 2007; Fava et al., 2001; Makara et al., 2003). Mice lacking ClC-2 (Clcn2-/- mice) exhibit vacuolation of the white matter that resembles the pathology of MLC patients (Blanz et al., 2007). MLC1 mutations account for only 75% of patients with MLC, but none of the patients without mutations in MLC1 carried bona fide disease-causing mutations in CLCN2 (Blanz et al., 2007; Schepfer et al., 2010). Tests for a crosstalk between ClC-2 and MLC1 also gave negative results. The proteins could not be coprecipitated, and reduction of MLC1 levels by RNA interference did not change ClC-2 protein levels (Duarri et al., 2011). Hence, no role of ClC-2 in human MLC could be established.

GLIALCAM was recently identified as a second MLC gene (López-Hernández et al., 2011a). GlialCAM is an Ig-like cell-adhesion molecule of poorly characterized function (Favre-Kontula...
et al., 2008). A role of GlialCAM in MLC was first suggested by biochemical assays that demonstrated that both proteins bind each other and colocalize in astrocyte-astrocyte junctions at astrocytic endfeet (López-Hernández et al., 2011a). GlialCAM targets MLC1 to cell-cell junctions (López-Hernández et al., 2011b) and GLIALCAM mutations identified in MLC patients impair the correct trafficking of GlialCAM and MLC1 to astrocyte-astrocyte junctions (López-Hernández et al., 2011a, 2011b).

Unlike MLC1, GlialCAM is also detected in myelin (López-Hernández et al., 2011a), mainly in oligodendroglial extensions (Favre-Kontula et al., 2008). In the present work, we show that GlialCAM interacts with CIC-2 in several glial cell types including oligodendrocytes, targeting it to cell junctions and dramatically increasing its conductance. We thus identified GlialCAM as an auxiliary subunit of CIC-2, potentially implicating the channel in the pathogenesis of MLC.

RESULTS

Identification of CIC-2 as GlialCAM Binding Partner
We used two different antibodies directed against GlialCAM (Figure 1A) to identify proteins from solubilized mouse brain membranes that copurify with GlialCAM. In addition to peptides from GlialCAM and MLC1, quantitative mass spectrometry identified peptides corresponding to the CIC-2 chloride channel (Figure 1B and see Figure S1 available online) as the only other consistently and specifically copurified protein in the eluate. Western blot analysis confirmed that CIC-2 was copurified with at least a fraction of GlialCAM (Figure 1C), which may result from a partial dissociation of the complex or may indicate that not all GlialCAM is associated with CIC-2. Coimmunoprecipitation experiments using an antibody against CIC-2 confirmed the interaction between GlialCAM and CIC-2 (Figure 1D). Similar experiments using extracts from cells transfected with CIC-2 and C terminally tagged GlialCAM (Figure 1E), as well as split-TEV interaction experiments (Figure 1F), suggested that CIC-2 and GlialCAM directly interact. The interaction appeared specific since no association was observed between CIC-2 and the related 2Cl⁻/H⁺ antiporter ClC-5, the unrelated polytopic adenosine 2A receptor (A2AR), or the unrelated single transmembrane span protein 4F2hc (Figure 1F).

Colocalization of CIC-2 and GlialCAM in Tissue
For the interaction of GlialCAM and CIC-2 to be physiologically relevant, both proteins must colocalize in native tissue. GlialCAM is found exclusively in brain, where it localizes to astrocyte-astrocyte junctions at endfeet, Bergmann glia, some pyramidal neurons and to myelin (López-Hernández et al., 2011a). In addition to neurons, CIC-2 is expressed on astrocytes and oligodendrocytes and was found in myelin-enriched fractions (Blanz et al., 2007; Fava et al., 2001; Földy et al., 2010; Makara et al., 2003; Rinke et al., 2010; Sík et al., 2000). GlialCAM colocalized in mouse brain with CIC-2 in cerebellar Bergmann glia which was counterstained for GFAP (Figure 2A). Both proteins were present at astrocytic endfeet surrounding blood vessels (Figure 2B; Blanz et al., 2007; López-Hernández et al., 2011a; Sík et al., 2000) in the cortex and in the cerebellum. In human cerebellum, immunogold electron microscopy detected CIC-2 at astrocyte-astrocyte contacts in the endfeet (Figures 2C and 2D), a location where also GlialCAM and MLC1 are present (López-Hernández et al., 2011a). GlialCAM and CIC-2 were also found to colocalize in myelinated fiber tracts along the circumference of oligodendrocytic cell bodies in mouse cerebellum (Figure 2E), where GlialCAM, CIC-2, and the oligodendrocyte-expressed gap junction protein Cx47 were present in the same cell membrane (Figure 2F; Blanz et al., 2007). In vitro cell culture...
studies have shown that GlialCAM is expressed in different stages of oligodendrocytic differentiation, including the bipotent-
tial O2-A progenitor NG2 positive cells (OPC cells) (Favre-Kon-
tula et al., 2008). Immunogold EM confirmed the presence of
ClC-2 in human myelin (Figure 2G).

Localization and expression of GlialCAM is independent of
MLC1 (Lo´ pez-Herna´ ndez et al., 2011b). We similarly asked
whether the expression of GlialCAM or MLC1 depends on
CIC-2. Western blots revealed that the total amount of GlialCAM
and MLC1 proteins were unchanged in the brain of Clcn2−/−
mice (Figure S2A). Likewise, there was no change in the subcel-
luar localization of GlialCAM and MLC1 in Bergmann glia, nor in
the astrocytic endfeet around blood vessels in Clcn2−/− mice (Figures S2B and S2C).

GlialCAM Changes the Subcellular Distribution of CIC-2
We then studied whether GlialCAM changes the abundance or
localization of CIC-2 in heterologous expression systems. We
could not detect that GlialCAM changes CIC-2 protein levels
data not shown) and CIC-2 surface expression after transfection
of HeLa cells or transduction of primary astrocytes, as ascer-
tained in a chemiluminescence assay (Figure S3).

Since GlialCAM has been described to target MLC1 to
cell-cell junctions (Lopez-Hernandez et al., 2011b), we as-
sayed if GlialCAM could also modify CIC-2 localization in the
same manner. In HeLa cells, CIC-2 transfected alone was
detected at the plasma membrane and intracellularly (Fig-
ure 3A). Coexpression with GlialCAM directed the CIC-2
channel to cell-cell contacts (Figures 3B–3D), where both
proteins colocalized (data not shown). Localization of CIC-2
together with GlialCAM was observed in long (Figure 3B) or
short (Figure 3C) cell-cell contact processes and in extensive
contact areas between opposite cells (Figure 3D). Such a clus-
tering was never observed in contacting cells expressing only
CIC-2 (Figure 3A). Similar results were observed in HEK293
cells (data not shown). We performed analogous experiments
in primary cultures of astrocytes, where both proteins are
endogenously expressed. In these cultures, adenoviral-medi-
at-ed expression of CIC-2 with or without GlialCAM showed
that the latter protein was necessary to target CIC-2 to astro-
cyte-astrocyte processes (compare Figures 3E and 3F). In
these junctions, CIC-2 and GlialCAM displayed colocalization
(Figures 3F–3H).

GlialCAM Modifies CIC-2 Currents
We next asked whether GlialCAM could modify CIC-2 function.
Coexpression of GlialCAM and CIC-2 in Xenopus oocytes
dramatically increased CIC-2-mediated currents and changed
their characteristics (Figure 4A). Initial currents measured
at +60 mV were more than 15-fold larger in cells coexpressing
CIC-2 and GlialCAM compared to CIC-2 alone. Whereas CIC-2
currents are strongly inwardly rectifying and activate slowly
upon hyperpolarization, CIC-2/GlialCAM currents were almost
ohmic and displayed time-independent, instantaneously active
currents (Figure 4B). Of note, the apparent inactivation observed
sometimes at very negative voltages is an artifact caused by
chloride depletion inside the oocytes.

Similar effects of GlialCAM on CIC-2 currents were seen in
transfected HEK293 cells, although a residual time-dependent
component was present (Figure 4C). Importantly, GlialCAM
alone does not induce any significant current in HEK cells or
Xenopus oocytes (Figure S4). Similarly, in transfected cells,
CIC-2 steady state currents at +60 mV were dramatically
increased by GlialCAM (Figure 4D). Specificity of the currents
was demonstrated by the characteristic block by extracellular
odide (Gru¨nder et al., 1992; Thiemann et al., 1992; Figure 4B) and cadmium (Clark et al., 1998) (data not shown).

To test if GlialCAM may alter native ClC-2 currents we performed whole-cell patch-clamp experiments in differentiated rat astrocytes. These cells exhibit typical hyperpolarization-activated ClC-2-like currents that were blocked by iodide (Ferroni et al., 1997; Makara et al., 2003; Figure 4E). After GlialCAM overexpression, currents were increased and showed a large instantaneous component and less rectification (Figure 4F), qualitatively similar to the effect on ClC-2 in the heterologous systems. These currents were also blocked by iodide to similar degree (Figure 4E).

Even if GlialCAM and connexins do not overlap significantly (Figures 2F and S4D), it may be hypothesized that GlialCAM expression increases ionic currents by stimulating currents through gap junction proteins. However, overexpression of GlialCAM did not modify expression and localization of connexin 43, the major connexin of astrocytes (Figures S4C and S4E). Furthermore, blocking gap junctions with glycyrrhetinic acid did not influence GlialCAM-induced currents in coupled astrocytes (Figure S4F), which were, however, blocked by iodide which is known to block ClC-2 (Gründer et al., 1992; Thiemann et al., 1992; Figure 4F).

We next addressed whether the effect of GlialCAM was specific to ClC-2. GlialCAM did not change currents of ClC-5 at positive or negative voltages (Figure 5A). We studied if human GlialCAM could interact with the ClC-2 ortholog from *Drosophila melanogaster* (DmClC-2) (Flores et al., 2006), whose genome lacks a GlialCAM ortholog. GlialCAM interacted biochemically and increased currents of DmClC-2 (Figures 5B and 5C), suggesting that GlialCAM evolved to interact with the channel at an interface that is evolutionarily conserved among ClC-2 like channels. Additionally, we addressed interaction with the closest homolog of GlialCAM named HepaCAM2. No biochemical and functional interaction was observed between HepaCAM2 and ClC-2 (Figures 5D and 5E). Finally, we asked whether wild-type MLC1 or MLC1 containing MLC-causing mutations could influence ClC-2 or ClC-2/GlialCAM induced current in *Xenopus* oocytes. We did not find any effect on ClC-2 mediated currents (Figure 5F).

**Insights into the Molecular Mechanism of ClC-2 Activation by GlialCAM**

Currents of *Xenopus* oocytes expressing GlialCAM/ClC-2 resemble those of an N-terminal deletion of ClC-2 (ΔN), in which the osmosensitivity and the voltage-dependence is drastically altered (Gründer et al., 1992). This might suggest that GlialCAM activates ClC-2 by interacting with its N terminus. However, we found that GlialCAM still interacted biochemically with (Figure S5A) and targeted the ΔN mutant to cell-cell contacts (Figure S5B) just like wild-type ClC-2. Moreover, GlialCAM potentiated ΔN currents in transfected HEK293 cells (Figure S5C).

We then compared the functional properties of ClC-2, ΔN and GlialCAM/ClC-2. Hypo-osmolarity increased currents of GlialCAM/ClC-2 and ClC-2, but had no effect on ΔN (Gründer et al., 1992; Figure 6A). All of them have the same anion permeability sequence (Figure 6B), strongly suggesting that GlialCAM has no effect on the open-pore properties of the channel. We also addressed whether GlialCAM could increase the single channel conductance of the channel by performing nonstationary noise analysis of currents induced by ClC-2 or by ClC-2/GlialCAM at −100 mV in transfected HEK cells. The conductance of ClC-2 was estimated at 2.9 ± 0.4 pS (n = 8), a value very similar to what has been previously reported (Weinreich and Jentsch, 1994).
2001). For ClC-2/GlialCAM we obtained a value of 2.6 ± 0.2 pS (n = 8), not statistically significantly different from the value for ClC-2 alone (p > 0.5). We conclude that GlialCAM does not modify single-channel properties of ClC-2. Interestingly, GlialCAM similarly diminished the inhibition by acidic pH of both ClC-2 and ΔN (Figure 6C). This result suggested that GlialCAM may activate ClC-2 by opening the common gate that acts on both pores of the homodimeric channel, as this gate is sensitive to acidic pH (Niemeyer et al., 2009).

GlialCAM displays a long cytoplasmatic C terminus comprising about 30% of the protein (Favre-Kontula et al., 2008). However, consistent with its poor sequence conservation between species, the deletion of the entire C terminus did not abolish the interaction with ClC-2, its targeting to cell junctions, and the

Figure 4. GlialCAM Modifies ClC-2 Currents in Xenopus Oocytes, HEK Cells, and Primary Rat Astrocytes
(A) Currents mediated by ClC-2 (left) expressed in oocytes and after coexpression of ClC-2 with GlialCAM (right).
(B) Representative steady-state current-voltage relationship of ClC-2 (circles) and ClC-2 coexpressed with GlialCAM (squares) in chloride (open symbols) or iodide (filled symbols). Average initial currents measured at +60 mV were 0.96 ± 0.17 μA (n = 14) for ClC-2 and 17.2 ± 2.2 μA (n = 10) for ClC-2/GlialCAM.
(C) Typical whole-cell currents from transfected HEK293 cells with ClC-2-GFP alone (left) or together with GlialCAM (right). The GFP tag does not affect ClC-2 current properties.
(D) Average steady-state current-voltage relationship of ClC-2-GFP (filled circles) or ClC-2-GFP/GlialCAM (circles) transfected HEK293 cells.
(E) Left: representative trace of whole-cell inwardly rectifying chloride currents in dbcAMP-treated cultured neocortical rat astrocytes. These currents, as described (Ferroni et al., 1997), were blocked when chloride was replaced by iodide (F) and were not blocked by tamoxifen (data not shown). Right: representative trace of chloride currents of dbcAMP-treated astrocytes transduced with adenoviruses expressing GlialCAM fused to GFP. The inset shows the voltage protocol used.
(F) Average steady-state current-voltage relationship of dbcAMP-treated astrocytes (circles, n = 14) or transduced with adenoviruses expressing GlialCAM-GFP (filled circles, n = 14) in chloride medium. Recordings were performed in symmetrical chloride concentrations. In some recordings chloride was exchanged by iodide (triangles or filled triangles). At hyperpolarizing voltages iodide block was by 32.7% ± 3.2% for control astrocytes (n = 6) and by 56.8% ± 2.9% for astrocytes transduced with adenoviruses expressing GlialCAM-GFP (n = 8).
See also Figure S4.
activation of ClC-2 currents in transfected cells (Figures S5D–S5F). Hence the interaction between both proteins may depend on the transmembrane and/or the N-terminal part of GlialCAM. Deletion of the N-terminal part of GlialCAM, while keeping the cleavable signal peptide, resulted in a lack of surface expression (data not shown), precluding proper biochemical studies.

**Impact of MLC-Related Mutations Identified in GLIALCAM on ClC-2**

Several GLIALCAM mutations found in patients with MLC truncate the protein before the transmembrane domain or result in amino-acid changes in the N-terminal, extracellular part of GlialCAM (López-Hernández et al., 2011a). We studied four of these missense mutations located within the IgV domain (Figure 1A). All GlialCAM proteins containing MLC-causing missense mutations retained their physical interaction with ClC-2 (Figures 7A and S6A) and increased ClC-2 activity similar to wild-type GlialCAM in Xenopus oocytes (Figures 7B and S6B) and in transfected cells (data not shown). In contrast, all of them abolished the targeting of ClC-2 to cell junctions in HeLa or HEK293 cells (Figures 7C and 7D).

We also analyzed the effect of the MLC-causing mutations in GlialCAM on the localization of ClC-2 in primary cultures of rat astrocytes through adenoviral-mediated transduction (Figure 8). Coexpression of ClC-2 with GlialCAM mutant variants resulted in intracellular and cell membrane staining of ClC-2 (Figures 8B–8E), but not the typical wild-type GlialCAM induced localization in cell junctions (Figure 8A).

**DISCUSSION**

In this work, we have identified GlialCAM as an interaction partner of the ClC-2 chloride channel. As ClC-2 is functional in the absence of GlialCAM, albeit displays different biophysical properties, and since GlialCAM shows a much more restricted expression pattern than ClC-2 (Thiemann et al., 1992), it is clear that GlialCAM is not an obligate α-subunit of ClC-2, but an auxiliary subunit that associates with ClC-2 only in some cell types. MLC1 wild-type or containing MLC-causing mutations, by contrast, does not modify ClC-2 currents neither in the presence nor in the absence of GlialCAM, and biochemical studies indicate that CIC-2 and MLC1 do not interact directly (Durri
whether ClC-2 function is altered in cells lacking MLC1. Testing hypothesis that should be tested in the next future is function in an indirect/unknown manner. Therefore, an inter-subunit, we cannot exclude that MLC1 could regulate ClC-2

MLC1 is unclear. As MLC1 and ClC-2 share GlialCAM as a very different biophysical characteristics (Jordt and Jentsch, 2011). However, VRAC is distinct from ClC-2 as evident from the volume regulated anion channel (VRAC) (Ridder et al., 2011). Recently, the lack of MLC1 has been correlated with a variable impairment in cell volume regulation that may be mediated by the volume regulated anion channel (VRAC) (Ridder et al., 2011). Furthermore, the mechanism of modulation of VRAC by MLC1 is unclear. As MLC1 and CIC-2 share GlialCAM as a subunit, we cannot exclude that MLC1 could regulate CIC-2 function in an indirect/unknown manner. Therefore, an interesting hypothesis that should be tested in the next future is whether CIC-2 function is altered in cells lacking MLC1.

GlialCAM by itself localizes to cell-cell junctions (López-Hernández et al., 2011b), probably being retained there by homophilic or heterophilic interactions with membrane proteins of the apposing cell. In other GlialCAM homolog proteins such as the members of the SLAM family (Engel et al., 2003), localization at the immunological synapse of SLAM proteins is achieved by trans-homophilic interactions between the IgV domains of opposite molecules. Furthermore, GlialCAM is also able to localize CIC-2 and MLC1 (López-Hernández et al., 2011b) to cell-cell junctions in heterologous expression systems and in primary cultures of astrocytes. The role of GlialCAM as a CIC-2 subunit appears to be specific within its protein family, as its closest homolog, HepaCAM2, did not interact with CIC-2. GlialCAM carrying MLC-related mutations (López-Hernández et al., 2011a) fails to arrive at cell-cell junctions (López-Hernández et al., 2011b). As a consequence, also their associated subunits, MLC1 and CIC-2, are not properly targeted to cell-cell junctions. Thus, GlialCAM function may be needed to cluster CIC-2 and MLC1 in particular to astrocyte-astrocyte junctions at astrocytic endfeet. Here, the CIC-2 chloride channel may be needed to support a transcellular chloride flux or to compensate proteins do not colocalize completely. Our experiments also exclude that GlialCAM activates astrocyte gap junctions, since their blockade did not influence currents induced by GlialCAM overexpression, and GlialCAM overexpression had no influence on connexin 43 protein levels or its subcellular localization.

Recent reports indicated that the CIC-2 channel in neurons constitutes a part of the background conductance regulating input resistance and providing an efflux pathway for chloride (Földy et al., 2010; Rinke et al., 2010), which may be a safeguard mechanism to prevent chloride accumulation in active GABAergic synapses. In contrast, the role of CIC-2 in glial cells is unknown. Recordings from mouse slices demonstrated that CIC-2-mediated current was reduced in reactive astrocytes after blocking action potential generation with tetrodotoxin (Blanz et al., 2007). Hence degeneration in both mouse models is required after neuronal repolarization. It has been suggested that CIC-2 may play a role in charge compensation during potassium influx or efflux in glial cells (Blanz et al., 2007). CIC-2-mediated currents were increased upon GlialCAM expression and showed less inward rectification. However,
ClC-2 activity recorded in cultured astrocytes (Ferroni et al., 1997) or in astrocytes in brain slices (Makara et al., 2003) resembles that of ClC-2 alone. This may be due to different recording conditions, or, alternatively, it may be that GlialCAM interacts with ClC-2 only under special circumstances, such as those occurring during high neuronal activity.

A polarized distribution of the Kir4.1 channel in astrocyte membranes in contact with endothelial cells, mediated by interaction with proteins of the DGC (dystrophin-glycoprotein complex) (Nagelhus et al., 2004), is required for potassium siphoning. In an analogous way, the polarized localization of ClC-2 mediated by GlialCAM in astrocyte-astrocyte or oligodendrocyte-astrocyte contacts may be also needed to support a directional flux of potassium from neurons to blood vessels. As a cell-adhesion molecule, GlialCAM could influence the expression of other molecules expressed in cell junctions such as connexins. Similar to DGC proteins, the localization in cell-cell contacts of GlialCAM itself and of associated molecules may be achieved by transmediated interactions or by interactions with intracellular scaffolds in each cell. It seems possible that GlialCAM may organize a more extensive cluster of proteins at the astrocytic junctions in the endfeet.

We propose that the lack of the stimulatory effect of GlialCAM on CIC-2 currents, or a mislocalization of this Cl− channel, or both, will impair glial chloride transport. This may impair not only chloride homeostasis, but also potassium siphoning and cell volume regulation that is particularly important during neuronal activity. This in turn may entail accumulation of osmotically driven water, lead to the vacuolization observed in MLC patients with mutations in GLIALCAM or in Clcn2−/− mice. Vacuolization observed in MLC patients with GLIALCAM mutations could also be due to defects in GlialCAM by itself, or to a mislocalization of MLC1, an established causal player in MLC. Additionally, the adhesive properties of GlialCAM, and their importance for the anatomy of the brain and the pathogenesis of MLC remain to be studied.

The fact that so far no disease-causing CLCN2 mutation has been found in patients with MLC (Blanz et al., 2007; Scheper et al., 2010) might be explained by the presence of additional symptoms (e.g., blindness, male infertility, as expected from the phenotype of Clcn2−/− mice [Bösl et al., 2001]) that could result in improper disease classification. The male infertility could also lead to an underrepresentation of CLCN2 mutations in the human population. Thus, proof of the involvement of CIC-2 in MLC disease will require, for example, immunolocalization studies in brain biopsies of MLC patients with GLIALCAM mutations.

In summary, the discovery of GlialCAM as the first auxiliary subunit of CIC-2 increases the complexity of regulation of the CLC chloride transporter/channel family for which so far only two β-subunits have been described (Estévez et al., 2001; Lange et al., 2006). Our work provides new clues to uncover the physiological role of the CIC-2 channel in glial cells, and suggests that
Proteomic analysis: for solubilization, membrane vesicles (1 mg) were resuspended in ComplexioLyte 47a, bound proteins were eluted with Laemmli buffer (DTT added after elution). Eluates were shortly run on SDS-PAGE gels and silver-stained prior to tryptic digestion for MS analysis. LC-MS/MS analysis was performed as described (López-Hernández et al., 2011a). Immunoprecipitation and western blot studies of HeLa cells transiently transfected or solubilized rat brain to confirm protein-protein interactions with CIC-2 and GlialCAM antibodies was performed as described (López-Hernández et al., 2011a). Relative MS sequence coverage of CIC-2 protein (Figure S1) was calculated as SC = Np/ (N + Nb), where Np is the number of amino acid residues of the identified peptides (with Mascot score ≥ 20) and Nb is the number of MS-accessible but not identified amino acids (peptides with mass of 740–3,000 u) of the respective Swiss-Prot sequence.

**Molecular Biology**

Rat CIC-2 and the N-terminal deletion (A16–61) mutant ΔN (Gründer et al., 1992) constructs for expression in oocytes were in the pTLN vector (Lorenz et al., 1998). For localization studies in HEK293 or HeLa cells, rCIC-2 and ΔN were C-terminally fused to GFP or to flag. DMIC-CIC-2 and CIC-2 with an HA extracellular tag was provided by LP Cid (Centro de Estudios Científicos, Chile). GlialCAM-ΔC was constructed eliminating residues from 289 until the stop codon.

**Voltage-Clamp Experiments**

Xenopus oocytes were injected and maintained as described (Estévez et al., 2003). For CIC-2, 5 ng cRNA and for ΔN 0.25 ng cRNA/oocyte were injected. When coexpressing, 1.25 ng cRNA of GlialCAM were co-injected with CIC-2. Oocytes were perfused with (in mM): 100 NaCl, 5 MgSO₄, and 10 HEPES/NaOH (pH 7.3). To estimate the specific CIC-2-mediated chloride currents, iodide (100 mM NaI replacing the NaCl), which blocks CIC-2-mediated outward currents (Gründer et al., 1992; Thiemann et al., 1992), was applied in every experiment. Oocytes which did not exhibit a significant block were discarded. For selectivity experiments (Figure 6B), 100 mM Cl⁻ was exchanged by 100 mM of the tested anion. For pH experiments, 10 mM buffer was used (pH 10–9: CAPS [N-cyclohexyl-3-aminopropesulfonic acid]; pH 8–7: HEPES; pH 6–5: MES; and pH 4: Glutamic acid). Hypotonicity effects were studied as described (Gründer et al., 1992). For CIC-2, an initial 1 s voltage pulse at +60 mV was applied, followed by 5 s voltage steps from −140 mV to +60 mV in 20 mV increments and a tail pulse of 1 s to 60 mV. To quantify expression levels, the initial tail current (at +60 mV) after the −140 mV test pulse was estimated by back extrapolation of a single exponential fit to the decaying tail current. To estimate the number of constitutively active channels, instantaneous currents were measured during a short test pulse to +60 mV without prior activation by hyperpolarization.

**Patch-Clamp Experiments**

Fluorescent HEK293 cells, expressing CLC-2-GFP or ΔN-GFP with or without GlialCAM, were measured with an extracellular solution containing (in mM): 140 NaCl, 2 MgSO₄, 2 CaCl₂, and 10 HEPES/NaOH (pH 7.3) using standard patch-clamp technique. Intracellular solution was (in mM) 130 NaCl, 2 MgSO₄, 2 EGTA, and 10 HEPES/NaOH (pH 7.3). Only cells for which currents were reversibly blocked by iodide were used for analysis. Patch-clamp of astrocytes was performed as described (Ferroni et al., 1997).

**Surface Expression by Chemiluminescence**

Surface expression in transfected mammalian cells or astrocytes was performed similarly as previously described (Duart et al., 2008; Teijido et al., 2004). Briefly, 48 hr after transfection, cells were cleaned with PBS and fixed with 3% paraformaldehyde. After PBS washing, cells were blocked with 1% BSA in PBS for 30 min, and incubated with 1 ml of 3F10 anti-HA antibody at 0.2 µg/ml in blocking solution for 1 hr at RT. Cells were washed six times with blocking solution, and incubated for 20 min with 1 ml of a 1:11,000 dilution horseradish peroxidase-coupled secondary antibody (donkey anti-rat IgG, Jackson, Suffolk, UK) in blocking solution. Cells were washed four times with blocking solution and eight times with PBS. Luminescence was measured....
of one dish at a time with 500 μl of Power Signal ELISA solution (Pierce) in a Turner TD-20/20 luminometer (Turner Biosystems, Madison, WI, USA).

Immunological Procedures

Two immune sera against CIC-2 were generated against overlapping sequences of the C terminus. In the first antibody (C1 Ab), the peptide used for immunization was (C)HGLPREGTPPSDSDKSQG. The native protein sequence contains a cysteine residue instead of the highlighted serine in order to avoid coupling this residue to the carrier protein. In the second antibody (C2 Ab), the peptide used for immunization was (C)RSPHGLPREGTTPSDSDKQC (C) is the cysteine that was used for coupling. Affinity purification of the antibodies was used as described (López-Hernández et al., 2011a). Mostly, the C1 antibody was used in western blot studies, and the C2 antibody was used in immunoprecipitation, immunocytochemistry, and EM immunogold. Both antibodies gave no staining in the Cln2−/− mice.

Primary Culture and Adenoviral Transduction

Rat primary quiescent astrocyte cultures were prepared as described previously (Duarri et al., 2008). Dibutyryl-cAMP differentiated rat astrocytes were obtained as described (Ferroni et al., 1997). Adenoviruses expressing three copies of the flag epitope fused to human GlialCAM, either wild-type or containing mutations (Duarri et al., 2008). Dibutyryl-cAMP differentiated rat astrocytes were transfected with the adenoviral constructs. The total DNA transfected was 2 μg, with the following ratios: 0.75 μg of each protein containing the TEV-N and the TEV-C fragments, 0.3 μg of the reporter gene pN[EB]-X1Gluc, and 0.2 μg of the pCMV-Gal vector, which was used to monitor the transfection efficiency. After 48 hr, 20 μl were removed from the supernatant of the cells and Gaussia luciferase activity was measured in a TD-20/20 luminometer (Turner BioSystems, Madison, USA), after the addition of 20 μM of native coelenterazine. To normalize the data, cells were solubilized and 30 μl of the cell lysates were used to measure the β-Galactosidase enzyme activity using the Luminiscent β-Galactosidase Detection Kit II (Clontech) in the same luminometer.

Statistical Analyses

For determination of the statistical significance between groups, either the Student’s t test or the Bonferroni’s comparison test were used. p values are annotated in each figure. Values depicted are means ± SEM.

SUPPLEMENTAL INFORMATION

Supplemental Information includes six figures and can be found with this article online at doi:10.1016/j.neuron.2011.12.039.

ACKNOWLEDGMENTS

We thank Pablo Cid for the gift of DmCIC-2 and human CIC-2 with an HA extra- cellular tag, Muriel Auberson for the generation of the CIC-2 C1 antibody and Soledad Alcantara for the NG2 antibody. We thank Alejandro Barrallo and Manuel Palacin for comments on the manuscript. This study was supported in part by SAF 2009-07014 (R.E.), PS09/0267-ERARE to R.E., ELA Foundation 2009-017C4 project (R.E. and V.N.), 2009 SGR 719 to R.E., SAF 2009-12606-C02-02 (V.N.), 2009 SGR01490 to V.N., FIS08/0014 (X.G.), FIS PI1/ 01601 (X.G.), and 2009 SGR869 (X.G.). R.E. is a recipient of an ICREA Academia prize, M.P. and E.J. are supported by the Compagnia San Paolo (Torino, Italy), Telethon Italy (GP08084), and the Italian Institute of Technology (progetto SEED). This work is dedicated to the memory of Günter Jevorutzi. Accepted: December 23, 2011

Published: March 7, 2012

REFERENCES

A Subunit of CIC-2 Defective in a Leukodystrophy


Neurobiol. Dis. 43, 228–238.


Insights into MLC pathogenesis: GlialCAM is an MLC chaperone required for proper activation of volume-regulated anion currents

(Human Molecular Genetics, 2013)

Contribució:

- Estudi de la localització de mutacions de MLC1 en presència de GlialCAM (Figura Suplementària 3)
Insights into MLC pathogenesis: GlialCAM is an MLC1 chaperone required for proper activation of volume-regulated anion currents


1 Sección de Fisiología, Departamento de Ciencias Fisiológicas II and 2 Sección de Genética, Departamento de Ciencias Fisiológicas II, University of Barcelona, Barcelona, Spain, 3 Department of Physiology and 4 Research Group Focused on Protein Structure, McGill University, Montréal, Quebec, Canada H3E 1Y6, 5 Laboratorio de Genética Molecular, IDIBELL, Barcelona, Spain, 6 U-730 and U-750, Centro de Investigación en red de enfermedades raras (CIBERER), ISCIII, Barcelona, Spain, 8 Neurophysiology Lab, Department Physiological Sciences I, Medical School, University of Barcelona, Barcelona, Spain and 9 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Received May 11, 2013; Revised and Accepted June 18, 2013

Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare type of leukodystrophy caused by mutations in either MLC1 or GLIALCAM genes and is associated with myelin and astrocyte vacuolation. It has been suggested that MLC is caused by impaired cell volume regulation as a result of defective activation of astrocytic volume-regulated anion currents (VRAC). GlialCAM brings MLC1 and the ClC-2 Cl\textsuperscript{−} channel to cell–cell junctions, even though the role of ClC-2 in MLC disease remains incompletely understood. To gain insights into the biological role of GlialCAM in the pathogenesis of MLC disease, here we analyzed the gain- and loss-of-function phenotypes of GlialCAM in Hela cells and primary astrocytes, focusing on its interaction with the MLC1 protein. Unexpectedly, GlialCAM ablation provoked intracellular accumulation and reduced expression of MLC1 at the plasma membrane. Conversely, over-expression of GlialCAM increased the cellular stability of mutant MLC1 variants. Reduction in GlialCAM expression resulted in defective activation of VRAC and augmented vacuolation, phenocopying MLC1 mutations. Importantly, over-expression of GlialCAM together with MLC1 containing MLC-related mutations was able to reactivate VRAC currents and to reverse the vacuolation caused in the presence of mutant MLC1. These results indicate a previously unrecognized role of GlialCAM in facilitating the biosynthetic maturation and cell surface expression of MLC1, and suggest that pharmacological strategies aimed to increase surface expression of MLC1 and/or VRAC activity may be beneficial for MLC patients.

INTRODUCTION

Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare type of leukodystrophy (genetic alteration of the white matter) that affects brain chloride and fluid homeostasis (1). MRI of patients shows diffuse signal abnormality, swelling of the cerebral white matter and the presence of subcortical cysts, mainly in the anterior temporal regions (2,3). Studies from an MLC patient brain biopsy revealed that the major phenotype of the disease was myelin vacuolation (4). These results, together with proton magnetic spectroscopic resonance data (5,6), suggested that MLC is caused by disturbed fluid homeostasis.

MLC1 was the first gene to be identified in MLC patients (7) and accounts for MLC in most patients. In mouse and human tissue, high MLC1 levels were present in astroglial–astroglial junctions, ependymal cells in blood–brain and CSF–brain barriers, apart from astrocytic junctions of Bergmann glia in the cerebellum (8–11). Thus, it has been proposed that MLC...
has an astrocytic origin (12), based on the fact that MLC1 is mostly expressed in astrocytes. In agreement with this hypothesis, depletion of MLC1 in astrocytes causes vacuolation, a phenotype that was also observed after re-examination of a MLC patient’s brain biopsy (13), which showed previously only myelin vacuoles. Interestingly, reduction in MLC1 in astrocytes and lymphoblast cell lines from MLC patients was found to be associated with a reduced activity of volume-regulated anion currents (VRAC) by an unknown mechanism (14). In parallel, the rate of regulatory volume decrease after cell swelling was reduced in MLC1-depleted cells (14). It has also been suggested that MLC1 could interact functionally with the β-subunit of the Na+/K+ ATPase (15) and with the TRPV4 ion channel (16). However, the role of MLC1 is still completely unknown, and whether these interactions are related to the effects of MLC1 depletion on VRAC activity is unknown.

GLIALCAM was recently identified as a second gene mutated in MLC (17). It was demonstrated that GlialCAM functions as an escort molecule necessary to target MLC1 to cell–cell junctions (18). Moreover, the changed localization of the MLC1/GLIALCAM complexes seems to play an important role in the development of the disease, as most GLIALCAM mutations impair the correct trafficking of GlialCAM and MLC1 to astrocyte–astrocyte junctions (17,18).

Histological studies in tissue indicated that GlialCAM is mostly localized in astrocytic–astrocyte junctions where it co-localizes with MLC1 (17), but also in oligodendrocyte processes (19,20). Proteomic studies searching for additional GlialCAM protein partners revealed that GlialCAM also acts as an auxiliary subunit of the ClC-2 chloride channel, targeting it to astrocytic cell junctions and modifying its functional properties (20). Similar to its effect on MLC1 targeting, GLIALCAM MLC-related mutations also impair the trafficking of ClC-2 to cell junctions. Strikingly, Clcn2 KO mice also displayed similar vacuolation to what is seen in MLC patients (21), suggesting its involvement in the pathogenesis of MLC. However, no CLCN2 mutations were detected in MLC patients (22) and no direct protein interaction was found between MLC1 and CLCN2 (13,20). Thus, the involvement of CLCN2 in MLC disease is unclear. However, very recently, it has been shown that CLCN2 mutations may cause certain forms of a human leukodystrophy characterized by white matter oedema (23).

Dominant mutations in GLIALCAM cause other type of disease called MLC2B characterized by transient features of MLC (24). Similar to the recessive GLIALCAM mutations, also dominant mutations cause MLC1 and ClC-2 trafficking defects (17,18,20). It is still unknown why dominant mutations and not recessive mutations show a trafficking dominant behavior. Furthermore, dominant mutations are also associated with different clinical phenotypes than MLC1 mutations, while the clinical and MRI phenotypes related to recessive MLC1 and GLIALCAM mutations are the same.

In the present work, we have analyzed biochemically and functionally what the consequences of a reduced GlialCAM expression are, and compared them with the effects of a reduced MLC1 expression. The effect of GLIALCAM and MLC1 mutations was also addressed. The results obtained indicate that GlialCAM is necessary for MLC1 protein expression, and its reduction affects the activity of VRAC, which may cause astrocyte vacuolation. Thus, this work extends the role of GlialCAM as a chaperone of MLC1 needed for proper VRAC activation. In addition, based on functional data obtained, we suggest that a therapeutic strategy aimed to recover the surface expression of MLC1 and/or the activation of VRAC currents can be envisaged as beneficial for all MLC patients.

RESULTS

Experimental approach to create an astrocyte cell model with reduced GlialCAM expression

To study the cellular effects of GlialCAM ablation, adenoviral vectors expressing two distinct shRNA (1 or 2) against rat GlialCAM with the fluorescent protein EmGFP, allowing visualization of transduced cells, were produced. An adenoviral vector expressing non-targeted or scrambled shRNA (SCR) was used as a control. RT-qPCR experiments performed 7 days after GlialCAM shRNA infection of astrocytes demonstrated that endogenous GlialCAM mRNA levels were profoundly depleted (Fig. 1A). Accordingly, western blot (WB) analysis indicated that the GlialCAM protein level was reduced by 80% when compared with the control SCR (Fig. 1B and Supplementary Material, Fig. S1). Immunofluorescence experiments confirmed no detectable GlialCAM protein in shRNA-treated cells (Fig. 1C). Both types of experiments (WB and immunofluorescence) also demonstrated the specificity of the GlialCAM antibodies used (17). As an additional control, to exclude side effects of shRNAs, we also complemented with an adenovector expressing human C-terminally flag-tagged GlialCAM, which was resistant to the rat-specific GlialCAM shRNAs (Fig. 1B and C).

Reduction in GlialCAM expression led to intracellular retention and reduced expression of MLC1 in rat astrocytes

We studied the consequences of reduced GlialCAM expression at the mRNA, protein and subcellular localization of MLC1 (Fig. 2). As a specificity control, we monitored the expression and subcellular localization of a subset of proteins associated with tight, adherent and gap junctions. Knockdown of GlialCAM led to a reduction (about 30%) of the MLC1 mRNA levels (not significant) (Fig. 2A). However, the MLC1 protein abundance was reduced to 60% of wild-type values (Fig. 2B and Supplementary Material, Fig. S1), which cannot be explained by the reduction in the mRNA levels. Protein levels of some junction proteins were not altered, excluding non-specific effects (Fig. 2B and data not shown).

Importantly, while MLC1 was predominantly confined to an intracellular perinuclear compartment (Fig. 2D, arrowheads) in astrocytes depleted of GlialCAM, MLC1 remained associated with cell–cell junctions in astrocytes transduced with control shRNA (Fig. 2C). Furthermore, the junctional localization of MLC1 was recovered after complementation of the astrocytes with flag-tagged human GlialCAM cDNA (Fig. 2E), which was resistant to this shRNA (Fig. 1 and Supplementary Material, Fig. S1). Therefore, altered processing and decreased stability of the MLC1 may account for the cellular phenotype of MLC1 rather than non-specific effects of the shRNA. Additional control experiments also showed that localization of some junction proteins was not changed in GlialCAM-depleted astrocytes (Supplementary Material, Fig. S2 and data not shown).
GlialCAM improves the protein stability and surface expression of MLC1 variants containing MLC-related mutations

The above results suggest that GlialCAM may function as a chaperone needed for correct MLC1 folding and expression. If this is the case, GlialCAM over-expression may correct the localization of MLC1 variants containing MLC-related mutations, which primarily affect MLC1 protein folding (25). To test this hypothesis, we constructed adenoviruses expressing a HA-tagged human MLC1 variant containing the MLC-related mutations Pro92Ser (P92S) or Ser246Arg (S246R), and they were used to transduce rat astrocytes with or without GlialCAM. The immunostaining of the mutant MLC1-P92S showed a perinuclear intracellular distribution in astrocytes (Fig. 3A), similar to the endoplasmic reticulum (ER) (25). However, co-expression with GlialCAM led to a re-distribution of the P92S variant to astrocyte–astrocyte junctions (Fig. 3B left, arrowheads), co-localizing with GlialCAM (Fig. 3B, right, arrowheads). Similar results were obtained with the MLC1-S246R mutant (Supplementary Material, Fig. S3A). We next asked whether MLC1 intracellular retention could be attenuated in HeLa cells expressed heterologously. GlialCAM was indeed able to rescue the intracellular accumulation of all MLC1 mutants studied (G59E, C85W, L311Ins and N141K) and re-locate them to the cell junction [Supplementary Material, Fig. S3B–E and (18)].

Using a chemiluminescence-based cell surface ELISA assay, the MLC1 cell surface density was determined as a function of GlialCAM expression, taking advantage of the extracellular HA epitope. The MLC1-P92S has an 80% reduced cell surface expression relative to its wild-type counterpart (Fig. 3C). GlialCAM over-expression increased the relative surface-expression levels of the MLC1-P92S in rat astrocytes (Fig. 3D).
Knockdown of GlialCAM affects MLC1 protein expression also in HeLa cells

The above results indicate that GlialCAM has two important functions. On the one hand, as reported previously, it is necessary to target MLC1 to cell–cell junctions (18,20). On the other hand, GlialCAM is necessary to stabilize MLC1 and this stabilization is important for translocation to the plasma membrane. This second role was unexpected, as MLC1 localization at the plasma membrane was detected without GlialCAM expression in HeLa cells. To explain this controversy, we hypothesized that GlialCAM is endogenously expressed in HeLa cells at low levels. Importantly, GlialCAM protein could be detected at the plasma membrane, using a monoclonal antibody directed against extracellular GlialCAM by a chemiluminescence-based ELISA assay (Fig. 4A). Transfection of two independent shRNAs against GlialCAM reduced the antibody signal, confirming that the plasma membrane signal detected by the antibody was due to GlialCAM (Fig. 4A).

To address whether the stabilization effect of GlialCAM in MLC1 could be also observed in HeLa cells, we transfected HeLa cells with wild-type MLC1 or MLC-related mutant variants P92S (PS) or C326R (CR) together with and unrelated shRNA as a control or shRNAs against GlialCAM, and assayed the cellular and surface MLC1 expression by immunoblotting and cell surface ELISA, respectively. Knockdown of GlialCAM reduced total (Fig. 4B) and cell surface (Fig. 4C) expression of all MLC1 variants, including the wild-type MLC1, as observed in rat astrocytes. Considering that GlialCAM and MLC1 physically interact [revealed by split-TEV or FRET studies (18)], these data strongly suggest that GlialCAM exerts a stabilizing effect on MLC1, which is independent of the cell system studied.

Effect of GlialCAM MLC-related variants on MLC1 expression

GlialCAM variants containing MLC-related mutations affect GlialCAM and MLC1 trafficking to cell junctions, without substantially interfering with GlialCAM expression or the biochemical interaction between GlialCAM/MLC1 (17,18,20). We thus addressed whether GLIALCAM mutations can compromise MLC1 stabilization in astrocytes. To this aim, we first depleted endogenous GlialCAM in astrocytes by adenovirus-mediated RNA interference, and then complemented with wild-type GlialCAM wild-type or two mutant variants, Arg92Gln (R92Q), found in MLC2A patients, or Arg92Trp (R92W), found in MLC2B patients. As a control for protein expression, we complemented with wild-type GlialCAM. Astrocytes were analyzed by WB or immunofluorescence (Fig. 5 and Supplementary Material, Fig. S1). Knockdown of GlialCAM reduced both GlialCAM and MLC1 expression (Fig. 5A and Supplementary Material, Fig. S1), and led to a mislocalization of MLC1 to an intracellular compartment (Fig. 5B). After knockdown of endogenous GlialCAM, complementation with human GlialCAM rescued MLC1 protein expression (Fig. 5A and Supplementary Material, Fig. S1) and junctional localization (Fig. 5C).

Complementation with GlialCAM variants containing the mutations R92Q or R92W also rescued MLC1 protein expression (Fig. 5A and Supplementary Material, Fig. S1). However,
the junctional localization of endogenous MLC1 was not corrected by the different mutated variants (Fig. 5D for R92Q and Fig. 5E for R92W).

Volume-regulated chloride currents are affected in MLC1- and GlialCAM-depleted astrocytes

Lack of MLC1 in rat astrocytes or in lymphoblast cell lines obtained from MLC patients have been related with a defective activation of VRAC (14), whose molecular identity is still unknown (27). We next addressed whether lack of GlialCAM may also affect VRAC currents.

Previous electrophysiological studies addressing VRAC currents were performed in mild trypsin-treated astrocytes (14). As this assays needed an enzymatic treatment to round astrocytes potentially leading to other effects related with the trypsin treatment (28), we switched to dB-cAMP-treated astrocytes that are already rounded due to the elongation of processes (29). We focused only in changes in VRAC activity, taking advantage of the fact that not all astrocytes express ClC-2 mRNA in isotonic conditions (30), but most express VRAC currents in hypotonic conditions. In both cases, reduction in MLC1 or GlialCAM led to a dramatic decrease of VRAC activity of 80%, although it was still detectable (Fig. 6).

Lack of GlialCAM and MLC1 causes astrocyte vacuolation

Lack of MLC1 in astrocytes and in MLC patients caused the appearance of vacuoles in the cytoplasm of astrocytes [(13) and compare Fig. 7A with Fig. 7B]. Similarly, knockdown of
GlialCAM also led to astrocyte vacuolation (Fig. 7C). Vacuoles appearing in MLC1 or GlialCAM-depleted astrocytes were also of endosomal origin, as revealed by staining with the endosomal protein marker EEA1 (early-endosomal antigen 1) (Fig. 7B and C).

We next aimed to correlate if vacuolation was directly linked to an increase in intracellular water. Treatment of astrocytes for 24 h with a hypoosmotic medium induced the appearance of water vacuoles of endosomal origin [(15) and Fig. 7D]. To test if a defective VRAC activity causally can contribute to the vacuolation phenotype, we inhibited VRAC activity, indirectly by attenuating the chloride gradient or directly. This was accomplished by incubating astrocytes with Bumetanide (Fig. 7E), which blocks sodium/potassium/chloride co-transporters (31–34), or by DCPIB (Fig. 7F), the most specific VRAC inhibitor known (35). Both treatments led to the appearance of vacuoles of endosomal origin. In order to correlate the biochemical and electrophysiological data with the vacuolation phenotype, we quantified the number of cells containing vacuoles for all experimental groups (see Materials and Methods). Quantification of the vacuolation phenotype in cells treated with Bumetanide or DCPIB revealed a similar degree of defect as cells treated with the shRNAs against MLC1 or GlialCAM (Fig. 8 and Supplementary Material, Fig. S4) [Bumetanide, 15.4 ± 2.3% (4 independent exp, 1033 cells); DCPIB, 18.8 ± 2.9% (4 independent exp, 1226 cells)].

Recovery of MLC1 in junctions rescued the vacuolation defect and VRAC activation

The astrocyte vacuolation caused by the lack of GlialCAM was rescued with complementation with human GlialCAM (Fig. 8A and Supplementary Material, Fig. S4). However,
Figure 6. VRAC activity is reduced in astrocytes with reduced expression of MLC1 and GlialCAM. Representative family of whole-cell chloride currents in dbcAMP-treated cultured neocortical astrocytes transduced with shRNA scrambled or shRNA against MLC1 or GlialCAM, elicited by the pulse protocol shown in the inset. Astrocytes that did not show CIC-2-like currents in isotonic conditions were selected. They correspond to about 60% of recorded cells. In about 85% of these cells do not having CIC-2 current in isotonic conditions, application of a hypotonic solution activated VRAC current. As expected, these currents were blocked by DCPIB, but not with iodide replacement (data not shown). The plot shows average steady-state current–voltage relationship of dbcAMP-treated astrocytes transduced with shRNA SCR (circles), shRNA MLC1 (filled circles) or shRNA GlialCAM (triangles) in isotonic and hypotonic conditions. Results corresponds to $n = 15$ for shRNA SCR, $n = 14$ for shRNA MLC1 and $n = 14$ for shRNA GlialCAM. $^*P < 0.05$ t-test versus scramble for both MLC1 and GlialCAM groups.

Figure 7. Similarities between the vacuolation induced by the lack of GlialCAM and the inhibition of VRAC activity. (A–C) Primary cultures of astrocytes were transduced with adenovectors expressing shRNA SCR, shRNA against MLC1 or shRNA against GlialCAM. After 7 days, cells were fixed and immunostained using antibodies against early-endosomal antigen 1 (EEA1). In (D–F), cells were transduced with adenovector expressing shRNA SCR and incubated with 50 μM bumetanide during 7 days (D) or 10 μM DCPIB during 7 days (E) or with a hypo-osmotic medium during 24 h (F). Cells were then fixed and immunostained using antibodies against EEA1. Green signal corresponds to GFP which is expressed together with the shRNA. Scale bar: 20 μm.
complementation with GlialCAM containing the MLC-related mutations R92Q or R92W, or further expression of MLC1 did not rescue the vacuolation defect (Fig. 8A). In agreement with these cellular defects, localization of over-expressed human MLC1 in GlialCAM-depleted astrocytes was detected mostly intracellularly (Supplementary Material, Fig. S5).

Similarly, vacuolation caused by the lack of MLC1 was rescued by expressing MLC1 or GlialCAM together with MLC1 (Fig. 8B). However, further expression of GlialCAM did not rescue the vacuolation phenotype. Rescue of MLC1 expression by MLC1 containing MLC-related mutations also failed to counteract the vacuolation phenotype (Fig. 8B), probably due to its intracellular localization (Fig. 3). However, restoring the localization of these proteins in junctions (Fig. 3) after co-expressing with GlialCAM successfully suppressed the vacuolation (Fig. 8B).

We next addressed whether the vacuolation could be correlated with changes in VRAC activity. Over-expression of MLC1 in dB-cAMP-treated astrocytes increased VRAC activity [Fig. 8C and (14)]. However, over-expression of GlialCAM alone or MLC1 containing the MLC-related mutation S246R did not increase VRAC activity [Fig. 8C and (14)]. In agreement with the rescue of the vacuolation defect, over-expression of MLC1 S246R together with GlialCAM also increased VRAC activity (Fig. 8C). Therefore, we suggest that defective VRAC activity may be directly linked to astrocyte vacuolation.

Figure 8. Correlation between VRAC activity and the vacuolation phenotype of astrocytes. (A and B) Quantification of the number of cells showing vacuolation after transduction with the shRNA-indicated and complemented or not with adenoviruses expressing the indicated constructs. In (A), data correspond to four to five independent experiments with the number of cells analyzed for each group as follows: shRNA SCR (n = 1483), shRNA Glial1 (n = 1646), shRNA Glial1 + Glial (n = 1502), shRNA Glial1 + Glial R92W (n = 1776), shRNA Glial1 + Glial R92Q (n = 1917), shRNA Glial1 + MLC1 (n = 1606). **P < 0.01 compared with shRNA Glial1. The background of cells with vacuoles of shRNA SCR (MOI 10) is 13.81 ± 1.98%. In (B), data correspond to four to five independent experiments with the number of cells analyzed for each group as follows: shRNA SCR (n = 1009), shRNA MLC1 (n = 1064), shRNA MLC1 + MLC1 (n = 1094), shRNA MLC1 + Glial (n = 1164), shRNA MLC1 + MLC1 P92S (n = 1585), shRNA MLC1 + MLC1 P92S + Glial (n = 1379), shRNA MLC1 + MLC1 S246R (n = 1248), shRNA MLC1 + MLC1 S246R + Glial (n = 1203). ***P < 0.001 compared with shRNA MLC1. The background of cells with vacuoles of shRNA SCR (MOI 5) is 5.38 ± 1.23%. (C) Representative traces at +80 mV of whole-cell chloride currents in isotonic (black) or hypotonic conditions (grey) elicited by the pulse protocol showed in the inset. In dB-cAMP-treated cultured neocortical astrocytes transduced with shRNA scrambled or adenoviruses over-expressing MLC1, GlialCAM, MLC1 S246R or GlialCAM + MLC1 S246R. Astrocytes that did not show ClC-2 currents in isotonic conditions were selected. The plot shows average conductance values at +80 mV in hypotonic conditions. Results correspond to n = 9 for shRNA SCR, n = 8 for MLC1, n = 5 for GlialCAM, n = 9 for MLC1 S246R and n = 9 for GlialCAM + MLC1 S246R. *P < 0.05 t-test versus Scramble for all groups. Differences in the kinetics of inactivation were observed between groups in an unrelated manner, even in the same experimental group, and probably are related with differences in ionic strength between cells.
DISCUSSION

In this work, we have studied the effects of reducing GlialCAM expression in astrocytes, a recently identified MLC1 and CIC-2 subunit (18,20). Taking into account these new results presented here, we conclude that whereas GlialCAM is necessary for the targeting to astrocyte–astrocyte junctions of both MLC1 and CIC-2 (18,20), it has an additional role as an MLC1-chaperone. Based on the fact that the stabilization is observed in HeLa cells, that GlialCAM interacts directly with MLC1 (18) and that GlialCAM stabilizes also ER retained folding variants of MLC1 (18), we propose that GlialCAM may protect MLC1 from ER-associated degradation. We hypothesize that this ER-protective effect of GlialCAM was not previously recognized due to the presence of endogenous GlialCAM expression in all the cell lines studied. Thus, it can be seen how expression of MLC1 in astrocytes without GlialCAM resulted in no plasma membrane staining of MLC1. As expression of MLC1 in astrocytes alone is able to arrive to the plasma membrane, it suggests that astrocytes should have an excess of endogenous GlialCAM compared with MLC1.

It has been shown that MLC-related mutations in GlialCAM do not substantially affect the interaction with MLC1 (18). Here, we also show that MLC-related GlialCAM variants are able to stabilize MLC1 protein, although they are not able to direct MLC1 to astrocyte junctions.

Reduction in both GlialCAM and MLC1 led to astrocyte vacuolation and a decreased VRAC activity (14). The function of VRAC currents which are heterogeneous is related with the efflux of water during the regulatory volume response (36). A decreased VRAC activity may cause an increase of intracellular water. We suggest that astrocyte vacuolation could be a consequence of increased water content, as blocking VRAC or the presence of a hypotonic medium (15) led to a similar type of vacuolation of endosomal origin. However, it is not clear how increased water content causes the appearance of vacuoles. It could be that astrocytes, which are cells evolutionary adapted to live in changing osmotic conditions, have gained the ability to keep the excess of intracellular water in the form of a vacuole, as happens in other organisms that form contractile vacuoles, and then they can survive in extracellular changing conditions (37–41).

How MLC1 and GlialCAM are related to VRAC activity? At this moment, it is very difficult to provide a clear answer to this question, as the function of MLC1 is unknown and the protein(s) responsible for VRAC activity still have to be discovered (27). Identification of the VRAC channel is a major and difficult task, as revealed by the reports of many potential candidates that later turned out to be wrong, such as ICln, p-Glycoprotein or the CIC-3 transporter (27,36). GlialCAM may affect VRAC activity due to the lack of MLC1, as GlialCAM over-expression by itself cannot compensate the vacuolation caused by the lack of MLC1. However, we believe that it is unlikely that MLC1 is directly responsible of VRAC, as VRAC activity is present in all the cells of the body (36), whereas MLC1 is mostly restricted to the brain and no other MLC1-homologous genes exists in mammals (7). In addition, VRAC activity is still present in astrocytes depleted of MLC1. MLC1 may affect VRAC activity indirectly, for instance, by modifying the adhesion strength of astrocytes or by affecting water or chloride handling in the brain. In this sense, aquaporin 4 depletion has also been shown to affect VRAC activity (42). It is worth to mention that MLC1 protein has also been found surrounding the endosomal membranes of astrocytes treated with a hypotonic solution (15) or with blockers such as DCPIB or Bumetanide (this work, data not shown). In these endosomal vesicles, MLC1 could contribute to the formation of water vacuoles by regulating water and/or chloride fluxes.

Interestingly, although GlialCAM proteins containing MLC-related mutations re-establish MLC1 protein expression, they do not direct MLC1 to junctions and are not able to rescue the vacuolation defect caused by the lack of MLC1. Therefore, we suggest that the correct localization of MLC1 is critical to perform its physiological function. In relation with putative roles suggested for MLC1 in ion transport or adhesion (10,14), its localization in junctions may be needed to allow transcellular fluxes of solutes or to detect easily changes in adhesion strength.

No treatment exists yet for MLC disease (1). Although the role of MLC1 is unknown, over-expression of GlialCAM rescues the vacuolation and the VRAC activity defect caused by some MLC1 mutants. Thus, the present data suggest that therapeutic strategies aimed at improving the surface expression of MLC1 or increasing the activity of VRAC may be envisaged as beneficial for MLC patients. This could be done by isolating pharmacologic-chaperones based on increased MLC1 plasma membrane expression (43) or molecules aimed to increase VRAC activity, as has been done for other chloride channels (44).

MATERIALS AND METHODS

Primary culture, adenoviral transduction and vacuolation analysis

Rat primary quiescent astrocyte cultures were prepared as described previously from P0–P2 pups (13). Dibutyril-cAMP differentiated rat astrocytes, which were used for electrophysiological measurements, were obtained as described (29). Adenoviruses expressing three copies of the flag epitope fused to human GlialCAM, either wild-type or containing the MLC-related mutations R92Q or R92W have been described (17). Similarly, adenoviruses expressing HA-tagged wild-type MLC1 or containing the MLC-related mutations S246R or P92S were also constructed. Transduction of astrocytes was performed as already described (25).

To study the vacuolation of astrocytes, we counted the cells with showed clear vacuoles. A cell was positive for vacuolation if have at least three vacuoles of a size bigger than 0.5 μm. The minor vacuolation observed in astrocytes transduced with the corresponding group expressing SCR shRNA instead of the specific shRNA was subtracted from all the experimental groups. This was done to compare directly MLC1 and GlialCAM depleted astrocytes, as the multiplicity of infection was different between both groups (MOI 5 for shRNA MLC1 and MOI 10 for shRNA GlialCAM) and the day of processing after the infection (5 days for shRNA MLC1 and 7 days for shRNA GlialCAM).

RNA interference and RT-qPCR

RNA entry-clone (Gateway, Invitrogen) vectors were prepared using the Block-it PoIII miR RNAi EmGFP expression vector kit following manufacturer’s instructions. Entry clones were...
recombinated using LR clonase into the vector pAdVD EST-CMV/V5. Adenoviruses were produced and titrated using fluorescence microscopy detecting EmGFP which is expressed together with the shRNA. The adenoviruses expressing a negative control shRNA (shRNA SCR, scrambled) or expressing an shRNA directed against rat MLC1 (shRNA 905) were described previously (13). The sequence of the oligos used to knockdown rat GlialCAM expression was: shRNA Glial1 (shRNA 1392); 5′aagatacgecctccacgctttggcacaagtgtgctgtgctgatt3′ and shRNA Glial2 (shRNA 908): 5′tatagagcgccattggatctgttttgccactgactgatttttgctgtgctgatt3′. Total RNA was prepared from a 10 cm culture plate using NucleoSpin RNA/Prot (Macherey–Nagel) as indicated by the manufacturer. RNA concentration was determined in a Nanodrop spectrophotometer. All samples had an A260/A280 ratio >1.8. RNA was stored at −80°C until further use. Eight hundred to 1000 ng of total RNA were reverse-transcribed with Transcriptor First Strand cDNA synthesis kit (Roche) following manufacturer’s instructions at 25°C for 10 min followed by 50°C for 10 min, using random hexamers as primers. cDNA was stored at −80°C. qPCR was performed with Lightcycler 480 probes master kit (Roche) following manufacturer’s instructions in a final volume of 10 μl, with cDNA at 1:10 dilution. The primers and UPL probes used were designed with the ProbeFinder version 2.45 (Roche) by the on-line application (https://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?Id=UP030000) considering exon spanning and covering all splicing species and have been previously indicated (13). qPCR was run in a LightCycler 480 II on 384 well plates with the settings previously indicated. Efficiency curves were used for each of the analyzed genes and relative gene expression for each sample was calculated using ACTB (actin) as reference. The standard deviation of the triplicates was inside the linear range. Data came from data coming from quadruplicate samples using a Infinite 1000 m PRO (Tecan Group Ltd, USA) fluorescence plate-reader at 544 nm excitation and 590 nm emission wavelengths. Total Ab binding was corrected with non-specific Ab binding, determined in mock transfected cells.

For immunoblotting, the cells were lysed in RIPA buffer containing 10 μM MG132, 10 μg/ml pepstatin + leupeptin, 1 mM phenylmethylsulfonyl fluoride and 5 mM N-ethylmaleimide.

For HeLa cells knockdown, constitutive (pGIPZ) lentivirus vectors, encoding shRNAmir-adapted short hairpin RNA specific for GlialCAM (GIPZ, V2LMM_69402 and V3LHS_413353), non-targeted variant (NT, ATTCCTGTTGGCGAGGTAAG), were obtained from Thermo Scientific, OpenBiosystems (USA). Lentivirus was produced and HeLa cells were transduced as described (46).

**Immunofluorescence, western and surface expression studies in cells**

For immunofluorescence staining, cells were fixed and processed as previously described (25). Antibodies used were the following: anti-GlialCAM [1:100, (17)], anti-MLC1 [1:100, (10)], anti-Occludin (1:100, Zymed), anti-β-Catenin (1:250, BD Transduction Lab), anti-Connexin 43 (1:100, Zymed) and anti-EAA1 (early endosomal antigen 1) (1:100, AbCAM). For WB studies, astrocyte lysates were prepared and processed as previously described (25). β-Actin protein levels were used as a loading control. To quantify signals by WB, we performed at least three extractions of all WBs, to ensure linearity. Scanned images were quantified using Multi gauge software (Fujifilm) or the freely available Image J program (http://rsbweb.nih.gov/ij/) with similar results. Surface expression in transfected mammalian cells or astrocytes was performed as previously described (25).

In HeLa cells, the PM density of MLC1 and GlialCAM knockdown efficiency were determined by ELISA-based assay. HeLa cells expressing shGlialCAM or shSCR were transfected with MLCl cDNA constructs with Lipofectamine 2000 (Invitrogen, USA) 72 h prior to analysis. Cells were seeded on 24 well plates 20 h after transfection and incubated at 37°C for 24 h. Cells were temperature rescued at 26°C for 24 h, and unfolding was performed at 37°C for 1 h prior to experiment. Primary and secondary Abs were bound on ice in DMEM containing 5% bovine serum (Gibco, USA). The extracellular epitope was detected with mouse anti-human HepaCAM (1:1000, R&D Systems, USA) and mouse anti-HA (1:1000 cl11, Covance, Canada) antibodies. Excess antibody was washed away and specific binding was determined by HRP-conjugated secondary Ab (Amersham Biosciences, Canada) with Amplex® Red (Invitrogen) as a substrate. The fluorescence intensity was measured from quadruplicate samples using a Infinite 1000 m PRO (Tecan Group Ltd, USA) fluorescence plate-reader at 544 nm excitation and 590 nm emission wavelengths. Total Ab binding was corrected with non-specific Ab binding, determined in mock transfected cells.

For patch-clamp experiments of astrocytes

Three days before the experiment, dB-cAMP differentiated astrocytes were trypsinized and replated at a density of 1- to 3 x 10⁴ onto 24-well plates containing a glass cover slip with DMEM supplemented medium and 250 μM dB-cAMP. For electrophysiological recordings, the glass cover slip was mounted on the stage of an inverted microscope equipped with phase-contrast optics and fluorescence illumination. Patch pipettes were pulled from borosilicate glass capillaries (Clark Electromedical, UK) and used after fire polishing (Narishige, Japan). Electrophysiological recordings were performed with a patch-clamp amplifier (Axopatch 200B, Molecular Devices, Union City, CA, USA) Patch electrodes were fabricated in a Flaming/Brown micropipettaper puller P-97 (Sutter instruments). Electrodes had a resistance between 2 and 5 MΩ when filled with intracellular solution (in mM): 144 NMDG-Cl, 2 MgCl₂, 5 EGTA, 5 HEPES at pH 7.3 and 308 ± 2 mOsm/kg. Extracellular solution contained (in mM): 144 NMDG-Cl, 2 CaCl₂, 2 MgCl₂, 5 HEPES, 5 glucose at pH 7.4 and 310 ± 3 mOsm/kg. Hypotonic extracellular solution (−25%) was prepared by decreasing NMDG-Cl concentration to 105 mM (229 ± 2 mOsm/kg). All solution osmolarities were adjusted with sorbitol. An Ag/AgCl ground electrode

Human Molecular Genetics, 2013, Vol. 22, No. 21

4414
mounted in a 3 m KCl agar bridge was used. Membrane currents were recorded in the whole-cell patch clamp configuration, filtered at 2 kHz, digitized at 10 kHz and acquired with pClamp 9 software (Molecular Devices). Data were analyzed with Clampfit 9 (Molecular Devices) and Prism 4 (GraphPad Software, Inc., La Jolla, CA, USA). Whole-cell capacitance and series resistance were compensated with the amplifier circuitry. Series resistance was always kept below 10 MΩ and compensated at 70–80%. All recordings were performed at room temperature (22–23°C). Currents were evoked with 4 s pulses from +80 to –120 mV from a holding potential of 0 mV.

SUPPLEMENTARY MATERIAL

Supplementary Material is available at HMG online.

ACKNOWLEDGEMENTS

We thank Michael Pusch, Thomas Jentsch and Herbert Schwarz for helpful comments about the manuscript.

Conflict of Interest statement. None declared.

FUNDING

This study was supported in part by SAF 2009-07014 (R.E.) and SAF2012-31486 (R.E.), PS09/02672-ERARE to R.E., ELA Foundation 2009-017C4 project (R.E. and V.N.), 2009 SGR 719 (R.E.), FISPI11/01601 (X.G.), 2009 SGR869 (X.G.), RD12/0034/0003 (X.G.), SAF 2009-12606-C02-02 (V.N.), 2009 SGR01490 (V.N.) and Canadian Institute of Health Research and Canada Foundation of Innovation (G.L.L.). G.L.L. is a Canada Research Chair and RE is a recipient of an ICREA Academia prize.

REFERENCES

Megalencephalic leukoencephalopathy with cysts without MLC1 defect. 


EMBO J., 30, 2140–2152.


Glia, 46, 419–436.


PLoS ONE, 7, e29725.


Exp. Neurol., 210, 514–520.


Cell Calcium, 53, 204–216.

Channels (Austin), 7, 43–46.

PLoS ONE, 6, e18013.


J. Neurochem., 100, 87–104.


Disrupting MLC1 and GlialCAM and ClC-2 interactions in leukodistrophy entails glial chloride channel disfunction
(Nature Communications, 2014)

Contribució:

- Estudi de l’expressió de MLC1, GlialCAM i ClC-2 en el model knock-out per Mlc1 (Figura 1)
- Estudi de la localització de MLC1, GlialCAM i ClC-2 en el model knock-out per Mlc1 (Figura 2).
- Estudi del fenotip vacuolitzant mitjançant ME en el model knock-out per Mlc1 (Figura 8, Figura Suplementària 9)
Disrupting MLC1 and GlialCAM and CIC-2 interactions in leukodystrophy entails glial chloride channel dysfunction

Maja B. Hoegg-Beiler1,2,*, Sónia Sirisi3,4,*, Ian J. Orozco1,2,*, Isidre Ferrer5, Svea Hohensee1, Muriel Auberson1,2,†, Kathrin Gödde1,2, Clara Vilches4, Miguel López de Heredia4,6, Virginia Nunes4,6,7, Raúl Estévez3,8 & Thomas J. Jentsch1,2,9

Defects in the astrocytic membrane protein MLC1, the adhesion molecule GlialCAM or the chloride channel CIC-2 underlie human leukoencephalopathies. Whereas GlialCAM binds CIC-2 and MLC1, and modifies CIC-2 currents in vitro, no functional connections between MLC1 and CIC-2 are known. Here we investigate this by generating loss-of-function Glialcam and Mlc1 mouse models manifesting myelin vacuolization. We find that CIC-2 is unnecessary for MLC1 and GlialCAM localization in brain, whereas GlialCAM is important for targeting MLC1 and CIC-2 to specialized glial domains in vivo and for modifying CIC-2’s biophysical properties specifically in oligodendrocytes (OLs), the cells chiefly affected by vacuolization. Unexpectedly, MLC1 is crucial for proper localization of GlialCAM and CIC-2, and for changing CIC-2 currents. Our data unmask an unforeseen functional relationship between MLC1 and CIC-2 in vivo, which is probably mediated by GlialCAM, and suggest that CIC-2 participates in the pathogenesis of megalencephalic leukoencephalopathy with subcortical cysts.
Several forms of leukodystrophies, degenerative disorders affecting the white matter of the brain, are associated with vacuolization of myelin sheaths that enwrap axons of central neurons. A particular subentity of this disease, mega-lencephalic leukoencephalopathy with subcortical cysts (in short MLC), can be caused by mutations in either MLC1 (ref. 1), encoding a protein predicted to span the plasma membrane eight times, or less frequently in GLIALCAM2,3, which encodes the adhesion molecule GlialCAM of the immunoglobulin superfamily4. MLC1 and GlialCAM bind each other, and this binding originally suggested GLIALCAM as a candidate gene for MLC2. GlialCAM was first identified as being downregulated in hepatic cancer (hence, its original name Hepacam5), but is predominantly expressed in glial cells. GlialCAM co-localizes with its binding partner MLC1 at astrocytic endfeet contacting blood vessels and at astrocyte–astrocyte contacts6. GlialCAM and MLC1 share this localization with the CIC-2 chloride channel7. In addition to other symptoms8, Clcn2−/− mice display leukodystrophy8, suggesting that CIC-2 deficiency might underlie human leukoencephalopathy9. Several for CLCN2 mutations in leukodystrophy patients were initially negative10,11 but a recent study identified CLCN2 mutations in a distinct form of leukoencephalopathy11. Clinical symptoms of either form of the disease include ataxia and sometimes spasticity. On the basis of a limited number of patients, CLCN2 leukodystrophy differs from MLC in the magnetic resonance imaging pattern of affected brains11. By contrast, clinical and magnetic resonance imaging features of patients with the MLC1 disease entity (mutations in MLC1) are virtually indistinguishable from those affected by MLC2A (GLIALCAM mutations on both alleles). The disease is more benign in patients with heterozygous GLIALCAM mutations in dominantly inherited MLC2B2.

GlialCAM binds not only MLC1 but also CIC-2 (ref. 12), a widely expressed Cl− channel activated by hyperpolarization and cell swelling13–15. CIC-2 is found in both neurons and glia. GlialCAM directs CIC-2 and MLC1 to cell–cell contacts in heterologous expression. This effect is abolished by several point mutations found in MLC2 patients3,7,12. GlialCAM drastically changes CIC-2 currents in various expression systems by increasing their amplitudes and almost abolishing their inward rectification12. It thus appears possible that GlialCAM mutations cause leukodystrophy by mislocalizing CIC-2 and/or by affecting its currents. By contrast, no effects of MLC1 on CIC-2 function, localization or abundance were found12,16. Thus, it remains unclear why patients with MLC1 mutations have the same symptoms as patients with recessive GLIALCAM mutations, who, based on these cell culture data, would be expected to be more severely affected.

Here we investigate the functional network of MLC1, GlialCAM and CIC-2 in vivo, and its role in leukodystrophy, by generating mice that lack MLC1 or GlialCAM proteins (Mlc1−/− and Glialcam−/−, mice, respectively) and Glialcamdn/dn knockin mice harbouring a dominant point mutation found in patients2,12. All three mouse lines develop progressive myelin vacuolization in the cerebellum. Loss of GlialCAM changes the localization and abundance of CIC-2 and MLC1, and surprisingly loss of MLC1 changes the localization of CIC-2 and GlialCAM. The linearization and enhancement of CIC-2 currents by GlialCAM that is known from heterologous expression is observed in OLs, but not in Bergmann glia (BG). Hence, GlialCAM-dependent anchoring of CIC-2 to plasma membrane domains is not necessarily coupled with changes in CIC-2 current characteristics. Crosses between different Ckn2 and Glialcam models indicate that the pathology observed with loss of GlialCAM or MLC1 may be partially attributed to a secondary loss of CIC-2 function, but that the loss of either GlialCAM or MLC1 has additional pathogenic effects.

**Results**

**Mlc1 and Glialcam mouse models.** Exons 2 and 3 of the Mlc1 gene were deleted to generate Mlc1−/− mice (Supplementary Fig. 1a,b). Western blots confirmed the absence of the MLC1 protein (Fig. 1a). A point mutation was inserted into the mouse Glialcam gene that changes G89 in the first immunoglobulin domain to serine (Supplementary Fig. 1c–e). This mutation (G89S) is found in MLC patients with dominant disease2. Exons 2–4 were flanked by loxP sites to generate Glialcam knockout (Glialcam−/−) mice by crossing Glialcam−/−G89S,loxP (in the following called Glialcamdn) mice with deleter mice17 (Supplementary Fig. 1c,e). Glialcamdn messenger RNA was expressed at normal levels in the brain (Fig. 1b). Western blots showed that the G89S mutation did not reduce Glialcam levels (Fig. 1c,d) and that Glialcam, although initially called Hepacam, lacks significant expression in the liver (Fig. 1a).

As expected, Glialcam was absent from Glialcam−/− brain. Mlc1−/−, Glialcam−/− and Glialcamdn/dn mice were viable and fertile. Similar to Clcn2−/− mice8, they lacked overt ataxia or spasticity as might have been expected from MLC patients with mutations in the MLC1 or GLIALCAM (HEPACAM) genes1,2.

**Interdependent protein expression of Glialcam MLC1 and CIC-2.** We wondered whether the expression of CIC-2 and MLC1, both of which bind Glialcam2,12, might be changed in the Glialcam mouse models. As myelin vacuolization is most pronounced in the cerebellum of Clcn2−/− mice and in the present Glialcam and Mlc1 models (see below), we separately studied protein expression in the cerebellum and the rest of the brain. CIC-2 was reduced by ~50% in Glialcam−/− and Glialcamdn/dn cerebella (Fig. 1c) but not in the remaining brain (Fig. 1d). MLC1 was strongly decreased in the whole brain of Glialcam−/− mice, whereas in Glialcamdn/dn mice, MLC1 was moderately decreased only in the cerebellum (Fig. 1c,d). Although MLC1 reportedly binds Glialcam, but not CIC-2 (refs 2,12), CIC-2 was reduced in Mlc1−/− cerebellum (Fig. 1c), whereas Glialcam appeared nearly unchanged (Fig. 1c,d). Agreeing with previous work12, Glialcam and MLC1 were not reduced in Clcn2−/− brain and MLC1 appeared even somewhat increased in Clcn2−/− cerebellum (Fig. 1c,d).

Hence, Glialcam stabilizes MLC1 and the G89S mutant partially retains this stabilizing effect. Both proteins stabilize CIC-2 in the cerebellum. However, CIC-2 is not required for the stability of either Glialcam or MLC1. These stabilizing effects occur post-transcriptionally as quantitative real-time PCR showed no changes in messenger RNA levels (Fig. 1b).

**Mutually dependent localization of Glialcam MLC1 and CIC-2.** Whereas Glialcam directs CIC-2 and MLC1 to cell–cell junctions, MLC1 co-transfection does not change the localization of either Glialcam or CIC-2 (refs 7,12). We asked whether these in vitro results are relevant in vivo. We first focused on cerebellar BG because their long, straight processes showed particularly prominent, overlapping labelling for CIC-2, MLC1 and Glialcam (Fig. 2a). Moreover, the morphology of BG allows easy visualization of changes in subcellular localization. Whereas CIC-2 disruption had no detectable effect on Glialcam and MLC1 in BG12 (Fig. 2a), ablation of Glialcam strongly reduced the labelling for both CIC-2 and MLC1 and changed their localization (Fig. 2a,b). Rather than being concentrated along BG processes, both proteins showed faint diffuse staining in the molecular layer and in BG somata where a sizeable portion of immunoreactivity appeared intracellular (Fig. 2b).

In Glialcamdn/dn mice, in which Glialcam-binding properties might be altered by the G89S mutation in the first extracellular...
GlialCAM antibodies did not label the straight BG processes, but still diffusely stained the molecular layer (Fig. 2a). Heterozygous Glialcam+/dn mice showed an intermediate phenotype with MLC1 being diffusely labelled in the molecular layer and only small amounts remaining along BG processes (Fig. 2a). In both homo- and heterozygous Glialcamdn/dn mice, CIC-2 was retained in BG somata with CIC-2 extending further into BG processes in Glialcam+/- mice (Fig. 2a).

Agreeing with the western blot analysis, overall labelling of CIC-2 was reduced in Mlc1-/- cerebella (Fig. 2a, c), and CIC-2 was retained in BG somata like in Glialcam-/- mice (Fig. 2a, b). GlialCAM immunolabelling was similarly diffuse in Mlc1-/- as in Glialcamdn/dn cerebellum.

CIC-2, GlialCAM and MLC1 localization at astrocytic endfeet along blood vessels was reduced in Glialcam-/-, Glialcamdn/dn and Mlc1-/- mice (Fig. 3a). In contrast, the localization of the water channel aquaporin 4 and the K+-channel Kir4.1 (KCNJ10), two proteins reported to reside in a complex with MLC1, were not changed in Mlc1-/- and Glialcam-/- mice (Fig. 3b).

In wild-type (WT) OLs, CIC-2, GlialCAM and MLC1 clustered around their somata (Fig. 4), as previously described for CIC-2 and GlialCAM8,12. However, unlike CIC-2 and GlialCAM, MLC1 is apparently not expressed in OLs8,19,20. As MLC1 was detected in neighbouring bona fide astrocytes (Fig. 4), the MLC1 staining at oligodendrocytic somata may stem from contact-forming astrocytic processes.

In Glialcam-/-, Glialcamdn/dn and Mlc1-/- mice, CIC-2 no longer formed distinct clusters at the oligodendrocytic plasma membrane but showed faint diffuse, inhomogenous cytoplasmic staining (Fig. 4). Similar changes were seen with G89S-mutant GlialCAM, which was additionally detected in more intense labelling in neighbouring cells. A similar distribution was found with WT GlialCAM in Mlc1-/- mice. In Glialcam-/- and Glialcamdn/dn mice, MLC1 was diffusely distributed throughout the cytoplasm of adjacent astrocytes, but not in oligodendrocytic somata (Fig. 4). Since OLs lack MLC1, its effect on oligodendrocytic GlialCAM and CIC-2 cannot be cell autonomous.

Hence, both GlialCAM and MLC1 were necessary for each other’s correct localization and for the correct targeting of CIC-2 in glial cells, whereas CIC-2 disruption had no significant effect on GlialCAM (see also ref. 12) and MLC1 (Table 1). The changed localization of CIC-2 and MLC1 in the Glialcam mouse models is compatible with in vitro results7,12. However, the effect of MLC1 deletion was unexpected because MLC1 is believed not to bind CIC-2 and to have no role in GlialCAM targeting7,12.

GlialCAM trans-interactions localize MLC1 and CIC-2 in vitro.

Our in vitro data agree with the effect of GlialCAM on CIC-2 and MLC1 localization in transfected cells, but contrast with the missing impact of MLC1 on GlialCAM7,12. To systematically analyse the localization of all three proteins, we separately transfected HeLa cells with different combinations of CIC-2, GlialCAM and MLC1 and later combined these cells to form contacts on further growth (Fig. 5). Immunofluorescent labelling revealed that GlialCAM expression in both cells was necessary and sufficient to direct CIC-2 or MLC1 to cell–cell contacts (Fig. 5a–c, filled arrows). This targeting did not require CIC-2 or MLC1 to be present in both cells (Fig. 5a,b). Expression of CIC-2

**Figure 1** | Expression of CIC-2, GlialCAM and MLC1 in Glialcam and Mlc1 mouse models. (a) Western blots for CIC-2 (top), GlialCAM (middle) and MLC1 (bottom) of membrane fractions isolated from organs of WT, and Clcn2−/−, Glialcam−/− or Mlc1−/− mice, respectively (age: 10–12 weeks). For CIC-2, equal amounts of protein per organ were loaded, whereas for GlialCAM and MLC1 blots, 10 times more protein was loaded for the eye, liver and testis compared with the brain (without cerebellum) and cerebellum (cb). (b) Quantitative real-time PCR to determine levels of Glialcam, Mlc1 and Clcn2 messenger RNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d. (mRNA in the cerebellum of different mouse models. Primers were chosen to amplify regions that were not deleted in corresponding knockout (KO) mice. Bars, relative expression level compared with WT sibling; error bars, s.d.
Figure 2 | Glialcam and Mic1 knockout alters localization of CIC-2, GlialCAM and MLC1 in BG. (a) Immunohistochemical (IHC) staining of CIC-2, GlialCAM and MLC1 in the molecular layer of the cerebellum. Co-staining for the astrocytic cytoskeletal protein GFAP (red) visualizes BG processes. Somata of BG are located in the Purkinje cell layer (pcl). Arrows with filled heads point to staining along BG processes, arrows with open heads point to labelled BG somata. Staining respective knockout (KO) sections controls the specificity of antibodies. Note that CIC-2 staining in the Purkinje cell layer of Clcn2−/− mice results from non-specific nuclear staining by the CIC-2 antibody. Scale bar, 50 μm. (b) IHC staining of CIC-2, GlialCAM and MLC1 in BG somata of the cerebellar Purkinje cell layer. Sections were co-stained for the astrocyte marker protein S100β (red) that localizes to the cytoplasm of BG. Nuclei were stained with 4',6-diamidino-2-phenylindole. Scale bar, 5 μm. For each genotype/antibody combination, two brain sections each of at least three different mice were analysed.
or MLC1 alone did not affect the localization of GlialCAM, MLC1 or ClC-2 in neighbouring cells even when they co-expressed two of these proteins (Fig. 5d–g). Hence, homophilic interactions of GlialCAM in trans may suffice to anchor and concentrate GlialCAM at cell–cell contacts. Binding in cis of GlialCAM to ClC-2 or MLC1 concentrates these latter proteins at the same site without requiring an interaction with ClC-2 or MLC1 on the adjacent cell.

Modification of ClC-2 currents by GlialCAM and MLC1 in glia. When overexpressed in Xenopus oocytes, HEK cells or primary astrocytes, GlialCAM increases ClC-2 currents and almost abolishes its inward rectification\(^1\). To examine whether these changes occur in vivo, we performed whole-cell patch clamp experiments in brain slices (Figs 6 and 7). Patch pipette solutions contained CsCl to suppress K\(^+\) currents and the gap junction blocker carbenoxolone to electrically isolate the patched cell from the pial network\(^2\). Control experiments with transfected HEK cells confirmed that carbenoxolone did not affect ClC-2 currents (Supplementary Fig. 3a–c). Na\(^+\) currents were suppressed by replacing extracellular Na\(^+\) with N-methyl-D-glucamine (NMDG\(^+\)) (Supplementary Fig. 3f).

We first measured BG (Fig. 6 and Supplementary Fig. 3g–i) because they prominently express ClC-2, GlialCAM and MLC1 and display strongly changed ClC-2 localization upon disruption of GlialCAM or MLC1 (Fig. 2a). We initially identified BG by fluorescence in mice expressing enhanced green fluorescent protein (eGFP) under the control of the glial fibrillary acidic protein (GFAP) promoter\(^2\) and later by dye filling through the patch pipette (Supplementary Fig. 3d,e). This labelling revealed

Figure 3 | Glialcam and Mlc1 knockout mislocalizes CIC-2, MLC1 and GlialCAM along blood vessels. (a) Immunofluorescent staining of CIC-2, GlialCAM and MLC1 along blood vessels of the hippocampus in mice of different genotypes. Sections were co-stained for perlecan (heparan-sulphate-proteoglycan) a marker for endothelial cells. (b) Immunofluorescent staining of aquaporin-4 (AQP4) and Kir4.1 along blood vessels of the hippocampus. Section were co-stained with the astrocyte marker GFAP that labels astrocytic endfeet contacting blood vessels. Scale bar, 5 \(\mu\)m. For each genotype and antibody combination, two brain sections each of at least two different mice were analysed.
no obvious differences in BG morphology among genotypes (Supplementary Fig. 3e). Surprisingly, BG Cl\(^{-}\) currents did not display the linear current–voltage relationship expected from ClC-2/GlialCAM heteromers\(^{12}\) (Supplementary Fig. 3a–c) but showed the slow activation by hyperpolarization (Fig. 6a) that is typical for ClC-2 (without GlialCAM)\(^{14}\). Later, an unusual apparent inactivation set in which became faster with hyperpolarization and appeared to reach completion after \(4\) s (Supplementary Fig. 3f). The absence of these currents from Clcn2\(^{-/-}\) BG (Fig. 6c), however, identified them as ClC-2 currents.

Whole-cell Cl\(^{-}\) currents obtained from BG somata of Glialcam\(^{-/-}\) or Glialcam\(^{dn/dn}\) mice did not display the expected\(^{12}\) increased rectification but lacked the apparent inactivation observed in WT glia (Fig. 6e,g,m, Supplementary Fig. 4a,c,d,f,j). Similar non-inactivating CIC-2 currents were observed with BG from Mlc1\(^{-/-}\) mice (Fig. 6i,m and Supplementary Fig. 4e,j). Heterozygous Glialcam\(^{+/-}\) BG showed currents similar to WT (Supplementary Figs 4b,g and 5d). These results might indicate that, rather than abolishing its rectification as in vitro\(^{12}\), in vivo GlialCAM causes CIC-2 to inactivate.

However, the cell capacitance of Glialcam\(^{-/-}\), Glialcam\(^{dn/dn}\), Mlc1\(^{-/-}\) and to a lesser extent of Clcn2\(^{-/-}\) BG was increased and more variable compared with WT (Fig. 6k). The augmented capacitance suggested an increased cell volume that might change whole-cell currents by reducing the dissipation of Cl\(^{-}\) gradients and/or the electrical access to ion channels in distant processes. Indeed, when we superfused BG with hypotonic solution to induce cell swelling (which resulted in the expected increase in cell capacitance (Supplementary Fig. 5a)), the apparent inactivation of WT and Glialcam\(^{+/-}\) Cl\(^{-}\) currents was attenuated or even abolished, whereas the non-inactivating currents of Glialcam\(^{-/-}\) BG and background currents of Clcn2\(^{-/-}\) BG were unchanged (Fig. 6b,d and Supplementary Fig. 5b–e). Conversely, exposure of Glialcam\(^{-/-}\), Glialcam\(^{dn/dn}\) or Mlc1\(^{-/-}\) BG to hypertonic solution partially reproduced the current ‘inactivation’ observed in WT BG at isoosmolarity (Fig. 6f,h and Supplementary Fig. 5f–h). Hence, cell swelling...
probably contributes to the lack of apparent CIC-2 inactivation in Glialcam\(^{-/-}\) and Mlc1\(^{-/-}\) mice. However, cell capacitance and the degree of ‘inactivation’ did not correlate across cells of different genotypes (Supplementary Fig. 6). As WT and mutant BG cells rather segregated into two distinct groups, additional factors like the changed compartmentalization of CIC-2 in mutant mice (Fig. 2a) or possibly loss of interaction with other proteins may play a role in suppressing the apparent ‘inactivation’ of CIC-2 currents. The decrease in current amplitudes upon hypertonic shrinkage (Fig. 6h,i,j) may be due to reduced electrical accessibility of CIC-2 in cell processes or due to the intrinsic osmosensitivity of CIC-2 (ref. 13).

From our previous in vitro data\(^{12}\) we had expected a large decrease of CIC-2 current amplitudes with Glialcam ablation, but averaged current amplitudes of Glialcam\(^{-/-}\) BG rather appeared larger than WT (Fig. 6a,e). When normalized to cell capacitance, however, current amplitudes of Glialcam\(^{-/-}\), Glialcam\(^{dn/dn}\) and Mlc1\(^{-/-}\) BG were moderately smaller compared with WT when measured at early time points (Fig. 6l), and nearly unchanged at 1.5 s when WT currents were reduced by the apparent inactivation (Fig. 6m). The mild reduction in CIC-2 current density in Glialcam\(^{-/-}\) and Mlc1\(^{-/-}\) BG is consistent with the decreased CIC-2 expression in these cells (Fig. 2).

Whereas overall BG morphology appears normal in our mouse models, myelin vacuolization (shown below) pointed to pathological changes in OLs, which were therefore included in our analysis (Fig. 7 and Supplementary Fig. 3j–m). Their identity was confirmed by dye filling that did not reveal obvious morphological differences among the genotypes (Fig. 7l). Unlike BG, Cl\(^-\) currents of OLs lacked time-dependent activation by hyperpolarization (Fig. 7a). About 60% of these currents could be attributed to CIC-2 by comparison with Clcn2\(^{-/-}\) OLs (Fig. 7a–c and Supplementary Fig. 7a). Consistent with effects of GlialCAM in heterologous expression\(^{12}\), Cl\(^-\) currents of Glialcam\(^{-/-}\) OLs were smaller and displayed the typical activation by hyperpolarization when corrected for background currents of Clcn2\(^{-/-}\) mice (Fig. 7d). Although currents were small, Cl\(^-\) currents of Mlc1\(^{-/-}\) and Glialcam\(^{+/+}\) OLs appeared similarly activating (Fig. 7a and Supplementary Fig. 7a). Consistent with the observation that human mutations in GlialCAM Ig domains interfere with its homophilic binding in trans, but not with its effect on CIC-2 currents\(^{12}\). The membrane capacitance of Glialcam\(^{-/-}\), Glialcam\(^{dn/dn}\), Mlc1\(^{-/-}\) and Clcn2\(^{-/-}\) OLs was increased, although not quite to the same extent as in BG (Fig. 7m compared with Fig. 6k).

Hence, the effect of GlialCAM on CIC-2 currents known from heterologous expression\(^{12}\) (Supplementary Fig. 3a–c) can be observed in OLs, but not in BG (Table 1). On the
basis of their increased capacitance, both types of glia appear to be swollen.

**Leukodystrophy in Glialcam Mlc1 and Clcn2 mouse models.** Brain sections from Glialcam$^{-/-}$, Glialcam$^{tn/tn}$ and Mlc1$^{-/-}$ mice revealed myelin vacuolization that slowly progressed over several months (Fig. 8a). Vacuolization was most prominent in fibre tracts of the cerebellum, similar to what was found in Clcn2$^{-/-}$ mice. While the degree and time course of vacuolization was comparable across Glialcam$^{-/-}$, Glialcam$^{tn/tn}$ and Mlc1$^{-/-}$ mice, they altogether developed vacuolization more slowly and less severely than Clcn2$^{-/-}$ mice. Not until around 1 year of age

---

**Figure 5 | Enrichment of ClC-2 GlialCAM and MLC1 at cell–cell contacts requires expression of GlialCAM in both neighbouring cells.** HeLa cells were transfected with different combinations of Clcn2, Glialcam and Mlc1 cDNAs (untagged or haemagglutinin (HA) tagged). Differentially transfected cells were plated onto coverslips and processed for immunofluorescent staining. Individual channel images are displayed in the first three columns, merged images are shown in the fourth column (from left to right). Labels in the lower left corner of each panel indicate the overexpressed protein that was stained with specific antibodies. cDNAs transfected into cells are indicated to the left of each row; in the fourth row cells are labelled with ‘’ and ‘#’ according to the cDNA combination they were transfected with. Arrows with filled heads point to cell–cell contacts with protein enrichment, arrows with open heads to contacts without protein enrichment. Scale bar, 20 µm; C2 = ClC-2; GC = GlialCAM; M1 = MLC1. Images shown are representative of at least four images from at least two independent experiments.
was discrete vacuolization apparent in cerebellar fibre tracts of Glialcam\textsuperscript{dn/dn} mice.

After appearing in the cerebellum, vacuolization extends to several brain regions in Clcn2\textsuperscript{−/−} mice\textsuperscript{8}. By contrast, myelin vacuolization was largely restricted to the cerebellum of Glialcam\textsuperscript{−/−}, Glialcam\textsuperscript{dn/dn} and Mlc1\textsuperscript{−/−} mice even after 1 year (Supplementary Fig. 8a). In contrast to early retinal degeneration of Clcn2\textsuperscript{−/−} mice\textsuperscript{9}, the retinæ of Mlc1 and Glialcam mouse models were unaffected up to 1 year of age (Supplementary Fig. 8b). Electron microscopy revealed vacuoles in myelin sheaths of cerebellar axons from Glialcam\textsuperscript{−/−}, Glialcam\textsuperscript{dn/dn} and Mlc1\textsuperscript{−/−} mice (Fig. 8b). Modest pathological changes were also seen in somata of astrocytes and OLs. Their cytoplasm appeared less electron dense and occasional vacuoles could be observed in astrocytes (Supplementary Fig. 9).

One may hypothesize that the leukodystrophy observed in Glialcam\textsuperscript{−/−} and Mlc1\textsuperscript{−/−} mice might be entirely due to the associated changes in CIC-2 and the resulting consequences for ion homeostasis\textsuperscript{8}. In this case, the additional loss of GlialCAM in Clcn2\textsuperscript{−/−}/Glialcam\textsuperscript{−/−} mice should not increase the severity of leukodystrophy over that of Clcn2\textsuperscript{−/−} mice. However, in mice lacking both proteins’ vacuolization appeared earlier and was more severe (Fig. 8c). We also crossed Glialcam\textsuperscript{−/−} with Clcn2\textsuperscript{hyp/hyp} mice that express CIC-2 at <10% of WT levels (Supplementary Fig. 1f–i). Clcn2\textsuperscript{hyp/hyp} mice lacked white matter vacuolization at 17 weeks of age (Fig. 8d), demonstrating that a small amount of CIC-2 suffices to maintain myelin integrity as long as CIC-2 is correctly targeted and regulated by GlialCAM. Furthermore, the reduction in CIC-2 protein levels in Glialcam and Mlc1 mouse models is \textit{per se} not responsible for myelin vacuolization, as their CIC-2 levels are considerably higher than in the hypomorphic mouse. Crossing Clcn2\textsuperscript{hyp/hyp} with Glialcam\textsuperscript{−/−} mice, however, strongly increased their myelin vacuolization (Fig. 8d), suggesting that CIC-2 and GlialCAM operate in the same pathogenic pathway.

**Discussion**

We have analysed several genetic mouse models for human leukodystrophy to dissect the pathogenic roles of the multipass membrane protein MLC1, the cell adhesion molecule GlialCAM and the Cl\textsuperscript{−} channel CIC-2. The clustering of these proteins at glial plasma membrane domains depended on the presence of both MLC1 and GlialCAM, but not on CIC-2. The reduction in oligodendrocytic Cl\textsuperscript{−} currents in Glialcam and Mlc1 mouse models indicated that impaired glial ion homeostasis contributes to MLC disease. Mice lacking both CIC-2 and GlialCAM, however, showed that MLC leukodystrophy cannot be attributed solely to a loss of CIC-2.

GlialCAM can bind MLC1 (ref. 2) and CIC-2 (ref. 12) within the same cell and this binding might be mutually exclusive\textsuperscript{12}.
GliCAM also forms cis-homo-oligomers within the membrane, but the relevant binding sites are not yet known. GliCAM also interacts with itself in trans through its extracellular Ig domains. These domains might interact also with other proteins. Indeed, GliCAM overexpression increases adhesion to the extracellular matrix and modulates cell migration, and GliCAM localizes to cell protrusions in spread cells.

By accumulating at cell–cell contacts through homophilic interactions in trans, GliCAM targets CIC-2 and MLC1 to these sites in cultured cells, and stabilizes MLC1. By contrast, CIC-2 levels do not increase with GliCAM cotransfection, and MLC1 expression lacks discernible effects on either GliCAM7 or CIC-2 (refs 12,16). The present systematic analysis of cell pairs revealed that accumulation of CIC-2 or MLC1 at cell–cell junctions only required GlialCAM, but neither CIC-2 nor MLC1, to be present in both cells.

Our work demonstrates that GliCAM localizes CIC-2 and MLC1 to distinct sites also in vivo. Without GliCAM, MLC1 and CIC-2 accumulated in BG somata. We were surprised that disruption of MLC1 also mislocalized GliCAM and CIC-2. As MLC1 may not bind CIC-2 (refs 12,16), its effect on CIC-2 might be mediated by the mislocalization of GliCAM. However, the effect of MLC1 on GliCAM is equally unexpected since knockdown of MLC1 in astrocytes changed neither the expression nor the localization of GliCAM7. Does MLC1 stabilize the GliCAM–GliCAM interaction in vivo, an effect easily overlooked in vitro because of overexpression? Or does MLC1 serve as a co-receptor for GliCAM, with GliCAM/MLC1 binding in trans not only to GliCAM but also to other proteins present in the brain but absent in cell culture?

Surprisingly, MLC1 disruption also destabilized GliCAM and CIC-2 in OLs, although they apparently lack MLC1 (refs 2,19,20). MLC1 expression appears to be restricted to astrocytes since MLC1 binding is found in vivo in patients with dominantly inherited MLC2B disease. It changes a residue in the extracellular Ig-like domain and probably interferes with binding to ligands. Indeed, when GliCAM carries disease-causing mutations in Ig domains (for example, G89D that affects the same residue as G89S), neither GliCAM nor MLC1 or CIC-2 accumulate at cell–cell junctions. However, mutants like G89D can still bind MLC1 (ref. 7) or CIC-2 and can modify its Cl− currents. Similarly, the GliCAM G89S mutant was mislocalized in Gliacalcldn/dn mice in vivo and consequently failed to correctly localize CIC-2 and MLC1. MLC1 abundance...
Figure 8 | Myelin vacuolization in Glialcam and Mic1 mouse models. (a) Haematoxylin–eosin (H&E) staining of sagittal paraffin sections of the cerebellum of 8, 16 and 52-week-old mice. (b) Ultrastructural analyses of myelin vacuolization. Myelin vacuolization at different magnifications. asterisk, myelin vacuole; arrow, aberrant myelin sheet inside vacuole; a, axon; bv, blood vessel; o, oligodendrocyte. Scale bars, 5 μm (upper row); 2 μm (middle row); 1 μm (bottom row). (c) H&E staining of the cerebellum of 8-week-old Clcn2−/−, Glialcam−/− double-mutant mice. (d) H&E staining of the cerebellum of 17-week-old Clcn2hyp/hyp, Glialcam−/− double-mutant mice. Scale bar, 400 μm (a,c,d). For each genotype and age, two animals (≥4 sections each) were analysed.

<table>
<thead>
<tr>
<th></th>
<th>WT</th>
<th>Clcn2−/−</th>
<th>Glialcam−/−</th>
<th>Glialcamdn/dn</th>
<th>Glialcam+dn</th>
<th>Mic1−/−</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>52 weeks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Glialcam−/−</th>
<th>Glialcam+dn</th>
<th>Mic1−/−</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Clcn2−/−; Glialcam−/−</th>
<th>Clcn2−/−; Glialcam+dn</th>
<th>Clcn2−/−; Glialcam−/−</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 weeks</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17 weeks</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
was robustly decreased in Glialcam\(^{-/-}\) mice, suggesting an increased stability of GlialCAM/MLC1 complexes. The GlialCAM mutant, although mislocalized, partially retained its stabilizing effect on MLC1, in particular outside the cerebellum (Fig. 1c,d). No such stabilization was observed for CIC-2, possibly indicating that mutant GlialCAM binds CIC-2 less strongly than MLC1. Western blots suggested that CIC-2 is more efficiently stabilized by GlialCAM in the cerebellum than in the rest of the brain. However, CIC-2 is also expressed in neurons where its expression should not depend on GlialCAM. Hence, this result may be due to a higher glial versus neuronal CIC-2 expression in the cerebellum.

CIC-2 is a widely expressed plasma membrane Cl\(^-\) channel that slowly activates on hyperpolarization, cell swelling and moderately acidic extracellular pH\(^{13,15}\). These characteristics were observed in heterologous overexpression and in native cells\(^{9,28}\) including neurons\(^{29,30}\) and astrocytes\(^{31-33}\). Upon heterologous co-expression, GlialCAM increases CIC-2 currents and drastically changes their properties from inwardly rectifying to a nearly co-expression, GlialCAM increases ClC-2 currents and drastically but neither at BG somata nor in astrocytes\(^{31-34}\) if all three cell types co-express these two proteins? One may hypothesize that binding of one GlialCAM molecule to a ClC-2, than the change in channel rectification. The stoichiometry of GlialCAM on ClC-2 localization and abundance in BG suggests that the majority of ClC-2 is normally anchored and stabilized by GlialCAM. This anchoring might require less GlialCAM per CIC-2 than the change in channel rectification. The stoichiometry of CIC-2/GlialCAM binding is currently unknown. One could speculate that binding of one GlialCAM molecule to a homodimeric CIC-2 channel suffices for anchoring, but that two (or more) GlialCAM \(\beta\)-subunits are required to change the gating of the two CIC-2 pores\(^{35}\).

An increase of up to twofold in membrane capacitance of BG and OLs suggested that their volume was increased when either MLC1, GlialCAM or CIC-2 was lacking. Independent evidence for cell swelling was obtained from the apparent inactivation of CIC-2 currents in WT BG that could be reversed by hypo-osmotic swelling and was abolished in Glialcam\(^{-/-}\) cells.

A common denominator for the increase in glial cell volume may be a reduction of CIC-2 currents. Loss of CIC-2, which is swelling activated\(^{13,15}\) and constitutively open when modified by GlialCAM\(^{12}\) may cause cell swelling because the Cl\(^-\) equilibrium potential of glia\(^{36-38}\) predicts an outwards direction of Cl\(^-\) flux and associated water transport. Although CIC-2 currents at BG somata were not reduced in Glialcam or Mlc1 mouse models, CIC-2 was strongly decreased along BG processes. At these sites, which escape our patch clamp analysis, CIC-2 currents might be linearized and enhanced by GlialCAM and might influence cell volume. MLC1 was reported\(^{39}\) to stimulate the ubiquitous volume-regulated anion channel (VRAC) that is distinct from CIC-2 (ref. 13) and is not known at the molecular level\(^{40}\). Short interfering RNA-mediated knockdown of GlialCAM or MLC1 reduced VRAC currents\(^{41}\). This effect is probably indirect as AQP4 knockdown also reduced astrocytic VRAC currents\(^{41}\).

Since both CIC-2 and VRAC mediate Cl\(^-\) currents, and because membrane capacitance was also increased in Clcn2\(^{-/-}\) mice, the simplest explanation for glial swelling remains a lack of CIC-2. Another factor may be the lack or downregulation of GlialCAM-mediated adhesion in Glialcam and Mlc1 mouse models, respectively. The somewhat larger increase in cell capacitance of BG from Glialcam\(^{-/-}\) and Mlc1\(^{-/-}\) mice compared with Clcn2\(^{-/-}\) mice is compatible with this notion.

Disruption of all three genes, that is, Clcn2, Glialcam and Mlc1, entails leukodystrophy in mice and humans. Since GlialCAM binds to both CIC-2 and MLC1 and disruption of either Glialcam or Mlc1 affects the localization and abundance of the two other proteins, this raises the question whether loss-of-function mutations in those genes cause leukodystrophy through a common pathway.

Four observations suggest loss of CIC-2 function as the prime suspect for such a pathway: first, CIC-2 localization was changed upon Glialcam or Mlc1 disruption, whereas lack of CIC-2 had no detectable effect on either GlialCAM or MLC1. Second, OLs, the cells mainly affected by vacuolization, showed decreased CIC-2 currents in both Glialcam\(^{-/-}\) and Mlc1\(^{-/-}\) mice. As OLs lack MLC1 (refs 2,19,20), the myelin vacuolization in Mlc1\(^{-/-}\) mice may result from the secondary loss of CIC-2 and/or GlialCAM. Third, leukencephalopathy was more severe in Clcn2\(^{-/-}\) mice than in Glialcam\(^{-/-}\) or Mlc1\(^{-/-}\) mice, which retain reduced CIC-2 levels in glia. The fact that disruption of Clcn2, but not of Glialcam or Mlc1, additionally causes testicular and retinal degeneration\(^{9}\) is because of the wider expression pattern of CIC-2 (ref. 14). Fourth, when Clcn2\(^{-/-}\) mice were crossed with Clcn2\(^{hyp/hyp}\) mice that express <10% of WT CIC-2 levels but lack leukodystrophy, myelin vacuolization of resulting Glialcam\(^{-/-}\)/Clcn2\(^{hyp/hyp}\) mice was more severe than in Glialcam\(^{-/-}\) mice, suggesting a common pathogenic pathway.

We have previously hypothesized\(^{8}\) that CIC-2 disruption causes leukodystrophy by disturbing the buffering of extracellular ions analogous to the postulated role of CIC-2 in regulating the milieu extérieur of sertoli cells and photoreceptors\(^{5}\). Indirect support for this model came from the co-localization at astrocytic endfeet of CIC-2 with the K\(^+\) channel Kir4.1 (refs 43,44), whose inactivation also entails leukodystrophy\(^{42,44}\) as does ablation of glial connexins 32 and 47 (refs 45–47). These proteins are thought to co-operate in ‘K\(^+\) siphoning’\(^{48}\). This model states that K\(^+\) released from neurons during action potential repolarization is taken up by Kir4.1 into the connexin-linked astroglial network and is then equilibrated with serum through astrocytic endfeet at blood vessels. Cl\(^-\) fluxes through CIC-2 may be needed for an overall electroneutral transport across glial
plasma membranes during K+ siphoning. The linearization of CIC-2 currents by GlialCAM may be important for K+-siphoning as a rise of extracellular K+ upon neuronal activity is expected to depolarize the glial membrane and shut down CIC-2. Dysregulation of Cl⁻ concentrations in the small extracellular clefts might also increase extracellular P inhibitors of HCO3- exchangers. Cell type-specific disruption of CIC-2 will be needed to clarify whether leukodystrophy results from a loss of CIC-2 currents in OLs, astrocytes or both.

Genetic evidence, however, showed that GlialCAM loss elicits leukodystrophy only in part through CIC-2. Since pathology was more severe in Clcn2/−/−/Glialcam/−/− than in Clcn2/−/−/ mice, GlialCAM ablation has additional, CIC-2-independent pathogenic effects. The lack of GlialCAM-mediated cell adhesion may also come into play, but the low abundance of GlialCAM in myelin sheaths and the prominence of other adhesion molecules makes a direct role in myelin vacuolization unlikely. Moreover, vacuolization developed after apparently normal brain development. ClC-2 currents by GlialCAM may be important for K+ concentration in the small extracellular clefts that might affect extracellular P inhibitors of HCO3- exchangers. Cell type-specific disruption of CIC-2 will be needed to clarify whether leukodystrophy results from a loss of CIC-2 currents in OLs, astrocytes or both.

In vitro studies had shown that the adhesion molecule GlialCAM directly interacted with either MLCl or CIC-2, changing their subcellular localization and profoundly altering CIC-2 currents. However, no effect of MLCl on GlialCAM or CIC-2 had been described. Here we showed that in addition to GlialCAM also MLCl, but not CIC-2, is important for tethering the protein complex to specific plasma membrane domains of both astrocytes and OLs. Although GlialCAM, together with MLCl, anchors CIC-2 in both types of glia, the rectification of CIC-2 Cl⁻ currents was only abolished in OLs. Hence, the localizing effect of GlialCAM can be dissociated from its impact on CIC-2 channel function. Reduction or change in CIC-2 currents is common to all forms of leukodystrophy studied here. Mutations in both GlialCAM and MLCl may cause leukencephalopathy in part through impaired brain ion homeostasis. Crosses between Clcn2/−/− and Glialcam/−/− mice, however, show that the loss of GlialCAM or MLCl has additional pathogenic effects unrelated to CIC-2. The unexpected similar effects of Mlc1 and Glialcam ablation on their protein partners rationalize the indistinguishable symptomatology of the MLCl and MLCl2A forms of human leukodystrophy.

Methods

Mice. All animal experiments were approved and in compliance with LaGeSo, Berlin, Germany, and the Animal Care and Ethics Committee of the IDIBELL and the rules set by the Government of Cataluña, Spain. Experiments were performed with mice at different ages (indicated in figure legends), and both sexes were used interchangeably. MiCl/−/− mice were generated by Institut Clinique de la Souris (Strasbourg, France). The targeting vector was obtained from amplification of BAC RP 24-467H19 (5’-arm) and from amplification of 129S2/SvPas genomic DNA (3’-arm). Exons 2 and 3 were flanked by loxP sites. Exon 3 contained additionally a neomycin cassette flanked by FRT sites. The targeting vector was introduced into the H129 embryonic stem (ES) cell strain by electroporation and positive clones were selected by PCR. Homologous recombination was confirmed by Southern blotting and chromosomal integrity was checked by karyotyping. Correctly targeted ES cell clones were injected into C57BL/6 Blastocysts and chimeric animals were crossed to FLPrecombinase expressing ‘deleter’ mice to remove the floxed exons 2 and 3. PCR genotyping was performed using primer sequences 5’-CTGAAATCTGAGTAGGATTGGTGCC-3’ (P1), 5’-GAACCCCTCCTTATTGTAAGGTG-3’ and 5’-ACAACTCCCATTCTGAG-3’ (P2) and 5’-GACCCAACAGCCACACATGC-3’ (P3).

Mice carrying the dominant-negative mutation G895S in exon 2 of the Glialcam (Hepaam) gene (GlialcamDeltaK) and additionally having exons 2-4 flanked by loxP sites were generated by TaconicArtemis (Cologne, Germany) and were kept in a C57BL/6J genetic background. Targeting vectors were designed by the International Neonatal Consortium (INN) of the C57BL/6J RPCIB-731 library. Two positive selection markers, a neomycin-resistant cassette flanked by FRT sites and a puromycin-resistant cassette flanked by F3 sites, were inserted into introns 1 and 4, respectively. The targeting vector was introduced into the C57BL/6J Ntcp ES cell line by electroporation and positive clones were selected by PCR. Homologous recombination was confirmed by Southern blotting. Correctly targeted ES cell clones were injected into C57BL/6 Blastocysts and chimeric animals were crossed to FLPrecombinase expressing ‘deleter’ mice (in C57BL/6 background) to remove neomycin and puromycin-resistant cassettes. To generate GlialcamDeltaK mice, GlialcamDeltaK/mice were crossed to Cre-deleter mice (in C57BL/6 background) to remove the ‘floxed’ exons 2-4. PCR genotyping was performed using primer sequences 5’-CATTTTTCTGGCATACTACCTCC-3’ (P1), 5’-TGCCTTTGTTTCCTCAGTC-3’ (P2) and 5’-TGAAGGAAGAGCAGAC-3’ (P3).

Generation of Clcn2/−/− mice has been described previously. Mice expressing low levels of CIC-2 (hypomorph) Clcn2/−/−/Mlc1/−/− were generated intentionally by insertion of loxP sites flanking exons 2 and 3 of Clcn2. A 10.6-kb fragment of R1 ES cell genomic DNA containing exons 1-21 of Clcn2 were cloned into pKo Scrambler Plasmid 901 (Lexicon Genetics Inc.). A neomycin-resistant cassette flanked by loxP sites and Ascl sites at both ends was inserted into the Clal site. Double homologous clones and a third loxP site and an additional EcoRV site to aid Southern blot analyses were inserted between exons 3 and 4. The targeting construct was introduced into R1 ES cells by electroporation and positive clones were selected by Southern blot analyses. Selected positive clones were then electroporated with a Cre recombinase expression construct for removal of the neomycin-resistant cassette. Clones that had not lost the neomycin-resistant cassette were removed from injection into C57BL/6 Blastocysts. PCR genotyping was performed using primers 5’-TTAGGCGGAATATTTCCGGAATGGGAGG-3’ (P1) and 5’-GGAGGAAGAGCAGAC-3’ (P2). PCR genotyping was performed using primers 5’-CCGAGCGGATGATACTC-3’ (P3) and 5’-AGGGAGAAGCAGAC-3’ (P4). Correctly targeted ES cell clones were injected into C57BL/6 Blastocysts and mice were in a C57BL/6-129/Sv mixed genetic background, while Glialcam/−/− and GlialcamDeltaK were in a C57BL/6 background. For some electrophysiological measurements mice were crossed to a transgenic line expressing enhanced green fluorescence protein under the control of the human GFAP promoter (EVB/N background), resulting in enhanced green fluorescence protein expression in astrocytes.

Generation of antibodies. Antibodies against mouse CIC-2 were raised in rabbits against two peptide sequences of different length corresponding to the extreme C terminus: (C)WGRPSRRHLPRGETPSDDDDKQ (used for western blotting) and (C)HLRGETPSDDDDQK (by Biogenes, Berlin, Germany; used for immunofluorescence staining). A cysteine in the native protein sequence was replaced by the highlighted serine to prevent coupling of this residue to the carrier protein.

GlialCAM-specific antibodies used for western blots were raised in rabbits against peptide (C)LKDDKSDDPENPATEPR and those used for immunostainings were raised in guinea pigs to peptide (C)AGVQRQIREQSGEQVSIA. Both peptide sequences correspond to non-overlapping parts of the intracellular C-terminal region of mouse GlialCAM.

Antibodies recognizing the amino terminus of mouse MLCl (used for immunostainings) were raised in rabbits and guinea pigs against peptide TREGQFREELGYDF (C)20. Antibodies to the MLCl C terminus (used for western blotting) were raised in rabbits against peptide CJPQERAVRGLPKLEDK.

Generation of antibodies was performed by Pineda Antibody Services (Berlin, Germany), unless indicated otherwise. ‘(C)’ indicates cysteines not included in the native protein sequence that were added to facilitate coupling to carrier protein. Antibodies were affinity purified from serum using the immunizing peptide.

Western blot analyses. For western blot analyses, membrane fractions were isolated from mouse tissue. To this end, tissue homogenate was prepared in 20 mM Tris–HCl pH 7.4, 140 mM NaCl, 2 mM EDTA with protease inhibitors (4 mM Pefabloc and Complete EDTA-free protease inhibitor cocktail, Roche) using a glass Dounce homogenizer and cleared by centrifugation for 10 min at 1,000 × g. Membrane fractions were pelleted from the cleared homogenate by ultracentrifugation for 30 min at 270,000 × g, and the pellet was resuspended by sonication in 50 mM Tris pH 6.8, 140 mM NaCl, 2 mM EDTA with protease inhibitors. Equal amounts of protein were separated by SDS–polyacrylamide gel electrophoresis and blotted onto nitrocellulose. Blots were reprobed with mouse anti–β-actin (Clone AC-74, Sigma A2228, 1:5,000) as a loading control.

Immunohistochemistry. Deeply anaesthetized mice were perfused with 1% paraformaldehyde (PFA) in PBS and 6 μm sagittal cryosections were prepared from brains. Sections were postfixed with 1% PFA/PBS for 10 min, permeabilized with 0.2% Triton-X100 in PBS and blocked with 3% BSA in PBS. Antibodies were

NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4475 | www.nature.com/naturecommunications

© 2014 Macmillan Publishers Limited. All rights reserved.
in diluting blocked buffer. Incubation with primary antibody (see below for dilution) was performed at 4 °C overnight, incubation with secondary antibodies (1:10,000) coupled to Alexa fluorophores (Molecular Probes) was carried out for 1 h at room temperature. Nuclei were stained with 4',6-diamidino-2-phenylindole (Sigma). In addition to the self-generated primary antibodies described above, the following commercial antibodies were used: mouse anti-GFAP (clone G-A-3, Sigma G5393, 1:10,000), mouse anti-S100β (clone SH-B1, Sigma S2532, 1:10,000), mouse anti- Glialcam 0 (clone A7L6, Merck Millipore MA1948B, 1:2,000), and goat anti-aquaporin-4 (Santa Cruz sc-9888, 1:50). The rabbit anti-
Kir1.4 (used here at a dilution of 1:100) was kindly provided by S. Takeuchi.

Images were acquired using an LSM510 confocal microscope and ZEN software (Zeiss).

Histology. For histological analyses of brains and eyes, mice were perfused with 4% PFA/PBS and organs were postfixed overnight. Haematoxylin–eosin staining was performed on 6 μm paraffin sections of brains and eyes.

Electron microscopy. For ultrastructural studies, deeply anaesthetized mice were transcardially perfused with 4% paraformaldehyde (PFA) and 2.5% glutaraldehyde in 0.1 M PB (pH 7.4). The brains were removed and cut vertically into two halves. The brain samples were postfixed in the same fixative overnight at 4 °C. Brains were cut into 150 μm sagittal sections of the cerebellum with a Leica vibratome. Cerebellum sections were cut into 1 mm2 fragments. They were rinsed in 0.1 M PB (pH 7.4) and postfixed with 2% aqueous osmium tetroxide and 1.5% potassium hexafluoracetate (K3[Fe(CN)6]) for 30 min. After rinsing with 50% ethanol, sections were stained en bloc with 1% uranylacetate for 1 h in 70% ethanol. Fragments were dehydrated in graded ethanol, followed by infiltration of propylene oxide and embedding in Epon (Electron Microscopic Supplies, Hatfield, PA, USA). Ultrathin sections (60 nm) were prepared with a Reichert Ultracut S, stained in 5% uranylacetate and 0.4% lead citrate (cC6H907Pb2). Stained ultrathin sections were examined with a Jeol 100CX electron microscope and a Gatan Ultrascan 1000 Camera. Two mice per genotype were examined, with more than 10 ultrathin sections each and that displayed consistent results.

Molecular biology. For quantitative real-time PCR, total RNA was isolated from the cerebellum of 11–18-week-old mice using the RNeasy lipid tissue mini kit with DNA-free protocol. Subsequently, PCR was performed using the following primer sequences for Glialcam: 5'-ATGCGGCGTCAATCAGGACCA-3' and 5'-TGGCTGCTGTGAACAGGGTTTT-3' for Glialcam; 5'-TCAGGCGATTTCTCCACATTTA-3' and 5'-GGACCGGGCCGAATGAT-3' for Mlc1. Primer sequences for Lcn2: 5'-CAGTGACAGCAAATGACCAGGACCA-3' and 5'-CATAAAGCTGGTCACTCCCA-3' and for β-actin: 5'-GGCCACGCTGGAGAAC-3' and 5'-GGATTAGCCAGGCTTCTCCTGAT-3' as described previously.133,134 Missplicing in Lcn2 has been associated with semiquantitative reverse transcription-PCR. Total RNA was isolated from brain using Trizol reagent (Invitrogen) and cDNA synthesis was performed as described above. Subsequently, PCR was performed using the following primer sequences: 5'-ATGGCGGCGTCAATCAGGACCA-3' and 5'-GGACCGGGCCGAATGAT-3' for Mlc1 were generated by PCR using full-length cDNA clones (SourceBioScience) as templates. Where applicable, C-terminal haemagglutinin (HA) tags were added by PCR and constructs were cloned into the pcDNA3.1 mammalian expression vector (Invitrogen). The cDNAs for rat Clcn2 and human Glialcam were cloned in the pRcRc vector for expression with the mammalian CMV promoter.

Cell culture/transfection. HEaL cells (DSMZ, Germany, ACC 57, lot 17) were transfected with Lcn2, Glialcam or Mlc1 expression constructs using poly-
ethyleneimine. One day post transfection, cells were split and seeded on coverslips. Three days after transfection, cells were fixed with 4% PFA/PBS, permeabilized with 0.2% Triton-X100/PBS and subjected to antibody staining as described for immunohistochemical on tissue sections.

Electrophysiological analysis of glial cells in brain slices. Unless specified, concentrations are in mM and all solutions for incubating slices were constantly 
flushed with 95% O2 / 5% CO2 at 37 °C. The bath solution was composed of (in mM): 117 NaCl, 1.3 MgCl2, 10 HEPES and 5 EGTA adjusted to pH 7.3 and to 290 ± 5 mOsM kg−1. In some experiments, slices were perfused with either a hypotonic diluted NMDG-Cl solution (80%) to 235 ± 5 mOsM kg−1 or a hypertonic NMDG-Cl solution with sucrose added to 325 ± 5 mOsM kg−1. A holding current of −120 mV was applied to the cells before returning back to the holding potential of −10 mV. Currents from each cell were averaged by genotype to obtain an average current (I) profile. In other analyses, the average I profile from each genotype was divided (Arithmetic mean) by its average capacitance (C) to obtain average current density (UC) profile. For further information regarding UC traces, see Figure 2G. Animals were examined to the C2-specific 1 or UC traces profiles in the different mouse lines.

Processing of biocytin-filled cells in brain slices. Following patch clamp experiments, slices were fixed in 4% PFA (in 1% PVS) overnight at 4 °C. Slices were washed in wash buffer containing 0.1 M PB pH 7.4 and 0.25% Triton-X100. Slices were blocked in wash buffer containing 5% normal goat serum for 2 h at room temperature. For secondary detection, Alexa Fluor 555 Streptavidin (Life Technologies) was added to the slices at a 1:500 dilution for overnight incubation at 4 °C. Slices were washed and mounted on gelatinized slides with Fluoromount G (SouthernBiotec). Images were acquired with a confocal 
microscope (Zeiss LSM 510).

Patch clamp measurements in HEK cells. HEK293 cells were transfected in 12-well plates at ~50% confluency with either 0.5 μg of plasmid encoding rat CIC-2 or 0.25 μg of plasmid encoding rat CIC-2 and 0.25 μg of plasmid encoding human Glialcam. All cells were co-transfected with a reporter plasmid expressing GFP. Using a custom-made microelectrode amplifier (Multiclamp 700B) with acquisition software (Clampex 10.3, Molecular Devices, USA), whole-cell currents were measured by patch clamp analysis 2 days after transfection. When filled with an intracellular solution containing (in mM): 140 NaCl, 1 MgCl2, 10 HEPES and 5 EGTA adjusted to pH 7.3 and to 290 ± 5 mOsM kg−1, patch pipettes registered resistances of 4–6 MΩ. The bath solution was composed of (in mM): 117 NaCl, 1.3 MgCl2, 10 HEPES and 5 EGTA adjusted to pH 7.3 and to 290 ± 5 mOsM kg−1 with sucrose. CIC-2 currents were elicited with 1 s voltage pulses from +40 to −120 mV and a final voltage pulse at +40 mV before returning back to the holding potential of −10 mV. Individual cells were first counted in the normal bath solution and again following superfusion of bath solution containing 200 μM disodium carbonoxalene. Signals were digitized at 10 kHz, filtered at 2 kHz and stored for off-line analysis using ClampFit software.


Acknowledgements

We thank L. Leisle for detecting aberrant splicing in Clcn2gymnmyc mice, N. Richter and H. Kettmann for advice on patching OLA, A. Duarri and M. Font-Llados for starting work with GliaCAM, M. C. Moh for help with electrophysiology, S. Takeuchi for the Kir4.1 antibody, and A. Weidlich, J. Jedamzik, P. Seidler, R. Silles, A. Alcántara, L. Gonzalez and E. Pratt for technical assistance. K.G. was supported by the Boehringer Ingelheim Fonds and is a student of the Freie Universität Berlin. This study was supported by ELA Research Foundation.
ELA2009-017C4, ELA2012-014C2B to R.E. and V.N., MINECCO SAF2009-12606-C02-02 to V.N., SAF 2009-07014, SAF 2012-31486, PS09/02672-ERARE and Icrea Academia prize to R.E., Catalonian Government SGR2009-1490 to V.N. and SGR2009-719 to R.E., and DFG (Exc 257) and Prix Louis-Jeantet de Médecine to T.J.J.

Author contributions
The Glialcam mouse models were generated from the lab of T.J.J. and the Mlc1 mouse model was generated from the labs of R.E. and V.N.. M.B.H.-B. generated antibodies and analysed all mouse models (histology, IHC, immunoblots) and transfected cells. S.S. generated antibodies and analysed the Mlc1 mouse model (histology, IHC, immunoblots). I.J.O. analysed all mouse models by electrophysiology. I.F. and S.H. performed EM analysis. M.A. generated the Clcn2hyp/hyp mouse model. K.G. developed the method for recording glial chloride currents. C.V. and M.L.d.H. performed histology and biochemical analysis on the Mlc1 mouse model. All authors planned and analysed experiments. T.J.J., R.E. and V.N. supervised experiments. T.J.J. was the primary writer and managed producing the manuscript with critical input from R.E., V.N. for design, content and style. All authors read and provided feedback on the manuscript.

Additional information
Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Høegh-Beiler, M. B. et al. Disrupting MLC1 and GlialCAM and ClC-2 interactions in leukodystrophy entails glial chloride channel dysfunction. *Nat. Commun.* 5:3475 doi: 10.1038/ncomms4475 (2014).
Megalencephalic leukoencephalopathy with subcortical cysts protein 1 regulates glial surface localization of GLIALCAM from fish to humans

(Human Molecular Genetics, 2014)

Contribució:

- Preparació del teixit per als estudis de ME (Figura 1)
- Generació dels constructes zGlialCAMa, zGlialG89S, zGlialG89D, zGlialD128N
- Estudis de localització de zMLC1 i rClC-2 en presència de zGlialCAMa (Figura 2 C,D,E,F,G,H)
- Anàlisis de les imatges de MRI i càlcul del volum cerebral (Figura 6 A,B,G)
- Estudis de localització realitzats en el teixit de la pacient (Figura 7)
- Posta a punt del cultiu primari d’astròcits del ratolí knock-out de Mlc1
- Anàlisis de MLC1 i GlialCAM en els astròcits del knock-out (Figura 8 A,B,C,D,E)
- Preparació dels cultius per als anàlisis electrofisiològics
- Estudi del fenotip vacuolitzant en els astròcits del knock-out (Figura 8 H,I,J)
- Estudi de localització de GlialCAM en condicions d’alt contingut de K⁺ (Figura 9)
- Estudi de l’expressió i la localització de les mutacions de zGlialCAMa (Figura Suplementària 3)
Megalencephalic leukoencephalopathy with subcortical cysts protein 1 regulates glial surface localization of GLIALCAM from fish to humans

Sónia Sirisi1,4,†, Mónica Folgueira5,†, Tania López-Hernández1, Laura Minieri6, Carla Pérez-Rius1, Héctor Gaitán-Peñas1, Jingjing Zang7, Albert Martínez2, Xavier Capdevila-Nortes1, Pedro De La Villa8, Upasana Roy9,10, A. Alia8,10, Stephan Neuhaus7, Stefano Ferroni6, Virginia Nunes3,4,11, Raúl Estévez1,12,†,* and Alejandro Barrallo-Gimeno1,12,†,*

1Sección de Fisiología, Departamento de Ciencias Fisiológicas II, 2Department of Cell Biology and 3Sección de Genética, Departamento de Ciencias Fisiológicas II, Universidad de Barcelona, Barcelona, Spain 4Laboratorio de Genética Molecular-IDIBELL, L’Hospitalet de Llobregat, Spain 5Department of Cell & Molecular Biology, University of A Coruña, A Coruña, Spain 6Department of Pharmacy and Biotecnology, University of Bologna, Bologna, Italy 7Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland 8Department of Systems Biology, University of Alcalá, Alcalá de Henares, Madrid, Spain 9Leiden Institute of Chemistry, Leiden University, Leiden, The Netherlands 10Institute of Medical Physics and Biophysics, University of Leipzig, Leipzig, Germany 11U-730 and 12U-750, Centro de Investigación en red de Enfermedades Raras (CIBERER), ISCIII, Barcelona, Spain

Received March 19, 2014; Revised and Accepted May 8, 2014

Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a leukodystrophy characterized by myelin vacuolization and caused by mutations in MLC1 or GLIALCAM. Patients with recessive mutations in either MLC1 or GLIALCAM show the same clinical phenotype. It has been shown that GLIALCAM is necessary for the correct targeting of MLC1 to the membrane at cell junctions, but its own localization was independent of MLC1 in vitro. However, recent studies in Mlc1−/− mice have shown that GlialCAM is mislocalized in glial cells. In order to investigate whether the relationship between Mlc1 and GlialCAM is species-specific, we first identified MLC-related genes in zebrafish and generated an mlc1−/− zebrafish. We have characterized mlc1−/− zebrafish both functionally and histologically and compared the phenotype with that of the Mlc1−/− mice. In mlc1−/− zebrafish, as in Mlc1−/− mice, Glialcam is mislocalized. Re-examination of a brain biopsy from an MLC patient indicates that GLIALCAM is also mislocalized in Bergmann glia in the cerebellum. In vitro, impaired localization of GlialCAM was observed in astrocyte cultures from Mlc1−/− mouse only in the presence of elevated potassium levels, which mimics neuronal activity. In summary, here we demonstrate an evolutionary conserved role for MLC1 in regulating glial surface levels of GLIALCAM, and this interrelationship explains why patients with mutations in either gene (MLC1 or GLIALCAM) share the same clinical phenotype.

INTRODUCTION

Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare type of congenital leukodystrophy characterized mainly by myelin vacuolization and early onset of macrocephaly (1). Magnetic resonance imaging (MRI) of patient’s brains shows diffuse signal abnormality, and this method is used for diagnosis during childhood (2). MLC is caused by mutations

†These authors contributed equally.
‡These authors share last authorship.
∗To whom correspondence should be addressed at: Facultat de Medicina, Departament de Ciències Fisiològiques II, Universitat de Barcelona, C/Feixa Llarga s/n 08907 L’Hospitalet de Llobregat, Barcelona, Spain. Tel: +34 934039781; Fax: +34 934024268; Email: restévez@ub.edu (R.E.); abarrollal@ub.edu (A.B.-G.)

#The Author 2014. Published by Oxford University Press. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
in either MLC1 (MIM #605908) or GLIALCAM (MIM #611642) genes (3,4).

MLC1 encodes for a membrane protein, which is expressed in several brain barriers, mainly in ependymal cells, astrocytes surrounding blood vessels and Bergmann radial glia in the cerebellum. In all cells, MLC1 is localized at cell junctions (5–7). Surprisingly, MLC1 is not expressed in oligodendrocytes, the site of the primary pathology of MLC (8). Mutations have been found across the whole coding sequence (3,9–11), which cause protein folding defects that lead to degradation of MLC1 (12,13). The function of MLC1 is still unknown, although it has been related to the activation of volume-regulated anion currents (VRAC) (14,15), involved in cellular osmotic response. It has been indicated that a reduced VRAC activity may lead to intracellular water accumulation and to the vacuolization observed in patients (15,16). In addition, other studies have suggested that MLC1 cooperates with the Na\(^{+}/K^{+}\)-ATPase and the TRPV4 channel (17,18), although the exact mechanism is still unknown.

GlialCAM (also called HEPACAM due to its original discovery in hepatic cancer cells) is a cell adhesion molecule of the immunoglobulin family (19) that is mostly expressed in glial cells (20) and co-localizes with MLC1 at astrocyte–astrocyte junctions (4). MLC patients with recessive mutations in GLIALCAM (known as MLC2A type of MLC, MIM #613925) present the same phenotype as patients carrying recessive mutations in MLC1 (MLC1 type of MLC, MIM #604004) (4,21). Some MLC patients have dominant mutations in the GLIALCAM gene (MLC2B type of MLC, MIM #613926), and these are associated to various degrees of phenotypic expression, ranging from severe retardation with or without autism (4,21).

Both data obtained from in vitro and from GlialCAM\(^{-/-}\) mice have demonstrated that GlialCAM is necessary for MLC1 to exit the endoplasmatic reticulum and target cell junctions (13,15,22). Furthermore, a mistargeting of both GlialCAM and MLC1 to cell junctions has been shown by in vitro studies with most missense GLIALCAM mutations (either recessive or dominant) and with GlialCAM\(^{dn/dn}\) knock-in mice harbouring a dominant mutation (4,13,22,23). In contrast, GlialCAM seems to be able to traffic to cell junctions by itself (13,19). Thus, the overlapping phenotype of MLC1 and MLC2A patients can be understood because of the cardinal role of MLC1 in the pathogenesis of MLC.

However, GlialCAM, but not MLC1, is detected in oligodendrocytes (4,20); it was also found that GlialCAM functions as an auxiliary glial-specific subunit of the broadly expressed CIC-2 chloride channel (24). Furthermore, MLC-related GLIALCAM mutations impair the trafficking of CIC-2 to cell junctions (23,24). Analyses of GlialCAM\(^{+/+}\) and GlialCAM\(^{dn/dn}\) knock-in mice have shown that localization of CIC-2 in glial junctions is dependent on GlialCAM (22). Thus, based on these in vitro and in vivo data, patients carrying recessive GLIALCAM mutations should be more severely affected than patients carrying recessive MLC1 mutations, as CIC-2 channel may also be affected in those carrying GLIALCAM mutations. However, there are no clinical differences between these two types of patients.

Recent studies with Mlc1\(^{-/-}\) mice have shown that, contrary to what was expected based on the lack of direct interaction between MLC1 and CIC-2, GlialCAM and CIC-2 are mislocalized in astrocytes and oligodendrocytes when MLC1 is absent (22). Based on cell culture data, it was indicated that MLC1 and CIC-2 could indirectly interact through homotypic extracellular GlialCAM-mediated interactions (22), as previously suggested (25). These results indicate that lack of function of CIC-2 may be involved in the pathogenesis of MLC (22). Lack of CIC-2 function has also been associated with a distinct form of leukoencephalopathy (26).

The mislocalization of GlialCAM found in Mlc1\(^{-/-}\) mice contradicts previous results obtained using RNA interference of Mlc1 in rat astrocytes and localization studies of GLIALCAM around blood vessels in a sample from an MLC1 patient (13). Although RNA interference may not completely reproduce the gene knockout phenotype, we have previously shown that Mlc1 RNAi induces a significant decrease in Mlc1 protein levels (12,13). Thus, it is unclear if GlialCAM is unstable without MLC1 only in mice, or whether this is a general mechanism.

To solve this controversy, we decided to examine the relationship between Mlc1 and GlialCAM in other animal species. We generated a zebrafish model for MLC based on the lack of mlc1. As in mice, characterization of the zebrafish model revealed that loss of mlc1 impairs the correct localization of glialcam, as GlialCAM was mislocalized in Bergmann glia. These results confirm that the MLC1-dependent localization of GlialCAM is a general mechanism, as data from Mlc1\(^{-/-}\) mouse had shown. As in the RNA interference experiments, cultured astrocytes from Mlc1\(^{-/-}\) mice show normal GlialCAM localization, but slightly reduced VRAC activity. However, we observed that mimicking neuronal activity in Mlc1\(^{-/-}\) astrocyte cultures causes GlialCAM mislocalization. Hence, data presented here explain previous discrepancies and reveal a conserved activity-regulated role of MLC1 in determining the localization of GLIALCAM.

RESULTS

GlialCAM is also mislocalized in Mlc1\(^{-/-}\) astrocytes close to ependymal cells

In situ hybridization and immunohistochemistry studies have demonstrated that MLC1 and GLIALCAM co-localize in astrocytes close to brain barriers, Bergmann glia and ependymal cells, and that GLIALCAM is additionally expressed in oligodendrocytes (4,6,7,20). In Mlc1\(^{-/-}\) mice, GlialCAM is mislocalized in astrocytes, Bergmann glia and oligodendrocytes (22). We examined whether GlialCAM was also mislocalized in ependymal cells by means of electron microscopy. To our surprise, gold particle-labelled antibodies showed that Mlc1 is not present in ependymal cells, but rather in astrocyte–astrocyte contacts below ependymal cells (Fig. 1A and C). Control experiments in Mlc1\(^{-/-}\) mice confirmed the specificity of the signal (Fig. 1B and D). GlialCAM co-localized with Mlc1 in subependymal astrocyte–astrocyte contacts (Fig. 1E and G), and, as observed previously in astrocytes and oligodendrocytes, GlialCAM was also mislocalized in astrocytes near ependymal cells in Mlc1\(^{-/-}\) mice (Fig. 1F and H). Thus, we conclude that the absence of Mlc1 in mice causes mistargeting of GlialCAM in all types of glial cells.
Identification of MLC-related genes in zebrafish

To address whether this Mlc1-dependent mislocalization of GlialCAM was a conserved feature, we decided to generate an Mlc1-deficient animal model in another species. By means of sequence database inspection, we found that genes encoding the orthologue of human MLC1 are present in all vertebrates, including zebrafish (Danio rerio), that has a single orthologue (Supplementary Material, Fig. S1A). In contrast, metazoan model organisms, such as Drosophila melanogaster and Caenorhabditis elegans, which lack myelin, do not possess MLC1 orthologues (3). For GLIALCAM, we observed that the teleost-specific genome duplication yielded two glialcam paralogues: glialcama and glialcamb (Supplementary Material, Fig. S2A).

Sequence comparison between zebrafish mlc1 and its human ortholog showed an overall 53% identity that was higher (63%) at the putative transmembrane domains and the terminal part of the C-terminus (Supplementary Material, Fig. S1B). Both glialcam paralogues showed a 76% identity with human
GLIALCAM across the two extracellular Ig-domains and the putative transmembrane domain, but the conservation of the C-terminal intracellular domain was very low, saved for a stretch of residues in the central part (Supplementary Material, Fig. S2B).

We cloned zebrafish mlc1 and both glialcam paralogues, fused to an intracellular FLAG tag, and expressed them transiently in HeLa cells. Importantly, glialcam could be predominantly detected in cell junctions (Fig. 2A), while glialcamb was found in a diffuse manner (Fig. 2B). Like its human counterpart (13), glialcamb was able to target zebrafish mlc1 (Fig. 2C–E) and rat chloride channel CIC-2 (24) (Fig. 2F–H) to cell junctions. Furthermore, glialcamb and not glialcamb was able to modify the functional properties of rat CIC-2-mediated currents in Xenopus oocytes. Glialcamb, as with the human ortholog (24), not only increased CIC-2-mediated currents, but also changed rectification and activation properties (Fig. 2I–L). To additionally verify that glialcamb behaves as human GLIALCAM, we analysed glialcamb variants containing MLC-related mutations in conserved residues (Supplementary Material, Fig. S2B) that have previously shown trafficking defects (13). As happened in human GLIALCAM (4), we observed that the introduction of MLC-related mutations in glialcamb negatively affected its junctional localization without substantially interfering with its expression levels (Supplementary Material, Fig. S3A–C).

These results suggest that zebrafish glialcamb, and not glialcamb, could perform the same physiological functions as human GLIALCAM. Therefore, we decided to focus our studies on this zebrafish paralogue.

Generation of a mutant mlc1 zebrafish line

We generated a zebrafish mlc1 knockout line by sequencing the first exons of the mlc1 gene on the ENU-based TILLING library at the laboratory of Dr C. Moens at the FHCRC (Seattle, USA). Unfortunately, we did not detect any stop, frameshift or splice site mutations that would potentially abolish normal protein expression. However, we detected a missense mutation (c.241T>G) in one allele (mlc1FH328), resulting in the substitution of a conserved hydrophobic residue (isoleucine) for a charged one (arginine; p.81I>R) on the predicted first transmembrane domain of the protein. We hypothesized that the introduction of a positive charge in the transmembrane domain could be deleterious for its protein expression. In order to test this, we introduced the equivalent mutation (V64R, Supplementary Material, Fig. S1B) in human MLC1 carrying HA epitope tags (one at the N-terminus and the other extracellular) and assayed surface expression by an ELISA-based luminescence assay in Xenopus oocytes (Fig. 3A). We used oocytes because their incubation temperature (18°C) would reveal whether the mutation causes folding defects (27). No surface expression could be detected, confirming our hypothesis that the mutation was deleterious.

Therefore, the heterozygous founder zebrafish were pair-wise mated and out-crossed for several generations to eliminate any other background mutations from the original ENU mutagenesis (see Materials and Methods). As the mutation results in a novel DdeI restriction site, it was possible to perform RFLP genotyping, and gene sequencing confirmed the presence of the mutation (Fig. 3B and C). As our previous antibodies against human or mouse Mlc1 proteins did not recognize the zebrafish orthologue (data not shown), we developed a new rabbit polyclonal antibody that was able to detect zebrafish mlc1 (Fig. 3D and E). We assayed mlc1 expression in brain extracts from wild-type, heterozygous and homozygous mlc1FH328 adult fish siblings. No mlc1 protein expression could be detected in homozygotes, validating the allele mlc1FH328 as an mlc1 knockout line, which we will refer to as mlc1−/− zebrafish from now on (Fig. 3F). As with the Mlc1−/− mouse (22), the homozygous mlc1−/− zebrafish turned out to be viable and fertile, with the expected mendelian ratio among adult descendants.

Expression pattern of mlc1 in the adult zebrafish brain and retina

We determined the expression pattern of mlc1 in adult tissues by RT-qPCR (Fig. 4A) and western blot (Fig. 4B). This showed that mlc1 is mainly expressed in the brain and at reduced levels in the eye. We performed immunofluorescence experiments to determine which cell types express mlc1 in the adult brain, using the mlc1−/− zebrafish as a control. Prominent immunoreactivity was observed at the ventricular and pial surface of the brain, and around some blood vessels (Fig. 4C, D, F). Additionally, mlc1 immunoreactivity was observed in radial processes within the brain parenchyma (Fig. 4D). Lack of staining in the mlc1−/− zebrafish confirmed the specificity of our results (Fig. 4E). Staining of mlc1 in the transgenic line fli1a:GFP, which expresses GFP in the vascular endothelium (28), confirmed that the mlc1 protein is present at astrocytic perivascular processes (Fig. 4F). Mlc1 staining around brain ventricles and radial-like structures was also positive for glial fibrillary acid protein (gfap) antibody (Fig. 4G and H), indicating that these are astroglial-like cells (29). Thus, expression of mlc1 in the zebrafish brain is very similar to that found in humans.

We also analysed the localization of mlc1 in the retina. High expression of mlc1 was detected at the inner limiting membrane of the retina. Specificity of the antibody was confirmed by lack of staining in mlc1−/− zebrafish retina (Fig. 4I and J). Double immunostaining with gfap demonstrated that mlc1 was strongly expressed in Müller glia end-feet in the inner limiting membrane (Fig. 4K). Furthermore, we also observed weak mlc1 and gfap co-expression at fine radial glial processes away from the vitreal surface of the retina (Fig. 4K).

Glialcama localization in the adult brain and retina is affected in mlc1−/− zebrafish

As with mlc1, we determined the pattern of expression of glialcama using RT-qPCR in adult tissues. mRNA for glialcama was more broadly expressed compared with mlc1, but showed the highest expression levels in the brain. Detection of glialcama protein in tissue extracts by western blot using a newly developed glialcama antibody (Supplementary Material, Fig. S3D) confirmed its higher expression in the brain (Fig. 5B), and its presence in the eye.

We next addressed the localization of glialcama in brain and retina from wild-type and mlc1−/− zebrafish (Fig. 5C and D). Similar to mlc1, we detected strong immunoreactivity to glialcama in radial glial cell bodies and their processes (Fig. 5C and D), which were also positive for gfap (Fig. 5E). In contrast,
Figure 2. Characterization of the zebrafish orthologues of Mlc1 and Glialcam. (A and B) g
tialcama and gialalcamb were transfected separately in HeLa cells and detected through
the FLAG epitope with immunofluorescence. While gialalcama is specifically located in cell–cell
junctions, gialalcamb protein presented a diffuse location. Scale bar: 10 μm. (C–E) Co-
transfection of gialalcama and mlc1 in HeLa cells reveals their co-localization at cell
junctions. Scale bar: 10 μm. (F–H) Co-transfection of gialalcama and rat CIC-2 in HeLa
cells reveals their co-localization at cell junctions. Scale bar: 10 μm. (I–L) A typical current
trace mediated by rat CIC2 (I) expressed in oocytes and after co-expression with gialalcama (J)
or gialalcamb (K). Only gialalcama is able to modify the functional properties of CIC-2. The
apparent inactivation observed sometimes at very negative voltages is an artefact caused by
chloride depletion inside the oocytes (J). (L) Average steady-state
current–voltage relationship of CIC-2 (black circles) and CIC-2 co-expressed with gialalcama (white circles) or with gialalcamb (triangles). Gialalcama increased
CIC-2-mediated conductance and changed its rectification properties.
a more diffuse glialcama staining was observed in the same brain regions in \textit{mlc}^{1/-} fish (Fig. 5F). We addressed if lack of detection was due to reduced protein expression by western blot using brain extracts, but no changes in protein expression levels were observed (Fig. 5G). We also studied glialcama localization in the retina, as its laminar arrangement could allow easier visualization of subcellular mislocalization. As observed for \textit{mlc}, glialcama was highly expressed at Müller glia end-feet at the inner limiting membrane (Fig. 5H and I). This expression was absent in \textit{mlc}^{1/-} fish. Thus, as we observed in the brain, glialcama was mislocalized in the retina of \textit{mlc}^{1/-} zebrafish (Fig. 5J).

We can conclude that lack of \textit{mlc} in zebrafish causes glialcama mislocalization in glial cells in the brain and retina, in a similar manner to that found in \textit{Mlc1}^{1/-} mice (22).

**Comparison of mouse and zebrafish Mlc1 knockout phenotypes**

The phenotypes of \textit{Mlc1} mouse and zebrafish knockouts were compared. Histopathology of brain sections from \textit{Mlc1}^{1/-} mice revealed largely restricted myelin vacuolization in fibre tracts of the cerebellum (22). In agreement with these histology results, \textit{T}2-weighted MRI of the brain of \textit{Mlc1}^{1/-} mice showed lesions in white matter tracts of the cerebellum from about 6 months of age that increased with age (Fig. 6A and B).

Measurement of brain volume revealed that the whole brain is bigger in \textit{Mlc1}^{1/-} than in wild-type mice at the same age (Fig. 6G).

In zebrafish, we analysed the brain of four adult (14 months old) \textit{mlc}^{1/-} zebrafish by MRI. We only observed very minor lesions in the telencephalon and mesencephalon (Fig. 6C–F) which showed similar relaxation times as cerebrospinal fluid, thus suggesting that they were due to increased fluid. As in mice, measurements of different brain areas revealed that the telencephalon seems larger in comparison with the whole brain in mutant than in wild-type zebrafish (Fig. 6H).

Thus, both animal models showed two typical MLC features: megalencephaly and increased fluid accumulation. However, we failed to observe the presence of vacuoles in any region of the zebrafish brain by general histological procedures (eight different animals; Supplementary Material, Fig. S4A and B) or electron transmission microscopy (four different animals; Supplementary Material, Fig. S4E and F). We conclude that the \textit{mlc}^{1/-} zebrafish develops less severe lesions than the \textit{Mlc1}^{1/-} mice in the brain, which in turn also develops a less severe phenotype than humans.

As glialcama and \textit{mlc} are co-expressed in Müller cells in the retina, we also studied and compared retina morphology between mice and zebrafish. As in \textit{Mlc1}^{1/-} mice (22), the retina of \textit{mlc}^{1/-} zebrafish did not show lesions after histological staining (Supplementary Material, Fig. S4C and D). We also
evaluated the visual function by recording electro-retinograms (ERG) in Mlc1^{-/-} mice and mlc1^{-/-} zebrafish (Supplementary Material, Fig. S5). No significant differences of the means of b-wave amplitude between wild-type and mlc1^{-/-} fish at any light condition were observed (Supplementary Material, Fig. S5A). The relation of normalized b-wave amplitude and the light intensity (inset in Supplementary Material, Fig. S5A) showed complete overlaps between the two groups, suggesting that the sensitivity in mlc1^{-/-} fish does not differ from wild-types. Similar observations have been found in 2-month-old adults (Supplementary Material, Fig. S5B). Similar tests were performed on 1-year-old adult Mlc1^{-/-} mice. Analysis of the

Figure 4. mlc1 expression and localization pattern in adult zebrafish. (A) qPCR with RNA from adult tissues shows the expression of mlc1 almost exclusively in the brain, and at a lesser level in the eye. (B) Western blot with the custom mlc1 antibody shows its expression on the brain and eye. As controls, we used extracts from mlc1-transfected and untransfected HeLa cells. (C–F) Immunofluorescence detection of mlc1 in the zebrafish adult brain. (C) mlc1 is expressed in radial glia processes (arrow) and pial end-feet (arrowheads). (D) mlc1 expression surrounds the ventricle of the brain (open arrow). (E) No immunoreactivity is observed in mlc1^{-/-}. Arrowheads point to the pial surface of the brain. Scale bars: 20 µm. (F) Localization of mlc1 (red) in glial perivascular processes (arrowheads) around blood vessels (green) in the brain of a fli1a::GFP transgenic zebrafish. Scale bar: 10 µm. (G and H) mlc1 co-localizes with the astrocytic protein gfap in the zebrafish adult brain at the pial (arrowhead in G) and ventricular surfaces of the brain (open arrow in H). Asterisk labels the ventricle. Scale bars: 15 µm. Inset: gfap and mlc1 co-expression at the cell body and radial processes of an astrocyte located in a subependymal zone. Scale bar: 15 µm. (I–K) Localization of mlc1 on the retina. (I) mlc1 is expressed in the inner limiting membrane (arrows) of the retina. (J) No immunoreactivity against mlc1 is observed in mlc1^{-/-} zebrafish retina. (K) Double immunofluorescence with gfap (red) confirms mlc1 expression (green) in radial glia processes and Müller glia end-feet (arrow) at inner limiting membrane. Scale bars: 100 µm.
amplitudes of the different components of the ERG showed no significant differences between wild-type and Mlc1−/− mice (Supplementary Material, Fig. S5C).

**Human GLIALCAM is also mislocalized in the Bergmann glia of a MLC1 patient**

Our studies with Mlc1−/− mice and mlc1−/− zebrafish have revealed mislocalization of GlialCAM in astrocytes and oligodendrocytes. However, previous studies from a biopsy of a MLC patient indicated that GLIALCAM was not mislocalized around blood vessels in the cortex (13).

We re-examined the localization of GLIALCAM in the cerebellum of this same human brain biopsy. We focused on the cerebellum, as it is more severely affected in Mlc1−/− mice (22). As previously shown (13), we could not detect MLC1 in Bergmann glia from the MLC patient (Fig. 7A–F). In addition, staining with GLIALCAM antibodies revealed that it was in fact mislocalized in Bergmann glia in the MLC patient (Fig. 7G–L). Control staining with GFAP revealed that these changes were not due to defects in the integrity of the tissue. Thus, we can conclude that the mislocalization of GLIALCAM caused by the absence of MLC1 is a conserved feature from fish to humans, even though the phenotype is more severe as we climb the evolutionary ladder.

**VRAC activity in cultured astrocytes from Mlc1−/− mice is still present**

We cultured astrocytes from Mlc1−/− mice and analysed GlialCAM localization. Unexpectedly, lack of Mlc1 did not change GlialCAM localization (Fig. 8A–D) and expression (Fig. 8E) in Mlc1−/− astrocyte cultures. This result agreed with previous experiments that showed that knocking down Mlc1 in rat astrocytes changed neither the expression nor the localization of GlialCAM in cell junctions (13).

As MLC1 have been related with the activity of VRAC (14,15), we analysed chloride currents in Mlc1−/− astrocyte cultures. In wild-type and Mlc1−/− astrocytes, replacing intra- and extracellular Na⁺ and K⁺ ions with Cs⁺ (to block sodium and potassium currents) and with symmetric Cl⁻, the whole-cell background conductance was very low (Fig. 8F). In both type of astrocytes, hypotonicity challenge promoted a large, reversible increase in ramp current in the whole range of membrane potentials (Fig. 8F and Supplementary Material, Fig. S6A and C). These hypotonicity-activated currents reversed at ≏ 0 mV, were blocked by the specific VRAC inhibitor 4-(2-butyl-6,7-dichlor-2-cyclopentylinden-1-on-5-yl) oxobutyric acid (DCP1B) (30), and showed instantaneous activation and time-dependent inactivation at more positive potentials (Fig. 8F and Supplementary Material, Fig. S6A–D). These data indicated that hypotonicity-activated VRAC channels in wild-type and Mlc1−/− mouse astrocytes which are functionally identical to those described in rat astrocytes (31,32). The observation that the putative CIC-2 inhibitor cadmium (33) did not affect the hypotonicity-activated currents (Supplementary Material, Fig. S6E and F) strongly indicated that these Cl⁻ currents were not mediated by CIC-2, which is also present in mouse astrocytes (34). Comparison of VRAC amplitudes between wild-type and Mlc1−/− astrocytes indicated that VRAC was slightly reduced in astrocytes obtained from Mlc1−/− mouse (Fig. 8G). These results support the view that Mlc1 does not mediate directly...
Figure 6. MRI of Mlc1\textsuperscript{−/−} mice and mlc1\textsuperscript{−/−} zebrafish. (A and B) MRI of mice from different ages show progressive presence of white matter lesions (arrows) in the cerebellum of Mlc1\textsuperscript{−/−} animals (B), but not in wild-type mice (A). (C–F) MRI of adult zebrafish reveals the presence of small lesions in the mesencephalon (thick arrow in D) and telencephalon (arrows in F) in mlc1\textsuperscript{−/−} zebrafish. Hyperintense signals in (D) and (F) may correspond to fat containing tissue in or around the brain. (C) and (E) correspond to images from wild-type zebrafish. Scale bars: 1 mm in (C) and (D), 500 μm in (E) and (F). (G) Brain volume is higher in Mlc1\textsuperscript{−/−} mice. Brain volume was estimated by quantifying the area of consecutive MRI images using ImageJ. Data correspond to seven wild-type and seven Mlc1\textsuperscript{−/−} mice (P < 0.0001). (H) Telencephalon appears bigger relative to the whole brain in mlc1\textsuperscript{−/−} zebrafish (P < 0.05).
VRAC current. To detect whether the non-statistically significant VRAC reduction may lead to astrocyte vacuolation, we stained wild-type (Fig. 8H) and Mlc1<sup>−/−</sup> astrocytes (Fig. 8I) with the freely diffusible fluorescent reagent calcein. Vacuoles were more frequently observed in Mlc1<sup>−/−</sup> astrocytes (Fig. 8J).

**Glialcam localization is dependent on Mlc1 with high extracellular potassium concentration**

Why is GlialCAM mislocalized in Mlc1<sup>−/−</sup> astrocytes in tissue and not in culture? Mislocalization of GlialCAM in humans was better observed in Bergmann glia, which are bathed in a high extracellular potassium concentration due to cerebellar neuronal activity (35). Thus, we treated cultured astrocytes obtained from wild-type and Mlc1<sup>−/−</sup> mice with physiological medium or with an isosmotic solution with higher potassium concentration, mimicking neuronal activity. In wild-type astrocytes under high potassium concentration, there was no change on the localization of Mlc1 (Fig. 9A–D), but there was a slight increase of GlialCAM in cell junctions. When similar experiments were repeated in astrocytes from Mlc1<sup>−/−</sup>, GlialCAM was detected intracellularly after high-potassium treatment (Fig. 9E–H). This effect was even more evident when astrocytes were infected with adenoviruses expressing human Flag-tagged GLIALCAM (Fig. 9I–L). Control staining with the junctional marker β-catenin revealed that these distribution changes caused by increasing extracellular potassium were specific to GlialCAM (Fig. 9M–P).

**Figure 7.** GLIALCAM is mislocalized in the cerebellum of a patient with a missense mutation in MLC1. (A–F) Immunofluorescence detection of MLC1 and GFAP proteins in the cerebellum of a control subject (A–C) and an MLC patient (D–F) carrying a homozygous mutation in MLC1 shows the absence of the MLC1 protein in the patient. Scale bar: 40 μm. (G–L) Immunofluorescence detection of GLIALCAM and GFAP proteins in the cerebellum of a control subject (G–I) and an MLC patient (J–L) carrying a homozygous mutation in MLC1 shows the diffuse signal for GLIALCAM in the absence of MLC1.
Figure 8. Cultured Mlc1−/− astrocytes do not show mislocalization of Glialcam and still present a VRAC response. (A and B) Immunofluorescence detection of Mlc1 in cultured astrocytes from newborn pups confirms the absence of the Mlc1 protein in Mlc1−/− mice. (C and D) Immunofluorescence detection of Glialcam in cultured astrocytes from newborn pups shows that Glialcam protein is present in cell junctions in Mlc1−/− mice, unlike it is seen in vivo. Scale bar: 10 μm. (E) Western blot of brain extracts show no difference in Glialcam protein levels between wild-type and Mlc1−/− mice. (F and G) Depression of the hypotonicity-evoked chloride current with the Volume Regulated Anion Channel (VRAC) inhibitor DCPIB in wild-type (WT) and Mlc1−/− mouse cultured astrocytes. (F) Bar graph of membrane current densities (mean ± SEM) at +80 mV (upper bars) and −120 mV (lower bars) measured in isotonic (Iso CsCl) and hypotonic conditions (Hypo CsCl) and after addition of DCPIB (10 μM) to the hypotonic solution (Hypo CsCl + DCPIB) in wild-type (n = 9) and Mlc1−/− (n = 17) astrocytes. Statistical significance was calculated using paired two-tailed Student’s t-test; *P < 0.05, **P < 0.01, ***P < 0.001. (G) Bar graph of DCPIB-sensitive currents (mean ± SEM) induced by hypotonic challenge at −120 and +80 mV in wild-type (n = 7) and Mlc1−/− (n = 7) mouse astrocytes. Differences in current densities were not significant (ns). (H and I) Typical pictures of astrocytes obtained from wild-type (H) and Mlc1−/− (I) mice. Arrowheads point to vacuoles observed mostly in Mlc1−/− astrocytes. (J) Quantification of the number of cells containing vacuoles. A cell was positive for vacuolation if have at least three vacuoles of a size bigger than 0.5 μm. Scale bar: 10 μm.
**DISCUSSION**

We have analysed two animal models (zebrafish, mice) lacking MLC1 protein and compared them with a brain biopsy from an MLC patient. In all cases, localization of GlialCAM at cell junctions is abolished by lack of MLC1. In cultured mouse astrocytes from Mlc1<sup>−/−</sup>, this effect is only observed when mimicking neuronal activity.

Despite the fact that Mlc1 is one of the most astrocyte-specific genes (36, 37) and its mutation leads to MLC (3), its precise function is still unknown. As MLC1 is a membrane protein with low homology to ion channels, a possible role as a channel or transporter has been suggested (6). However, no such function has been found so far. RNA interference experiments of Mlc1 in cultured astrocytes indicated that it may be a component or regulator of VRAC (14, 15). Here, we demonstrate that VRAC activity is

---

### Figure 9. Glialcam localization to astrocyte junctions depends on Mlc1 and the presence of high extracellular potassium concentration.

(A – D) Mlc1 localization in cell junctions in cultured mouse astrocytes do not change between physiological conditions or high extracellular potassium exposure. Scale bar: 10 µm. (E – H) Glialcam localization in cell junctions in cultured mouse astrocytes is lost when Mlc1<sup>−/−</sup> astrocytes are subjected to 6 h treatment with high extracellular potassium. Four independent experiments gave similar results. (I – L) Adenoviral-mediated expression of human Flag-tagged GLIALCAM in wild-type and Mlc1<sup>−/−</sup> cultured mouse astrocytes confirms the effect of the high extracellular potassium concentration on GlialCAM localization in cell junctions (arrows) in the absence of Mlc1, when it is found almost exclusively in the cytoplasm (asterisks). Dotted line in (L) labels the junctions between three adjacent astrocytes. Four independent experiments gave similar results. (M – P) High extracellular potassium concentration does not alter of the localization of a control junctional protein (β-catenin) in cultured mouse astrocytes.
still present in the absence of Mlc1. We conclude that MLC1 may affect VRAC activity in an indirect manner and is not a molecular component of VRAC. In agreement with this hypothesis, very recently it has been demonstrated that VRAC activity is mediated by LRRC8 heteromers (38,39). Further work will be needed to define the biochemical relationship between MLC1/GlialCAM and LRRC8 proteins.

Further insight into MLC1 biology came from the finding that another MLC-causing gene, which encodes the cell adhesion molecule GLIALCAM (4), is necessary for stabilizing and targeting MLC1 to astrocyte junctions (4,15). In contrast, GLIALCAM targeting in vitro was independent of MLC1 (19,13). However, recent work performed with Mlc1−/− and GlialCAM−/− mice demonstrated that both mutants reproduce MLC symptoms and that Mlc1 is necessary for GlialCAM localization (22).

We decided to expand the repertoire of MLC animal models to solve this contradiction. We have characterized the orthologues of MLC1 and GLIALCAM in zebrafish. The zebrafish (and other teleost fishes) genome contains two glialcam paralogues of which only glialcama behaves as mammalian Glialcam in terms of subcellular localization and modulation of the chloride channel CIC-2 (24). Both mlc1 and glialcama show a similar expression pattern in the brain as murine Mlc1 and Glialcam (4). mlc1 and glialcama are localized to glial cells especially around brain barriers, radial glia processes and end-feet, and also in Müller glia of the retina.

We have generated a zebrafish line carrying a mutation in mcl1 that abrogates its protein expression. However, the conservation of mcl1 in zebrafish does not translate into a severe MLC-like phenotype. We could only detect minor lesions and megalencephaly in the brain of mcl1−/− zebrafish by MRI, but not myelin vacuolization even in fish older than 1 year. Although in humans MLC is evident during the first year of life (1), mouse knockout models of both Glialcam and Mlc1 did not present vacuolization during their firsts months of life (22). This difference could reflect their heterochrony of myelination, and that MLC manifests when myelination is at its highest level (1). Zebrafish show regular compact myelin (40), but protein composition differs: P0 is the major component of CNS myelin, rather than PLP, like in mammals (41). In the transition from an aquatic to a terrestrial environment, there was a switch from P0 to PLP as the major CNS myelin protein, which provided more neuroprotection (42). Myelination in zebrafish larvae starts at 3 days postfertilization (dpf), and myelin basic protein expression increases at least till 29 dpf (43), but new myelin deposition has been reported in trout even older than 1 year (44). Another significant difference with mammalian brains is the capacity of the adult zebrafish brain for neurogenesis (45) and even repair after injury (46). This is linked to the capacity for re-myelination (47,48). Therefore, it is possible to speculate that zebrafish are able to repair myelin sheath damage produced by the lack of mlc1 protein, so vacuolization never reaches a detectable stage by means of histological methods.

Absence of mlc1 in zebrafish brain leads to the misslocalization of glialcama, as we observed in Mlc1−/− mice. This prompted us to re-examine a human MLC biopsy. We found similar results in the cerebellum of the MLC patient. Thus, the reciprocal relationship between MLC1 and GlialCAM for their correct membrane localization has been conserved throughout evolution. This relationship also explains the fact that mutations in either MLC1 or GLIALCAM cause a similar phenotype in MLC1 and MLC2A patients (21).

It has been well described that MLC1 depends on GLIALCAM for exiting the endoplasmatic reticulum and reaching its junctional localization (15). However, a question remains: why does GLIALCAM mislocalize in the absence of MLC1 in vivo? We believe that MLC1 is not working as a chaperone of GLIALCAM, as GLIALCAM in vitro is able to traffic to cell junctions in the absence of MLC1. In agreement with this hypothesis, GlialCAM mislocalization in Mlc1−/− astrocytes in culture only appeared when mimicking neuronal activity by an increase in extracellular potassium. Thus, differences between in vivo and in vitro effects of MLC1 on GlialCAM localization may be due to the presence of interacting molecules in vivo that are not present in culture.

We also suggest that GlialCAM/MLC1 may have a role in the process of potassium siphoning by glial cells. As a result of neuronal electrical activity, potassium is released in order to repolarize the membrane potential, and this excess of potassium needs to be disposed of in a process known as 'potassium siphoning' (49). Glial cells surrounding neurons take up potassium by Kir4.1 channels and then transfer it through Connexin junctions to the astrocytic end-feet surrounding blood vessels, where it is eliminated. Ablation of Kir4.1 (50) or Connexins 32 and 47 (51) results in leukodystrophy characterized by water accumulation in myelin. Work with Mlc1−/−, GlialCAM−/− and Clcn2−/− mice models (22,60) and the identification of mutations in CLCN2 in human patients with leukodystrophy (26) have suggested that the chloride channel CIC-2 may also have a role in potassium-coupled chloride influx. In this sense, GlialCAM changes the rectification of the CIC-2 channel (24), allowing chloride influx at depolarized voltages. Interestingly, new studies with CIC-2 from C. elegans have also shown that the primary role of CIC-2 is to mediate chloride influx but not efflux (52). Unfortunately, the precise role of MLC1 in this process is still not known. However, based on these studies, we can speculate that it may have a regulatory role controlling the surface expression of GLIALCAM, which may be needed to regulate in turn the activity of CIC-2. Possibly, the severity of the phenotype caused by the depletion of Mlc1 from fish to mouse and human could be explained based on differences in neuronal activity between species, making Mlc1 or Glialcam more necessary to keep ionic homeostasis in the possibly more active human CNS.

In summary, our work show that the functional relationship between the two proteins causing MLC in vertebrates is evolutionary conserved. We have also increased the diversity of vertebrate animal models for this disease that can offer further insights into the molecular interactions between these two proteins. Our work also explains the similarity of phenotypes caused by mutations in either gene. More importantly, we uncovered a role for MLC1 in GlialCAM localization at astrocyte junctions in the presence of neuronal activity, offering new mechanistic insights into the pathophysiology of MLC.

MATERIALS AND METHODS

Zebrafish maintenance

AB or AB/TL strains were used in all the experiments. Adult fish were maintained in the animal facility at the University of...
Barcelona, School of Medicine in Bellvitge Campus, under the standard culture conditions: 28°C, 14 h/10 h light/dark period (53). All experimental procedures conformed to the European Community Guidelines on Animal Care and Experimentation and were approved by animal care and use committees.

The mlc1<sup>fl328</sup> allele was obtained from the laboratory of Dr Cecilia Moens, as a result of an ENU-based TILLING screening (62). The mutant line was generated in an islet1::GFP background, which was eliminated by out-crossing to AB wild-type fish. Similarly, two other embryonic recessive lethal phenotypes that were not linked to mlc1<sup>fl328</sup> were eliminated by pair-wise mating and out-crossing. The mlc1<sup>fl328</sup> mutation is a T/G transversion in mlc1 exon 3 that generates a novel Ddel restriction site (CTNAG), which was used for genotyping after amplifying the corresponding fragment of genomic DNA by PCR. The following oligonucleotides were used: TAAATGTGTCTATCTG TATCTGACCGTCAAG (underlined is a mutation introduced to generate a novel Ddel restriction site, 16 nucleotides upstream from the Ddel restriction site generated by the mutation) and TACTCTGCAAGCCAAAAGCA. Genomic DNA was obtained from tail clipping and extraction by NucleoSpin Tissue kit (Macherey-Nagel).

Mlc1 knockout mice

Mlc1<sup>−/−</sup> mice were generated by ICS (Institut Clinique de la Souris, Strasbourg, France) as described previously (22).

Human samples

The MLC patient sample analysed here was already reported (13). Briefly, she carried a homozygous mutation in the MLC1 gene, resulting in an amino acid change (p.S69L) that leads to the reduced stability of the MLC1 protein and its practical absence.

Molecular biology

Plasmids used were constructed using standard molecular biology techniques employing recombinant PCR and the Multi-site Gateway system (Invitrogen). The integrity of all cloned constructs was confirmed by DNA sequencing. For localization studies in HeLa cells, proteins were C-terminally fused to the FLAG epitope or HA-tagged and cloned into the pcDNA3 vector (Invitrogen).

RT-PCR

Adult zebrafish were euthanized using an overdose of tricaine (MS222, Sigma), and tissues were quickly dissected and flash-frozen in liquid nitrogen. Total RNA was isolated with TRIZOL (Life Technologies) and retro-transcribed (RT-PCR) using random hexamers with SuperScript III system (Life Technologies). The following oligonucleotides pairs were used for qPCR: GCACGTTCAGTGGACAACTG and CACAATCATTAC, TAAATGTGTCTATCTG TATCTGACCGTCAAG (underlined is a mutation introduced to generate a novel Ddel restriction site, 16 nucleotides upstream from the Ddel restriction site generated by the mutation) and TACTCTGCAAGCCAAAAGCA. Genomic DNA was obtained from tail clipping and extraction by NucleoSpin Tissue kit (Macherey-Nagel).

TTGAGAGCAG (rpl13a), qPCR was performed with SYBR Select reagent (Life Technologies) in a StepOne apparatus (Life Technologies). The expression levels were calculated using the comparative C<sub>T</sub> method normalized to the internal control genes. The final results were expressed as the relative RNA levels as indicated in the corresponding figures, taking into account the efficiency of each primer pair with the Pfaffl method (55).

Generation of custom antibodies against zebrafish proteins

Immune sera against synthetic peptides from zebrafish mlc1 (QREEASAQEVSFAQSTM, corresponding to amino acids 2–19, in green in Supplementary Material, Fig. S1B) and zebrafish glialcama (EDPPTDGENTMHHSILPR, corresponding to amino acids 405–422, in green in Supplementary Material, Fig. S2B) were raised in rabbits using the services provided by Eurogentec. The peptide was coupled to keyhole limpet haemocyanin via a cysteine residue that has been added to the N-terminal end of the peptide for mlc1 and to the C-terminal end of the peptide for glialcama. After four boosts of immunization, the antisera were affinity purified using the peptide covalently coupled to Sulphohlink (Pierce). The polyclonal antibodies were tested by immunoblotting and immunofluorescence on HeLa cells expressing mlc1 or glialcama and on zebrafish brain tissue.

Cell culture and immunofluorescence microscopy

HeLa cells were grown on DMEM containing 10% (v/v) fetal bovine serum (Sigma) and 1% penicillin/streptomycin at 37°C in a humidity controlled incubator with 10% CO<sub>2</sub>. Cells were cultured and transfected with the Transfectin reagent (BioRad). Twenty-four hours after transfection, the cells were splitted and transferred into glass-covered petri dishes in which experiments were performed after further 24–48 h. To detect expressed proteins, immunofluorescence staining of cells was performed. They were fixed with phosphate-buffered saline (PBS) containing 3% paraformaldehyde for 15 min, blocked and permeabilized with 10% FBS and 0.1% Triton X-100 in PBS for 2 h at room temperature (RT). Primary antibodies were diluted in the same solution and incubated overnight at 4°C. Cells were washed and incubated for 2 h at RT with secondary antibodies. Cover slips were mounted in Vectashield medium (Vector Laboratories) with 1.5 μg/ml DAPI (Sigma) and visualized using an Olympus DSU spinning disk confocal.

Images were analysed using ImageJ. Pairs of cells were analysed manually and quantified as being in junctions or not being in junctions (around the plasma membrane or intracellular). Intensity profile analysis was used to discern the localization.

Histological staining methods

For immunofluorescence in zebrafish, individuals were deeply anaesthetized in 0.1% tricaine (MS222, Sigma) in fresh water, and then transcardiacally perfused with 4% paraformaldehyde. Fish heads were post-fixed for 24 h at RT. Then brains and eyes were dissected out, cryoprotected and frozen with liquid
nitrogen-cooled methylbutane. Transverse sections (12 µm thick) were cut on a cryostat and mounted onto gelatinized slides. Sections were rinsed in PBS and pre-incubated with normal goat serum (Sigma, 1:100) for 1 h. Next, they were incubated with a primary antibody or a cocktail of primary antibodies overnight at room temperature. Antibody dilutions used were: rabbit anti-zebrafish mlc1, 1:100; rabbit anti-zebrafish glialcam, 1:100; mouse anti-gfap (ZIRC), 1:500; rat anti-GFP (Nacalai Tesque), 1:1000. After PBS washes, sections were incubated with secondary fluorescent antibodies (Alexa Fluor 488 or Alexa Fluor 568, 1:500, Invitrogen) for 1 h. After additional PBS washes, sections were mounted using the glycerol-based mounting medium.

For haematoxylin–eosin staining, we used paraffin sections from tissue fixed in Bouin’s fixative. Sections were de-waxed and stained using Meyer’s haematoxylin followed by eosin. Sections were dehydrated and mounted for imaging.

Zebrafish sections were observed and photographed under a laser scanning confocal microscope (Nikon A1R) or a bright-field microscope (Nikon E100). Images were adjusted for brightness and contrast with Adobe Photoshop or Corel Photopaint, and they were assembled with Adobe Illustrator.

Human samples were processed and analysed as described previously (13).

**Electron microscopy**

For electron immunogold experiments, small samples of brain tissue were obtained and fixed in 4% paraformaldehyde and 0.1% glutaraldehyde in 0.12 M phosphate buffer, and processed. They were cryoprotected gradually in sucrose and cryo-fixed by immersion in liquid propane. Freeze substitution was performed at −90°C during 3 days in an Automatic Freeze Substitution System (AFS, Leica); methanol containing 0.5% uranyl-lactate was used as a substitution medium. Infiltration was carried out in Lowicryl HM20 at −50°C and then polymerized with UV light. Ultrathin sections were collected, and when needed, processed for post embedding immunostaining. For immunostaining, grids were incubated with rabbit anti-Mlc1 (1:10) or mouse anti-GlialCAM (1:10) antisera. The binding of the primary antibody was visualized by incubating with a secondary antibody conjugated to 18 nm gold particles (British BioCell, International). Ependymal cells were recognized by their epithelial location, presence of microvilli and cilia, and high density of organelles in the cytoplasm. Astrocytic processes showed a cytoplasm light appearance with the presence of some fibrils and a very few number of organelles (56).

For electron microscopy of zebrafish myelin sheaths, zebrafish were anaesthetized and transcardially perfused using 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1 M cacodylate buffer with 0.5% calcium chloride. Small pieces of tissue were post-fixed in the same fixative (2 h) and then in 1% osmium tetroxide—with 1.5% potassic ferrocyanide (2 h). Tissue was then dehydrated and included in an epoxy resin. Semithin and thin sections were obtained using an ultramicrotome, mounted and imaged in an electron transmission microscope.

**Astrocyte cultures from wild-type and Mlc1−/− mice**

Mouse astrocyte cultures were performed as previously described from P0 to P2 mouse pups of the corresponding genotype (16). Calcein stainings were performed by treating the astrocytes with Calcein-AM 2 µM (Life Technologies) for 10 min and then with physiological solution (122 mM NaCl, 3.3 mM KCl, 0.4 mM MgSO4, 1.3 mM CaCl2, 1.2 mM KH2PO4, 25 mM Hepes, 10 mM glucose, pH 7.2, 300 mM Osm/kg). In some experiments, astrocytes were treated for 6 h with physiological solution or high potassium medium (60 mM NaCl, 60 mM KCl, 0.4 mM MgSO4, 1.3 mM CaCl2, 1.2 mM KH2PO4, 25 mM Hepes, 10 mM glucose, pH 7.2, 300 mM Osm/kg), to mimic neuronal activity. Then, they were fixed in 4% PFA and processed for immunofluorescence as described above.

**Mouse magnetic resonance imaging**

Mouse MRI experiments were conducted on a 7.0T BioSpec 70/30 horizontal animal scanner (Bruker BioSpin), equipped with a 12 cm inner diameter actively shielded gradient system (400 mT/m) in at least seven animals of the same age. Receiver coil was a phased array surface coil for mouse brain. Animals were placed in a supine position in a Plexiglas holder with a nose cone for administering anaesthetic gases (isofluorane in a mixture of 30% O2 and 70% CO2), fixed using a tooth bar, ear bars and adhesive tape. Tripilot scans were used for accurate positioning of the animal’s head in the isocentre of the magnet.

High-resolution T2-weighted images were acquired by using TurboRARE (rapid acquisition with rapid enhancement) sequence applying repetition time of 2969 ms, echo time of 36 ms, RARE factor = 8, 10 averages, slice thickness = 0.3 mm, number of slices = 25 for horizontal view, 25 coronal slices, field of view = 25 × 25 mm, matrix size = 240 × 240 pixels, resulting in a spatial resolution of 0.104 × 0.104 mm in 0.3 mm slice thickness. T2 relaxometry maps were acquired with multislice-multiecho (MSME) sequence by applying 16 different TEs, from 11 to 176 ms, TR = 4764 ms, slice thickness = 0.5 mm, number of coronal slices = 18, FOV = 20 × 20 mm and matrix size = 256 × 256 pixels, resulting in a spatial resolution of 0.078 × 0.078 mm in 0.50 mm slice thickness.

**Zebrafish magnetic resonance imaging**

Magnetic resonance microimaging (µMRI) of zebrafish was performed on a vertical wide-bore 9.4T Bruker Avance 400WB spectrometer, with a 1000 mT/m actively shielded imaging gradient insert (Bruker Biospin GmbH). A birdcage RF coil with an inner diameter 1 cm was used for excitation and detection. The system was interfaced to a Linux PC running Topspin 2.0 and Paravision 5.0 software (Bruker Biospin GmbH). For µMRI, adult zebrafish were euthanized and fixed in 4% buffered paraformaldehyde (Zinc Formal-Fixx, ThermoShandon) for 3 days and subsequently embedded in Fomblin. Before each µMRI measurement, the magnetic field homogeneity was optimized by shimming. Each session of measurements began with a multislice orthogonal gradient-echo sequence for position determination and selection of the desired region for subsequent experiments. High-resolution T2, -weighted imaging was acquired by using TurboRARE (rapid acquisition with rapid enhancement) sequences with echo time (TE) = 10.5 ms; repetition time (TR) = 5000 ms; RARE factor = 4; slice thickness 0.2 mm; number of slices 15; field...
of view 12 × 12 mm; image matrix of 256 × 256 pixels, resulting in an in-plane resolution of 47 μm.

$T_2$ relaxation time measurement in zebrafish brain was performed with MSME sequence by applying eight different TEs (8.5, 17.0, 25.5, 34.0, 42.5, 51.0, 59.5 and 68.0 ms); TR = 1.5 s; slice thickness 0.5 mm; number of slices 6, FOV 12 × 12 mm$^2$ and matrix size 256 × 256 pixels, resulting in an in-plane resolution of 47 μm. For calculation of $T_2$ relaxation time, regions of interest (ROIs) were drawn at various locations within the zebrafish brain. Another ROI in the muscle was used as an internal control. Means and standard deviation for $T_2$ relaxation times for each ROI were calculated.

Two-electrode voltage clamp, western and surface expression in Xenopus oocytes

*Xenopus* oocytes were injected and maintained as described (57). For rat CIC-2, 10 ng cRNA were injected. When co-expressing, 5 ng cRNA of *glialcamo* or *glialcamb* were co-injected with rat CIC-2. Oocytes were perfused with ND96 (in mM): 96 NaCl, 2 KCl, 1.8 CaCl$_2$, 1 MgCl$_2$ and 5 HEPES/TRIS (pH 7.4). To estimate the specific CIC-2-mediated chloride currents, iodide (80 mM NaI replacing the NaCl), which blocks CIC-2-mediated outward currents (58), was applied in every experiment. Oocytes that did not exhibit a significant block were discarded. Currents were measured using a TEC-05X voltage amplifier and the CellWorks program (npi).

Western blot experiments and surface expression in oocytes were performed similarly as previously described (6).

Zebrafish electroretinogram recordings

ERGs were performed at 1-month and 2-month-old young adults (at least five animals). The young adults were anaesthetized by fish system water containing 0.75 mM 3-aminobenzoic acid methyl ester (MESAB, Sigma-Aldrich) and 4.6 mM NaHCO$_3$ before recording. All the experiments were performed at room temperature (20°C).

Fish were dark adapted for at least 30 min and then were placed on the filter paper in the middle of a plastic recording chamber which was filled by 1% agarose. The reference electrode was inserted into the agarose. After the fish was moisturized by a voltage amplifier and the CellWorks program (npi). Electrical signals were digitized at 20 kHz, using a Power Lab data acquisition board (AD Instruments) and displayed on a PC computer monitor. The ERG responses were elicited by stimulation of the retina with light intensities ranging between 10$^{-4}$ and 10$^2$ cd/s/m$^2$. A series of ERG responses were averaged (≈20 ERG traces) for each light intensity, after adjusting the time interval between flashes to ensure complete recovery of the response. Standard ERG waves were recorded according to the method recommended by the International Society for Clinical Electrophysiology of Vision (ISCEV).

Electrophysiological measurements on mouse astrocytes

Electrophysiological measurements were performed with the whole-cell configuration of the patch-clamp technique as previously described (60). Briefly, pipette had a resistance of 2–4 MΩ when filled with the intracellular solution. Membrane currents were amplified (amplifier List EPC-7) filtered at 2 kHz (−3 dB) and acquired at a sample rate of 5 kHz on a microcomputer for offline analysis (pClamp 6, Axon Instruments and Origin 6,0, MicroCal). The access resistance (below 10 MΩ) was corrected for 60–80%. Current densities were calculated by dividing the current values measured at each membrane potential by the cell capacitance estimated from the capacitive transients of the recorded cells corrected by means of the analogous circuit of the patch-clamp amplifier. For the isolation of the Cl$^-$ conductance, the external perfusing saline, called isotonic (Iso CsCl), was (mM): 122 CsCl, 2 MgCl$_2$, 2 CaCl$_2$, 10 TES, 5 glucose, pH 7.4 with CsOH and osmolality ≈320 mOsm with mannitol. The intracellular (pipette) solution was composed of (mM): 126 CsCl, 2 MgCl$_2$, 1 EGTA, 10 TES, pH 7.2 and osmolality ≈300 mOsm with mannitol. Hypotonc extracellular solution (Hypo CsCl) ≈260 mOsm was obtained by omitting mannitol. Osmolality was measured with a vapour−pressure osmometer (Wescor 5500, Delcon). All salts and various
molecules were from Sigma. The DCPIB was prepared in DMSO at a concentration 1000-fold higher than that used in the perfusing saline.

**SUPPLEMENTARY MATERIAL**

Supplementary Material is available at HMG online.

**ACKNOWLEDGEMENTS**

We thank Marisol Montolio and Hernan López-Schier for their help in the initial stages of the project, Esther Prat and Laura González for the management of the Mlc1 colony, Lara Sedó and Beatriz Gamarrá for excellent fish care, Verónica López-Guillín and Catalina Suero for assistance with electron microscopy and histology and Lupe Soria for mice MRI. We also thank Thomas J Jentsch and Ian Orozco for critical reading of the article. We also thank IDIBELL and Alvaro Gimeno (Estabulari Bellvitge) for their help to setup the zebrafish facility.

**Conflict of Interest statement.** None declared.

**FUNDING**

This work was supported in by SAF 2009-07014 (R.E.) and SAF2012-31486 (R.E.), PS09/02672-ERARE to R.E., ELA Foundation 2009-017C4 and 2012-014C2B project (R.E. and V.N.), 2009 SGR 719 (R.E.), SAF 2009-12606-C02-02 (V.N.), 2009 SGR01490 (V.N.). R.E. is a recipient of an ICREA Academia prize.

**REFERENCES**


